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8Abstract
Iron is an important micronutrient essential in carrying oxygen and maintaining the
function of many body enzymes. It is of particular importance during gestation as body
demands increase leading to iron deficiency in women with inadequate iron stores at
the start of pregnancy. Animal studies have shown that iron deficiency in pregnancy
leads to offspring with adverse cardiovascular risk profiles compared to offspring of
iron replete mothers. This thesis aimed to examine the association of maternal iron
intake and status in pregnancy with short and long term birth outcomes that are
considered cardiovascular risk indicators later in life.
Analysis of data from three cohorts and one Mendelian randomisation study was
included in this thesis. Total maternal iron intake in early, but not late, pregnancy was
positively associated with birth size. There was no evidence of association between
taking iron-containing supplements in pregnancy and size at birth. However, taking
multivitamin-mineral supplements, which contain iron, in late pregnancy was
associated with an increased risk of preterm birth. Also taking iron supplements up to
32 weeks gestation was associated with lower offspring systolic blood pressure at 10
years. Maternal iron deficiency and anaemia in early pregnancy were associated with
an increased risk of giving birth to a SGA baby. Infant brachio-femoral PWV measured
at 2-6 weeks of age was found to be higher in women who were anaemic in early
pregnancy, but not in those who were only iron deficient. Finally, using a Mendelian
randomisation design, maternal iron status measured by serum ferritin with C282Y
mutation as an instrumental variable, was not found to be associated with adult
offspring BP and adiposity.
9In conclusion, maternal iron intake and status in early pregnancy seem to be
associated with short term birth outcomes like size at birth, while associations with
long term offspring cardiovascular indicators were not detected in this thesis.
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1 Introduction
1.1 Setting the scene
Obesity, high blood pressure (BP) and arterial stiffness are major risk factors that
contribute to premature death from heart disease and stroke. Factors affecting the
development of the fetus before birth, including maternal nutrition in pregnancy, may
influence these risk factors later in life. Diet deficient in essential nutrients including
iron is a common problem during pregnancy. Iron is an essential micronutrient and is
important not only in carrying oxygen, but also to the catalytic activity of a variety of
enzymes. In the fetus, it is vital to the synthesis of haemoglobin (Hb) and brain
development. Iron deficiency anaemia (IDA) in pregnancy is a common problem, even
in high income country settings. Around 50% of pregnant women worldwide are
anaemic, with at least half of this burden due to iron deficiency (ID).
IDA is associated with adverse short-term maternal and birth outcomes, particularly if
present during the first half of pregnancy. Iron supplements are widely recommended
and used during pregnancy globally. However, the evidence on the extent of benefit
they contribute to the offspring’s health is not well established, and their routine use
has its side effects and drawbacks. Dietary iron intake is difficult to assess accurately
and it is unlikely to be sufficient to meet the demands of pregnancy if women start
with inadequate body iron stores at conception.
Evidence from experimental animal models suggests that maternal ID during
pregnancy is associated with fetal growth restriction, as well as offspring obesity and
high BP later in life. The possible biological mechanisms for this observed association
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may be due to ID-induced changes in placental structure and function, enzyme
expression, nutrient absorption and fetal organ development. These observed causal
associations in animal models need to be investigated in humans using epidemiological
study designs high up in the evidence hierarchy.
This thesis describes a lifecourse approach to exploring the associations between
maternal iron intake and status during pregnancy and offspring potential markers of
cardiovascular disease (CVD) risk in population studies. These markers include both
short-term outcomes (size at birth, preterm birth, infant arterial elasticity) and longer-
term outcomes (child and adult BP, adiposity, arterial stiffness and endothelial
function). In this thesis, different epidemiological study designs were utilised to
examine these associations using data collected specifically for this project, as well as
data from multiple existing longitudinal UK birth cohorts.
1.2 Hypothesis
Maternal ID during pregnancy is associated with increased cardiovascular risk in the
offspring.
1.3 Aim & objectives
The work included in this thesis aims to assess the relationship between both maternal
iron status and intake during pregnancy and potential cardiovascular indicators in the
offspring.
The objectives are to:
27
1. Examine the relationship of maternal dietary iron intake and iron-containing
supplements with immediate birth outcomes including birth weight and preterm
birth (<37 weeks gestation) (chapter 3)
2. Examine the relationship of maternal iron status measured in early pregnancy,
using serum ferritin (sF) and serum transferrin receptor (sTfR) levels, with birth
weight, preterm birth and infant arterial stiffness (chapter 4)
3. Examine the relationship of maternal iron intake from diet and supplements during
pregnancy with offspring’s vascular profile (BP, arterial stiffness and endothelial
function) and body size in childhood at around 10 years (chapter 5)
4. Examine the relationship of maternal iron status, using HFE genotype as an
instrumental variable (IV), with BP and measures of adiposity including body mass
index (BMI) and waist circumference (WC) in the adult offspring (chapter 6)
5. Examine the relationship of maternal Hb levels and anaemia during pregnancy with
short term birth outcomes (birth weight and preterm birth) and cardiovascular
indicators in the offspring including BP, endothelial function and adiposity at age
10, and arterial stiffness in infancy and at age 10 (chapters 3, 4, 5)
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1.4 Thesis overview
This thesis includes four studies using multiple epidemiological research designs
including Mendelian randomisation, historical and prospective cohort study designs.
The research databases investigated in this thesis come from four sources:
1. CARE:
The Caffeine and Reproductive Health study
2. Baby VIP:
Baby’s Vascular health and Iron in Pregnancy study
3. ALSPAC:
The Avon Longitudinal Study of Parents and Children
4. UKWCS-IBPS:
The UK Women’s Cohort Study – Iron and Blood Pressure Sub-cohort
An outline of how these studies fit together to provide a lifecourse approach to
addressing the hypothesis under investigation in this thesis is illustrated in Figure 1.
The second chapter is a summary of the relevant background evidence linked to the
thesis objectives. Chapters 3 - 6 will describe the four component studies of this
research programme, each going through a study-specific introduction, methodology,
results, discussion and conclusion. In chapter 7, the results of the four studies will be
pulled together in a general discussion chapter, followed by the conclusion in chapter
8.
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CARE: Caffeine and Reproductive Health study (chapter 3)
Baby VIP: Baby’s Vascular health and Iron in Pregnancy study (chapter 4)
ALSPAC: The Avon Longitudinal Study of Parents and Children (chapter 5)
UKWCS-IBPS: The UK Women’s Cohort Study – Iron and Blood Pressure Sub-cohort (chapter 6)
Figure 1: Thesis overview
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2 Background
2.1 Chapter summary
This chapter investigates the research evidence relevant to the hypothesis of interest
in this thesis. It first examines iron status in pregnancy (section 2.2). It then
investigates the evidence linking maternal ID during pregnancy with short-term
adverse birth outcomes including low birth weight (LBW) and preterm birth (sections
2.2.4 and 2.2.5). Intake of iron from the diet and supplements is discussed, and the
evidence linking it to birth outcomes is presented (sections 2.2.7 and 2.2.8).
This is followed by an evaluation of the experimental and the epidemiological evidence
supporting associations between maternal ID in pregnancy and cardiovascular
outcomes in the offspring, and the biological mechanisms potentially underlying such
associations (sections 2.3). It then explores the advantages and limitations of the
available biomarkers to measure iron status (section 2.4), and reviews the
cardiovascular indicators used as outcomes in this thesis, with a particular focus on
arterial stiffness measured by pulse wave velocity (PWV) as a predictor of future CVD
risk (section 2.5). This chapter concludes with a note on the originality and significance
of the research included in this thesis (section 2.6).
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2.2 Iron status in pregnancy
The human body requires iron for essential physiological functions including oxygen
transport, Hb and myoglobin synthesis, and cell growth and differentiation (Cetin et
al., 2009). It is vital for the function of body enzymes necessary for electron transfer
and oxidation-reduction reactions (Vijayaraghaven, 2004). Its deficiency limits oxygen
delivery to cells. In the fetus, iron is used to synthesize Hb (Milman, 2006b), and is
essential in brain development (Lozoff, 2000). The size of iron stores required at each
stage of pregnancy to ensure an optimal outcome for the mother and the child is still
not exactly known (Lynch, 2011).
Iron balance in the body is determined by several elements: iron intake and
absorption, iron loss and body iron stores. Inadequate iron intake leads to enhancing
dietary iron absorption, mobilizing body iron stores, reducing iron transport to the
bone marrow and eventually lowering Hb levels leading finally to anaemia
(Vijayaraghaven, 2004). Genetics also influence body iron. Women who carry a C282Y
mutation in the HFE gene are more likely, in the homozygous state, to suffer from
haemochromatosis, a condition which is characterised by iron overload in the liver
(Rhodes et al., 1997, Willis et al., 1999). About 12-20% of Northern Europeans are
heterozygotes for this mutation (Rhodes et al., 1997). These HFE gene mutation
carriers are usually asymptomatic. However, they tend to have higher total body iron
stores (Chan et al., 2005, Cade et al., 2005, Beutler et al., 2002, Jackson et al., 2001)
32
During pregnancy, all the iron delivered to the fetus comes from maternal stores,
absorption of dietary iron, or turnover of maternal erythrocytes (Wu et al., 2004). As
there is an increased demand for iron during this period to cover the mother’s and the
baby’s needs, this is likely to affect iron balance in the body leading to deficiency,
particularly if the pregnancy starts with inadequate iron stores.
2.2.1 Stages of iron deficiency
ID refers to a spectrum ranging from iron depletion to IDA as illustrated in Figure 2.
Women can experience one or more of these stages at different time points prior to
conception, during pregnancy and post-partum. Biomarkers referred to below that are
used to measure iron status are discussed in detail in section 2.4.
Source: Guidelines for control of iron deficiency anaemia; Ministry of Health, India (National Iron+
Initiative 2013)
Figure 2: Stages of iron deficiency
2.2.1.1 Iron depletion
In iron depletion the amount of stored iron which is measured by sF concentrations is
reduced, however the amount of transport and functional iron may not be affected.
Those with iron depletion do not have iron stores to mobilise if the body requires
additional iron, as in the case of pregnancy (Pavord et al., 2011). This leads to iron-
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deficient erythropoiesis (IDE). In this thesis, a WHO cut-off of 15 ug/l in sF was used to
indicate depleted iron stores in pregnancy (WHO, 2011).
2.2.1.2 Iron deficient erythropoiesis
In IDE, stored iron is depleted and transport iron, measured by transferrin saturation
(TS), is reduced further. The amount of iron absorbed is not sufficient to replace the
amount lost or to provide the amount needed for growth and function. In this stage
the shortage of iron limits red blood cell production and results in increased
erythrocyte protoporphyrin concentration and increase sTfR levels (Pavord et al.,
2011, Vijayaraghaven, 2004). This in turn leads to the development of IDA.
2.2.1.3 Iron deficiency anaemia
Anaemia accounts for 9% of the total disability from all conditions in 2010, with
children under 5 years and women having the highest burden. IDA is the most
common aetiology of anaemia. It is defined as anaemia accompanied by depleted iron
stores and signs of a compromised iron supply to the tissues. It is the most severe form
of ID. Shortage of iron stores, transport, and functional iron result in reduced Hb
production leading to a fall in its blood levels, in addition to low sF, low TS, increased
sTfR and erythrocyte protoporphyrin concentrations (Pavord et al., 2011).
The WHO defines anaemia in pregnancy as a Hb concentration of <11 g/dl (WHO,
2001), while the Centers for Disease Control and Prevention (CDC) defines the cut-off
at 10.5 g/dl from 12 weeks gestation on (Dowdle, 1989, Ramsay et al., 2000). In the
UK, the National Institute for Health and Care Excellence (NICE) defines the cut-off as
11 g/dl at around 12 weeks gestation, and 10.5 g/dl at around 28 weeks gestation,
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which are the two routine antenatal screening points for anaemia in the UK (National
Institute for Clinical Excellence (NICE), 2008).
2.2.2 Iron requirements during pregnancy
During pregnancy, extra iron is required to cover the increasing red cell mass, plasma
volume and the growth of the fetoplacental unit. The body’s capacity to increase
absorption during pregnancy starts with around 8% of ingested iron in the first
trimester and progressively increases to 37% by 36 weeks gestation (Whittaker et al.,
1991). One study when all women had sF >12 ug/l at recruitment in the first trimester
found the proportion of ferrous iron absorbed to be 7, 36 and 66% in gestational
weeks 12, 24 and 36 respectively (Barrett et al., 1994), compared to around 11% in
non-pregnant women (Milman, 2006a). It appears that the increased absorption of
iron during pregnancy is elicited by depleted iron stores. This is shown by the
demonstration of an inverse relationship between sF and iron absorption during
pregnancy (Barrett et al., 1994, O'Brien et al., 1999, O'Brien et al., 2003).
The average total amount of iron which a women needs to mobilize during her
pregnancy is 1200 mg (Milman, 2006a, McMahon, 2010). The fetus takes up about 400
mg over full gestation, with up to 175 mg accumulating in the placenta. Pregnant
women require an extra 1 mg/day in the first trimester, 4-5 mg/day in the second
trimester, and a minimum of an extra 6 mg/day in the third trimester if they were to
meet their pregnancy iron demands (Whittaker et al., 1991). However, it is still
unlikely that iron requirements during late pregnancy can be met through diet alone,
even with optimal absorption, if the pregnancy starts with inadequate iron stores
(Milman, 2008). Therefore, a woman must enter pregnancy with iron stores of ≥300 
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mg if she is to meet her requirements fully (Bothwell, 2000). In fact, in a study that
assessed iron status in early pregnancy, women with initial iron depletion (sF<12 ug/l)
were more likely to have iron depletion and ID (sF<12 ug/l and TS<16%) throughout
pregnancy compared to women who start their pregnancy non–iron depleted, despite
the iron-depleted women receiving iron supplements (Ribot et al., 2012).
2.2.3 Epidemiology of iron deficiency in pregnancy
ID remains the leading single nutrient deficiency in the world (WHO, 2010). It is
estimated to affect 1 to 2 billion people, with women of child-bearing age, infants, and
young children particularly at risk. Around 50% of pregnant women worldwide are
anaemic, with at least half of this burden due to ID (WHO, 2010, WHO, 2001). The
prevalence of IDA varies from 31% of pregnant women in South America to 64% in
south Asia, with about 88% in India alone (Vijayaraghaven, 2004). Up to 40% of women
worldwide have very low iron stores (Scientific Advisory Committee on Nutrition,
2010). ID during pregnancy is not just a problem in low and middle income countries. It
is also common in high income countries (Beard, 1994, Milman et al., 1998, Robinson
et al., 1998). About 25 to 40% of pregnant women in Western societies are estimated
to have ID (Bergmann et al., 2002), with this problem being more pronounced in lower
socioeconomic groups (Godfrey et al., 1991). In Denmark, 42% of women of child-
bearing age were found to have small iron reserves (Milman et al., 1998).
2.2.4 Iron deficiency anaemia in pregnancy and birth outcomes
ID can cause an increased production of norepinephrine, which then stimulates
production of corticotropin-releasing hormone and in turn possibly restricts fetal
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growth (Allen, 2001). There is research evidence that links IDA at different stages of
pregnancy with size at birth and gestational age. A few studies have assessed early
pregnancy Hb in relation to birth outcomes. In a cohort of Chinese textile workers
likely to become pregnant, preconceptional anaemia was associated with reductions in
birth weight, birth length, and head circumference, with an increased risk of LBW and
fetal growth restriction (Ronnenberg et al., 2004). In another Chinese study, rates of
LBW and preterm birth, but not small for gestational age (SGA), were related to early
pregnancy Hb concentration in a U-shaped manner (Zhou et al., 1998). In a cohort
from the United States, IDA in early but not in late pregnancy was associated with
greater risk of LBW and preterm birth (Scholl et al., 1992, Scholl and Hediger, 1994).
Another historical cohort study of around 173,000 pregnant US women found an
increased risk of preterm birth with low Hb levels in the first and second trimester. In
this study, however, high Hb level (>14 g/dl) during the first and second trimester was
associated with SGA (Scanlon et al., 2000).
The mechanism for the association between maternal IDA in early pregnancy and LBW
or prematurity is not clear. However, a few mechanisms have been postulated such as
the role of chronic hypoxia in increasing stress hormones production, increased
oxidative stress and higher risk of maternal infections (Allen, 2001). The main clinical
significance of LBW as an outcome is that it is associated with adverse health
consequences both in the short and long terms. Adverse effects in the short term
include increased risk of infant morbidity and mortality (Richardson et al., 1993). LBW
is associated with around 60–80% of neonatal deaths in low income countries (Lawn et
al.). In the long term, LBW has been shown to be strongly associated with increased
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risk of CVD (Gluckman and Hanson, 2006, Forsén et al., 1999, Poulter et al., 1999, Rich-
Edwards et al., 2005, Stene et al., 2001, Hyppönen et al., 2001, Reilly et al., 2005,
Barker, 1995).
On the other hand, the relationship between maternal IDA in late pregnancy and birth
outcomes seems to be different. In a prospective UK study, the risk of SGA birth was
lower in women with IDA in the third trimester compared to non-anaemic women
(Baker et al., 2009). A retrospective British study of about 154,000 women found that
the lowest incidence of LBW and preterm birth occurred with Hb concentrations
between 9.5 – 10.5 g/100 ml in the third trimester (Steer et al., 1995). High Hb
concentration in late pregnancy has been shown to be associated with adverse birth
outcomes including LBW and preterm birth. One suggested mechanism for this
observed association is the potential for iron to lead to a high-level of production of
reactive oxygen species and increased blood viscosity leading to reduced placental
perfusion (Steer et al., 1995, Milman, 2006a, Casanueva and Viteri, 2003, Casanueva et
al., 2006, Goldenberg et al., 1996).
2.2.5 Iron depletion without anaemia in pregnancy and birth
outcomes
Not much research has explored the effect of iron depletion without anaemia on birth
outcomes, particularly at the start of pregnancy. Ronnenberg et al. reported an
association between preconceptional maternal ferritin with birth weight (Ronnenberg
et al., 2004).  Both low (<12 ug/l) and high (≥60 ug/l) ferritin were associated with 
lower birth weight. sTfR was not associated with adverse birth outcome, but elevated
sF was associated with increased risk of LBW. A Spanish prospective study of 205
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pregnant women found those with iron depletion (sF<12 ug/l) in the first antenatal
visit delivered babies weighing around 200 g less than women without iron depletion,
despite receiving iron supplements during gestation (Ribot et al., 2012).
There is some evidence from another Spanish cohort, where all pregnant women are
recommended iron supplements, linking maternal ID during pregnancy with neonatal
neurological outcomes including general autonomous response, motor performance
and self-regulation capabilities ( Ribot et al., 2012). This could be a direct relationship
or mediated by infant iron status. Maternal ID in pregnancy reduces fetal iron stores
well after birth and into the first year of life. Insufficient iron accretion into liver
storage as a result of preterm birth or maternal ID during pregnancy is a risk factor for
developing infant ID (Kelleher, 2006).
2.2.6 Infant iron deficiency
Infant ID may have adverse effects on infant development (Allen, 2000). Perinatal ID
and IDA during infancy has been associated with an increased risk of delayed
psychomotor and cognitive development as well as behavioural problems into mid-
childhood (Beard, 2008, de Ungria et al., 2000). Some studies suggest that these
changes cannot be reversed with iron repletion therapy beyond 2 years of age
(Grantham-McGregor and Ani, 2001). There is evidence that exclusively breast-fed
infants of ID mothers are at higher risk of developing IDA, with weekly or daily iron
supplementation in the first three months of life not reducing this risk (Yurdakök et al.,
2004).
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2.2.7 Dietary iron intake during pregnancy
In this section, I will review sources of dietary iron, dietary recommendations during
pregnancy, associations of dietary iron with birth outcomes and some possible
interventions to prevent and correct ID and IDA during pregnancy including
fortification. Figure 3 illustrates the types of such interventions in the general
population.
Source: Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers
(WHO, 2001).
Figure 3: Interventions to prevent and correct iron deficiency and iron deficiency
anaemia
2.2.7.1 Sources of dietary iron
The modern British diet is thought to be lower in total iron than that consumed 30
years ago (Heath and Fairweather-Tait, 2002). Dietary iron occurs in two forms: haem,
which comes from meat sources, and non-haem. Iron status is influenced by dietary
iron intake, particularly haem iron, as well as factors affecting its bioavailability for
absorption (Brussaard et al., 1997).
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Recent evidence shows that haem and non-haem iron potentially have different
effects on individual health outcomes (Tzoulaki et al., 2008). Haem iron, which comes
from Hb and myoglobin in animal sources, has a higher bioavailability and is well-
absorbed. Its absorption is further facilitated by organic compounds present in meat
called meat-factors, and is influenced little by other dietary constituents. It also
enhances non-haem iron absorption from other foods consumed at the same time
(Skikne and Baynes, 1994).
About 95% of iron in the average British diet is in the form of non-haem iron (Food
Standards Agency, 2003). The extent to which non-haem iron is absorbed is highly
variable and depends on the individual’s iron status and other dietary components.
Vitamin C enhances non-haem iron absorption when consumed as part of a meal
(Skikne and Baynes, 1994), while high calcium intakes from milk/dairy products during
pregnancy may reduce non-haem iron absorption. In a sample of 576 pregnant
women, ferritin concentrations fell with increasing calcium intake with the proportion
of women with sF values ≤12 ug/l rising from 14% of the women in the lowest quarter
of calcium intake to 29% of the women in the highest quarter (Robinson et al., 1998).
Other potential inhibitors of non-haem iron absorption include phytate in cereal
grains/wholemeal bread, oxalic acid in some vegetables such as spinach and beetroot,
seeds and nuts, and polyphenols in tea/coffee (Skikne and Baynes, 1994). However, a
recent analysis using data from 4 complete diet studies found that sF was the most
important factor in explaining differences in non-haem iron absorption, and that
between-person variations explain a large proportion of the differences in non-haem
iron absorption (Armah et al., 2013). These findings were supported by a recent
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systematic review, with diet having a stronger effect on absorption at low sF levels
(Collings et al., 2013). It is worth noting that inhibitory effects of dietary components
on iron absorption are extended to the absorption of iron supplements as well. The
absorption of iron supplements has been shown to be 40% lower when taken with a
meal (Brise, 1962).
Intake of animal tissue was shown to be directly related to women’s iron stores (Heath
et al., 2007). There is evidence that sF is only positively associated with haem iron
intake and not non-haem or total dietary iron (Cade et al., 2005). Therefore the rising
number of vegetarians in high income countries may increase the prevalence of ID. In
addition to the absence of haem iron from their diet, vegetarians usually have a high
intake of beans, lentils, cereals and fruit which contain inhibitors of non-haem iron
absorption such as phytates and polyphenols (Hallberg, 2002). Consumption of a
lacto-ovo vegetarian diet results in 70% lower non-haem iron absorption compared to
a non-vegetarian diet (Hunt et al. 1999).
2.2.7.2 Dietary iron recommendations during pregnancy
In the UK, the Reference Nutrient Intake (RNI) for women aged 19-50 years is 14.8
mg/day with no specific recommended increment during pregnancy (Department of
Health, 1991). The RNI is the amount of a nutrient that is enough to ensure that the
needs of 97.5% of the population are being met. The Lower Reference Nutrient Intake
(LRNI) is the amount adequate for only the small number of people who have low
requirements (2.5%), which is 8 mg/day for iron in women of child-bearing age
(Department of Health, 1991). National-level data on iron intake of pregnant women in
the UK are not available, however the average intake in the UK for women of
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childbearing age is below the RNI. The mean daily dietary intake of total iron from the
2001 National Diet and Nutrition Survey (NDNS) in Great Britain is 10 mg/day for
women aged 19-64 years, with an average of 0.5 mg/day from haem-iron (Foods
Standards Agency, 2003). Around 25% of all women aged 19-64 years, 41% of women
aged <34 years and 53% of women receiving income-benefits had daily dietary iron
intakes lower than the LRNI of 8 mg/day (Scientific Advisory Committee on Nutrition,
2008).
In the United States, the recommended iron intake during pregnancy is 27 mg/day
(IOM, 2001). However, median iron intake in pregnant women was 15 mg/day in the
US National Health and Nutrition Examination Survey (NHANES III) (National Center for
Health Statistics, 1994). Relatively low iron intake is also seen in other European
countries, for example, Denmark (Andersen et al., 1995). There is also evidence from a
nutritional survey in Norway suggesting that women’s dietary patterns do not change
with pregnancy (Crozier et al., 2009, Trygg et al., 1995). In this survey, 96% of pregnant
women had an iron intake <18 mg/day with an average iron intake of 11 mg/day
(Trygg et al., 1995). In the 4th edition of Nordic Nutrition Recommendations (NNR), the
recommended daily intake of dietary iron was 15 mg/day for women of childbearing
age, including pregnant and lactating women, even though it stated that the
physiological need of some women for iron during the last two thirds of pregnancy
cannot be satisfied from food alone (without supplements) (Nordic Council of
Ministers, 2004). The 5th edition of NNR did not change this recommendation due to
insufficient available evidence (Domellöf et al., 2013).
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The Scientific Advisory Committee on Nutrition (SACN) report on Iron and Health
recommends reducing red and processed meat consumption due to links with
colorectal cancer incidence (Scientific Advisory Committee on Nutrition, 2010). The
report states that setting a maximum recommended intake of 70 g cooked meat/day
would have little impact on the proportion of the adult population with low iron
intakes. The above recommendation is largely based on evidence from prospective
studies of diet and colorectal cancer in middle-aged participants. However, a pooled
analysis of around 61,566 younger participants from the EIPC-Oxford cohort aged 35-
69 years at baseline observed no significant difference in colorectal cancer incidence
between meat eaters and vegetarians (Key et al., 2009). Therefore, recommending
meat as the source of haem iron during the limited span of pregnancy is unlikely to
have adverse effects in relation to the lifetime risk of colorectal cancer given the
available research evidence and potentially positive benefits due to iron availability.
2.2.7.3 Iron fortification
Fortified foods may have the potential to reduce micronutrient deficiencies including
iron during pregnancy (Yang and Huffman, 2011). In the Americas, iron-fortified flour is
wide-spread (Walter et al., 2001). In the UK, the addition of iron to white and brown
flour is mandatory (Heath and Fairweather-Tait, 2002). Breakfast cereals are
commonly iron-fortified as well. However, fortification-iron is regarded to have poor
bio-availability (Hurrell, 1997). Despite the increase in breakfast cereals consumption,
the apparent decrease of red meat intake may be more influential on population iron
levels as it has much better absorption (Heath and Fairweather-Tait, 2002). A study in
Denmark found that 40% of women of child-bearing age had low iron status despite
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having a national iron fortification program of flour (Milman et al., 2003). In order to
meet the iron demand in pregnancy, women should make considerable changes in
their dietary pattern which some argue to be unrealistic, hence the recommendation
of iron supplements.
2.2.7.4 Dietary iron in pregnancy and birth outcomes
Few studies have explored the association of iron intake from dietary sources and birth
outcomes compared to those that have explored the effect of iron supplements. This
section attempts to review the available evidence linking dietary iron intake and two
main birth outcomes, birth weight and preterm birth. The studies described below
were retrieved as a result of an electronic database search (Appendix 10.1). The search
was limited to the English Language and human research. A total of 654 papers were
retrieved, and their titles were scanned for relevance. The references of retrieved
relevant papers were also hand-searched.
There were no interventional studies found investigating these relationships. In terms
of observational studies, there were five UK studies that examined the relationship of
dietary iron intake in pregnancy with birth outcomes. A cohort study in London, which
included 513 pregnant women at 12 weeks gestation and assessed intake via a 7-day
food diary, found a social gradient in median iron intake from the diet ranging from
11.4 mg/day in women from social class V to 14.7 mg/day in women from social class I
(Wynn et al., 1994). The median iron intake was 11.8 mg/day in mothers with babies
weighing 3500-4500 g (n=165) and 9.8 mg/day in mothers of LBW babies (<2500 g)
(n=28). The correlation between total dietary iron intake and birth weight was stronger
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in mothers with babies weighing less than the median birth weight of 3270 g (r=0.25)
compared to those weighing more than 3270 g (r=0.08) (Doyle et al., 1990).
Another British cohort study undertaken in Southampton measured dietary intake
during pregnancy using a 100-item food frequency questionnaire (FFQ) and a 4-day
diary (Godfrey et al., 1996). The women in this study had a mean iron intake (from
food and supplements) of 15.5 and 16.8 mg/day in early and late pregnancy
respectively. These levels were higher than that observed in other studies and the
British NDNS levels (Food Standards Agency, 2003). For every 1 mg/day decrease in
iron intake in late pregnancy, birth weight fell by 63 g. However, a cohort undertaken
in Portsmouth showed no evidence of association between maternal iron intake and
birth weight. This study used two methods to assess dietary iron intake; a 7-day food
diary at antenatal booking, and a FFQ at 28 weeks gestation. The median iron intake
was 10.2 mg/day from food alone and 10.8 mg/day in total using the diary, compared
to 12.4 mg/day from food alone and 15.7 in total mg/day using the FFQ (Mathews et
al., 1999). These results suggest that FFQs may lead to overestimation.
A prospective study in London and Manchester recruited 500 pregnant adolescents
(14-18 years) and assessed micronutrient dietary intake by another dietary assessment
method; three 24-hour recalls in the third trimester (Baker et al., 2009). The median
intake of iron of 10.8 mg/day, including supplements, was similar to that described by
Mathews et al. using the 7-day diary. Participants with dietary iron intake (from food
only) below the lowest quartile of 7.7mg/day were almost 4 times more likely to
deliver SGA infants (OR=3.7, 95% confidence interval (CI) 1.2, 11.8) (Baker et al., 2009).
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The association of iron intake with smoking was examined in a London study that
assessed maternal dietary intake using a 7-day weighed diary at 28 and 36 weeks
gestation (Haste et al., 1991). The mean iron intake was 9.3 mg/day for smokers, 11.7
mg/day for non-smokers at 28 weeks, and 8.5 mg/day for smokers and 11.2 mg/day
for non-smokers at 36 weeks. Lower dietary iron intake between 28 and 36 weeks of
pregnancy was associated with higher risk of SGA, reinforcing the findings by Baker et
al. However, there was no association detected in this study between iron intake and
gestational age at delivery (Haste et al., 1991).
In terms of studies outside the UK, a prospective study of 826 pregnant women aged
12-29 years in Camden, New Jersey, ascertained dietary intake using two 24-hour
recalls and supplement use by interview at each trimester of pregnancy. This study
investigated the association between maternal iron status and intake. Lower sF was
associated with lower iron intake in early pregnancy (Scholl and Hediger, 1994, Scholl
et al., 1992). There was a mean difference of about 4.5 mg/day in iron intake between
anaemic and non-anaemic women (defined by sF <12 ug/l). These associations were
not observed in the third trimester. There was a significant association between ID and
both LBW and preterm birth in this study. This is in contrast to another US study
performed in Boston which found no evidence of association between iron intake and
birth size. This study assessed micronutrients intake from food and supplements at 27
weeks gestation using a FFQ (Lagiou et al., 2005). A longitudinal study in Iran which
assessed dietary iron intake among other micronutrients using a 24-hour recall found a
significant positive association between iron intake in the third trimester of pregnancy
with birth weight (Tabrizi and Saraswathi, 2011). Regarding other study designs such as
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case-control studies, one study in New Zealand which assessed dietary intake at birth
using a FFQ, reported an association of iron supplements only with a reduced risk of
SGA (Mitchell et al., 2004). However, a study in Saudi Arabia, also estimating maternal
iron intake from a FFQ administered after delivery, found no difference in mean birth
weight between mothers with above and below the recommended dietary intake of
iron of 30 mg/day using univariable analysis (Al-Shoshan, 2007).
There is recent evidence from a Korean birth cohort which included 1087 pregnant
women of an effect modification of the relationship between maternal iron intake
during pregnancy and birth weight by maternal genotype (GSTM1 polymorphism) (Hur
et al., 2013). This suggests that the potential effect of increasing dietary iron intake in
pregnancy on offspring outcome might be selective depending on the mother’s
genotype. Table 1 summarises the characteristics of the studies discussed above.
2.2.7.4.1 Limitations of studies on maternal iron intake and birth outcomes
Many studies that assessed total iron intake did not model the relationships separately
for iron from food and that from dietary supplements (Doyle et al., 1990, Godfrey et
al., 1996, Mathews et al., 1999). Studies that combine dietary iron intake with a
measure of iron status in pregnant women are rare (Scholl et al., 1992). These studies
have not considered the potential different effects of haem and non-haem iron
considering their different bioavailability profile. Also, the potential of effect
modification by other micronutrients such as vitamin C has not been investigated.
Some of the studies reviewed above had design and statistical analysis limitations
which are likely to affect the generalisability of their results. The research described in
chapters 3 and 5 of this thesis takes the above-mentioned limitations into account.
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Study ID Design Study
size (n)
Exposure
assessment
Main
outcome
Main finding
Al-Shoshan
2007
Retrospective 1771 FFQ* 24 hours
after delivery
BW**
(grams)
No evidence of
association
Baker 2009 Prospective 500 three non-
consecutive 24-
hour recalls in
trimester 3
SGA** &
preterm
birth
Higher SGA risk in
lowest quartile of
iron intake
Godfrey 1996 Prospective 538 Two FFQs at < 17
weeks and 32
weeks
BW &
placental
weight
Total iron intake
positively associated
with BW
Haste 1991 Prospective 169 7-day weighed
food diaries at 28
& 36 weeks
SGA &
preterm
birth
Lower iron intake
associated with
higher SGA risk
Hur 2013 Prospective 1087 24-hour recall BW
(grams)
Positive association
stratified by
genotype (GSTM1)
Lagiou 2005 Prospective 222 FFQ at 27 weeks BW
(grams)
No evidence of
association
Mathews 1999,
2004
Prospective 693 7-day food diary
at booking & FFQ
at 28 weeks
BW &
placental
weight
(grams)
No evidence of
association
Mitchell 2004 Case-control 844 FFQ at birth SGA Iron supplements
associated with
higher SGA risk
Scholl 1992,
1994
Prospective 826 Two 24-hour
recall “early in
pregnancy”
3 interviews
at first, second &
third trimesters
BW
(grams)
&
preterm
birth
Association between
ID with low BW and
preterm birth
Tabrizi 2011 Prospective 450 Three 24-hour
recalls for each
trimester
BW (kg) Positive association
Wynn 1994,
Doyle 1990
Prospective 513 7-day food diary
at booking
BW
(grams)
Total iron intake
positively correlated
with BW
*Food frequency questionnaire **Birth weight *** Small of gestational age
Table 1: Summary of studies of dietary iron intake in pregnancy and birth outcome
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2.2.8 Iron supplementation in pregnancy
Iron supplements are widely recommended and used during pregnancy worldwide.
Iron supplementation is commonly recommended from the second trimester of
pregnancy because iron demand starts to increase at around that period. However, the
timing of supplementation is critical in terms of evidence of effectiveness or harm.
2.2.8.1 Routine iron supplementation programmes
World Health Organization (WHO) guidelines for pregnant women recommend a
standard daily dose of 60 mg of iron for 6 months or 120 mg iron daily if taken for less
than 6 months. WHO also recommends weekly folic acid and iron (60 mg)
supplementations to all women of reproductive age in areas were the prevalence of
anaemia is higher than 20% of women in this age group , or higher than 40% in
pregnant women (WHO, 2006).
In the USA, routine low-dose iron supplementation (30 mg/day) is recommended for
all pregnant women (CDC, 1998). In Canada, the current recommendation is to provide
supplements of ≈16 mg/day throughout pregnancy (Cockell et al., 2009). European 
Union guidelines recommend iron supplements in the second half of pregnancy
(Commission of the European Communities, 1993). Recently, a review by the 5th Nordic
Nutrition Recommendations concluded that 40-60 mg/day of iron supplementation
should be offered from week 18-20 of gestation or earlier, depending on sF measured
in early pregnancy. The purpose is to prevent ID and IDA at delivery as the review
acknowledges that there is no evidence of benefit on the offspring (Domellöf et al.,
2013).
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In the UK, NICE does not recommend routine iron supplementation during pregnancy.
Rather it recommends that Hb levels less than 11 g/dl in the first trimester and 10.5
g/dl at 28 weeks gestation are investigated by testing for sF levels and iron
supplementation considered if indicated (National Institute for Clinical Excellence
(NICE), 2008). The Scientific Advisory Committee on Nutrition’s (SACN) Iron and Health
Report supports the NICE guidelines in not recommending routine iron supplements to
pregnant women (Scientific Advisory Committee on Nutrition, 2010). However, there is
no recommendation for detection or intervention in pregnant women who are iron-
deficient but not anaemic.
2.2.8.2 Experimental evidence of effectiveness/harm of iron
supplementation
Most randomised controlled trials of iron supplementation in pregnancy have
concentrated on maternal indices of ID and/or anaemia as outcomes. Many have
shown positive effects on maternal iron status (Pena-Rosas and Viteri, 2009). One
randomised controlled trial (RCT) showed that a supplement of at least 40 mg/day iron
from 18 weeks gestation onwards prevented IDA in 90% of women during pregnancy
and post-partum (Milman et al., 2005). However, other studies show that routine iron
supplementation of non-anaemic women in pregnancy does not prevent iron
depletion by late pregnancy, particularly in women who start their pregnancy with
inadequate iron stores (Ribot et al., 2012, Cogswell et al., 2003).
The evidence surrounding the effects of iron supplements in pregnancy on infant
outcomes is less consistent (Scholl and Reilly, 2000, Rasmussen, 2001, Scholl, 1998,
Haram et al., 2001, Lao et al., 2001, Allen, 2000). The evidence in favour of iron
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supplementation to increase average birth weight and significantly reduce the
incidence of LBW is observed more clearly in studies conducted in low income country
settings where the prevalence of ID is substantially high (Mishra et al., 2005). Many
studies examining the relationship between routine iron supplements and birth weight
have not differentiated between iron-deficient and non-iron-deficient mothers.
However, one small study found that supplementation with iron during pregnancy
improves newborn birth weight only in those women who start pregnancy with ID
(Aranda et al., 2011). A Cochrane review found that a mother is less likely to have IDA
if taking iron supplements. Higher infant ferritin concentrations at 3 and 6 months and
birth length were also observed in the supplemented group. However, it concluded
that the evidence for benefit was inconclusive in relation to clinically-important infant
outcomes (Pena-Rosas and Viteri, 2009).
A placebo-controlled RCT in Hong-Kong published after the Cochrane review showed
favourable effects of taking iron supplements in the second trimester on birth weight
and incidence of SGA (Chan et al., 2009). In a recent systematic review by Haider et al.
of 48 RCTs and 44 cohort studies, iron supplement intake during pregnancy was
associated with higher Hb levels and lower risk of anaemia in the mother, and lower
risk of LBW in the infant (Figure 4). There was also a dose-response positive
relationship between iron dose and birth weight. However, intake of iron supplements
was not associated with duration of gestation, risk of preterm birth or SGA births
(Haider, 2013).
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I−V=inverse variance method  D+L=DerSimonian and Laird method 
Source: Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and
meta-analysis (Haider, 2013).
Figure 4: Forest plot for effect of iron supplement use on low birth weight
2.2.8.3 Potential adverse effects of iron supplements
Despite the inconclusive evidence on the benefit of routine iron supplementation
during pregnancy on infant outcomes, it remains widely recommended on a national
and international level. The assumption underlying this recommendation is that
supplementation, even if not beneficial, would be harmless to mother and baby.
However, based on some emerging research evidence, this assumption may not be
true. There are potential drawbacks of taking routine iron supplements, particularly in
late pregnancy, that need to be weighed against the benefits of correcting maternal
IDA. High-dose iron supplements (>100 mg/day) are associated with side-effects such
as nausea, vomiting and constipation (British Medical Association and Royal
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Pharmaceutical Society of Great Britain, 2010). The United States’ Institute of Medicine
has established an upper tolerable dose of 45 mg/day to minimize the risk of side-
effects (IOM, 2001).
In addition to gastrointestinal side effects, iron can inhibit the absorption of other
minerals such as manganese, copper and zinc (O'Brien et al., 2000, Rossander-Hulten
et al., 1991, O'Brien et al., 1999, Gambling et al., 2011). There is concern that giving
iron supplements could lead to other micronutrient deficiencies by competing for
gastrointestinal uptake (Langley-Evans, 2009). Hence, the interaction of different
micronutrients needs to be taken into consideration, and the potential for negative
interactions is likely to increase if iron is taken as part of a multivitamin-mineral
supplement (MVM). Iron supplements can also reduce the absorption of dietary non-
haem iron (Roughead and Hunt, 2000), and can increase oxidative stress and the
production of free radicals (Casanueva and Viteri, 2003, Scholl, 2005). It has also been
shown that iron transfer to the fetus is better in non-iron-supplemented than in
supplemented women (O'Brien et al., 2003). A better understanding of iron regulation
and its interactions with other micronutrients would be useful to maximise
effectiveness of iron supplementation programmes.
Iron in supplements can be found in two forms: ferrous and ferric. Ferrous iron
supplements such as ferrous fumarate, ferrous sulphate, and ferrous gluconate are
better absorbed than ferric iron (Hoffman et al., 2000). The amount of iron available
for absorption varies according to the supplement with ferrous fumarate having the
highest amount of elemental iron available for absorption. As the dose of iron in the
supplement increases, the proportion of iron absorbed decreases so that if iron
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supplements are recommended they should be taken in two or three equally spaced
doses.
About 10-15% of Northern European population is heterozygous for the common
mutations in the HFE gene that predispose to iron overload (Merryweather-Clarke et
al., 2000). Blanket routine supplementation may be harmful in women with this
genetic predisposition (Zoller and Cox, 2005). Individually-tailored use of iron
supplements according to blood indices for iron status may be recommended to avoid
the potential harms (Milman, 2006b). However, this may not be cost-effective on a
population level.
It has been postulated that iron supplements in ID women may increase the risk of
oxidative damage and haemoconcentration (Lynch, 2011). Studying animal models
suggests that glucose tolerance is reduced by iron supplementation (Dongiovanni et
al., 2008). Links have been made between iron intake and the risk of type 2 diabetes
and gestational diabetes (GDM) (Rajpathak et al., 2006, Qiu et al., 2011, Bowers et al.,
2011). However, these are mainly observed for haem iron from meat sources and
therefore the relationship could be between meat consumption and diabetes risk
rather than iron per se. Evidence from a RCT in Iran showed that iron supplementation
in women with Hb >13.2 g/dl in the second trimester is positively linked to gestational
hypertension, as well as an increase in the risk of SGA birth (Ziaei et al., 2007).
However, this association was not supported by another RCT which found no link
between iron supplements in the second trimester and GDM (Chan et al., 2009). In
other studies, multiple biomarkers of iron status were also elevated in pre-eclamptic
compared to healthy pregnant women (Rayman et al., 2002).
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2.2.8.4 The case for selective iron supplementation
Taking account of the above, some experts caution the administration of iron
supplements to iron-replete women, especially those at risk of pregnancy
complications such as pre-eclampsia and GDM (Weinberg, 2009), and those who are
genetically predisposed to iron overload. It seems that any positive effects of iron
supplementation on infant outcomes such as birth weight are enhanced the earlier
iron supplements are taken in pregnancy (Agarwal et al., 1991). Therefore, individually-
tailored use of iron supplements according to blood indices for iron status in early
pregnancy such as ferritin levels can avoid any potential harms of mass
supplementation to all pregnant women regardless of their iron status (Milman,
2006b).
One of the dilemmas of selective iron supplementation is the choice of a cut-off point
beyond which iron supplements potentially have no benefit on health of the mother
and baby. It has been suggested that pregnant women with sF >70 ug/l have no need
for iron supplements (Milman et al., 2006). However, clinically significant cut-off
points may vary according to stage of pregnancy. Also, selective supplementation may
be considered unrealistic and not cost-effective for health services. There is a need for
further research into the effectiveness, cost-effectiveness and feasibility of such
selective supplementation policies in high and middle income countries. Routine iron
supplementation to all pregnant women seems to be the most effective option in low
income countries due to high prevalence of ID and anaemia.
56
2.3 Maternal iron in pregnancy and cardiovascular
disease risk in the offspring
Fetal life is a period of rapid development. Inadequate or imbalanced maternal
nutrition during this period can alter physiological structures and/or functions leading
to an increased risk of chronic disease in later life (Hanson et al., 2009). Fetal growth
and development is likely to be most sensitive to maternal dietary deficiencies during
early pregnancy (Wu et al., 2004). Birth weight has been strongly linked to CVD
morbidity and mortality (Barker, 2004). The initial Barker and colleagues finding 25
years ago of an association between weight at birth and mortality from ischaemic
heart disease has resulted in extensive research into the developmental origins of
health and disease (Lawlor and Davey Smith, 2005, Barker et al., 1989). However, the
epidemiological evidence for the association between fetal growth during pregnancy
and adult chronic disease risk still comes mainly from studies that have used birth
weight as a proxy for fetal nutrition during pregnancy (Scientific Advisory Committee
on Nutrition, 2011). There is a gap in the research evidence with regards to examining
the relationship between maternal micronutrient status, including iron, during
pregnancy and CVD outcomes and risk factors in the offspring. In this thesis, the
markers of cardiovascular status used to assess outcomes are discussed in section 2.5.
2.3.1 Experimental studies
Maternal ID during pregnancy in animal models results in the development of offspring
obesity, hypertension and other adverse cardiovascular outcomes in the long-term
(Zhang et al., 2005, Gambling et al., 2003a, Lisle et al., 2003, Andersen et al., 2006,
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Gambling et al., 2004b, Gambling et al., 2003b, Crowe et al., 1995). This effect is
observed even when the pups maintain normal iron levels throughout postnatal life
(Gambling et al., 2003b, Gambling et al., 2003a, Crowe et al., 1995, Gambling et al.,
2004b). The effect of maternal ID seems to be strongest when it is present in early
pregnancy. In one study, diet-induced IDA in rhesus monkeys by the third trimester of
pregnancy did not have an effect on growth or neurological development of the
offspring (Golub et al., 2006).
Pups of rat models fed an iron-deficient diet prior to and throughout pregnancy have
higher mortality rate, are born smaller, have larger hearts and smaller kidneys and
spleens. Raised BP in males born to mothers in the intervention group was observed
despite the offspring having a normal iron status (Gambling et al., 2003b). In another
study, systolic BP was raised in both males and female offspring of iron-restricted
dams at 3 months of age (Lewis et al., 2001). The postnatal rise in systolic BP
associated with maternal anaemia during pregnancy was not related to the greater
placental to birth weight ratio (Crowe et al., 1995). Iron supplementation during early,
but not late, pregnancy reverses the effect of ID on birth size and the expression of
iron metabolism genes (Gambling et al., 2004a).
2.3.2 Postulated biological mechanisms for the association
between maternal ID and CVD risk in the offspring
Evidence from animal studies shows that birth weight is dependent on the mother's
iron status and not that of the neonate (Gambling and McArdle, 2004). Thus, maternal
ID may affect fetal development by indirect mechanisms (Figure 5). ID-induced
changes in maternal metabolism may have downstream effects on placental structure
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and function, enzyme expression, nutrient interactions and fetal organ development
(Gambling and McArdle, 2004, McArdle et al., 2006). These potential biological
pathways are reviewed below.
*FGR: fetal growth restriction
**Reversal window of adverse offspring outcomes if iron is administered by 12.5 days of rat gestation
(Andersen et al., 2006)
Figure 5: Potential biological pathways for the observed effect of maternal iron
deficiency on offspring CVD risk
2.3.2.1 Placental structure and function
The placenta is the principal organ that delivers nutrients to the developing fetus.
Therefore, any stress that interferes with placental development or function is likely to
have adverse consequences for the developing fetus. The placental structure is altered
in maternal anaemia. Changes due to maternal IDA include reduced capillary length
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and surface area and increased placental vascularisation at term (Lewis et al., 2001,
Gambling et al., 2003a). The surface area of capillaries involved in gas exchange is
strongly and inversely related to maternal sF concentrations (Steer et al., 1995).
Maternal anaemia has also been shown to be associated with increased placental
weight and the ratio of fetal weight to placental weight (Godfrey et al., 1991,
Ronnenberg et al., 2004). The relationship between maternal ID with placental size and
birth weight exists across the normal range for these measures and is not just
restricted to severely anaemic mothers. This increase in placental weight has been
interpreted as compensatory placental hypertrophy.
In terms of placental function, increased cytokine, leptin and tumour necrosis factor
levels in the placenta have been associated with ID. Maternal ID has also been shown
to cause fetal plasma amino acid and cholesterol and triacylglycerol levels to be
decreased, suggesting decreased placental transport of amino acid and non-esterified
fatty acids to the fetus (Lewis et al., 2001).
2.3.2.2 Enzyme expression
ID may reduce the activity of the enzymes that use iron as a cofactor, for example
enzymes involved in neurotransmitter synthesis and neuronal energy (Gambling and
McArdle, 2004). There is evidence that maternal ID leads to a reduction in γ-
aminobutyric acid metabolism that is not reversible by postnatal iron supplementation
(Cockell et al., 2009). In addition, areas of the brain that are involved in higher
cognitive functions have lower cytochrome c oxidase activity in neonatal rats born to
ID mothers (Vijayaraghaven, 2004)
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2.3.2.3 Nutrient interactions
The effect of altered iron status on the metabolism of other metals, such as copper,
and mediators of cell function during pregnancy have been observed (Gambling et al.,
2003a). Generally, ID results in increased copper levels in the liver and rise in serum
ceruloplasmin concentrations (Gambling and McArdle, 2004). In pregnancy, maternal
ID has a differential effect on copper metabolism in the mother and fetus (Gambling et
al., 2004b). In the maternal liver, copper levels are inversely correlated with those of
iron, while in the fetus both iron and copper levels are reduced. A similar differential
effect between mother and fetus is also seen in vitamin A metabolism. Maternal liver
retinol levels are reduced in maternal ID, while in the fetus the opposite is seen, as the
level of iron decreases the levels of retinol in the fetal liver increase (Gambling et al.,
2001). This restriction in nutrient supply may have an impact on fetal development.
2.3.2.4 Fetal organ development
ID may also interfere with normal fetal kidney development by reducing nephron
number (Gambling and McArdle, 2004). This may result in the observed association
between maternal ID and high BP in the offspring as kidney nephron number is an
important determinant of BP. Nephron number is established during kidney
development, beyond which point the number cannot be increased (Golub et al.,
2006). Low nephron number reduces the surface area available for filtration, and
therefore limits the ability of the kidney to excrete sodium and maintain normal
extracellular fluid volume and BP (Brenner et al., 1988). Expanding on their earlier
work with the Wistar ID model, Hales and colleagues (Lisle et al., 2003) have
investigated the effect of maternal ID on the renal morphology of the adult offspring in
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rats. Their results show a reduction in the number of glomeruli in the kidney of
offspring born to ID mothers. Offspring from both control and ID mothers also show an
inverse relationship between glomerular number and BP.
2.3.3 Epidemiological studies
There is some indirect epidemiological evidence supporting the associations observed
in animal studies described above. Godfrey et al. found that maternal ID during
pregnancy in humans is associated with a high ratio of placental weight to birth
weight, which is considered a predictor of adult hypertension (Godfrey et al., 1991).
The relationship between maternal iron status in pregnancy and children’s BP has been
directly investigated in few studies. All of them have used maternal Hb as a proxy for
maternal iron status in pregnancy, with two of them including iron intake from diet
and supplements as an additional marker for maternal iron status (Belfort et al., 2008,
Brion et al., 2008). Table 2 summarises the characteristics of studies that have
investigated the associations of indicators of maternal iron status in pregnancy with
long-term health outcomes in the offspring.
Brion et al. analysed data from the ALSPAC cohort with a sample size of 1255 women
in Bristol, UK with Hb information. In this study, there was an association between
maternal anaemia with lower offspring systolic BP at 7 years only in women who did
not take iron supplements during pregnancy (Brion et al., 2008). This is a direction of
association opposite to what is expected from animal study findings. This study will be
further discussed in chapters 5 and 7, in comparison with analysis included in this
thesis using data from the same cohort.
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In another study with a sample size of 1167 pregnant American women, there was no
association between first and second trimester maternal Hb and anaemia with
offspring BP at 3 years. However, offspring BP was positively associated with first
trimester iron intake, again in contrast to animal studies findings. No relationship was
observed in this study between second trimester iron intake and offspring BP (Belfort
et al., 2008).
In a follow-up of a calcium supplementation trial in pregnancy in Argentina, Bergel et
al. found a positive association between maternal Hb during pregnancy and offspring
systolic BP at 5-9 years (Bergel et al., 2000). In contrast, Law et al. found an
association between maternal anaemia in pregnancy (<10 g/dl) and higher offspring
systolic BP at 4 years of 405 British children (Law et al., 1991). Godfrey et al. also found
a negative association between systolic BP of 77 Jamaican children with an average
age of 11 years and lowest maternal Hb during pregnancy (Godfrey et al., 1994).
Whincup et al. found no evidence of association between lowest maternal Hb and
change in mean corpuscular volume (MCV) during pregnancy with BP at 9-11 years of
662 children (Whincup et al., 1994).
To summarise, the direction of association between maternal Hb and offspring BP
during childhood in two of these studies was against that expected from the results of
animal studies as discussed in section 2.3.1 (Brion et al., 2008, Bergel et al., 2000). Two
studies supported the direction of association observed in animal studies, i.e. maternal
anaemia associated with higher offspring BP (Law et al., 1991, Godfrey et al., 1994),
while the remaining two found no association (Belfort et al., 2008, Whincup et al.,
1994). However, it is important to note that all of these studies did not use a direct
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biomarker of iron status such as sF, and only two of them assessed maternal iron
intake as an exposure ((Belfort et al., 2008, Brion et al., 2008).
In terms of other offspring health outcomes, data from the ALSPAC study on maternal
HFE, TF and TMPRSS6 genotypes were used as instrumental variables to investigate the
association of maternal iron status and offspring’s IQ at 8 years using a Mendelian
randomization (MR) design (Lewis et al., 2014). The study found strong associations
between maternal Hb levels in pregnancy and the selected genotypes. However, there
was no evidence of association between offspring’s cognitive function at 8 with either
maternal genotype or Hb levels in pregnancy.
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Study ID Design Study size (n) Exposure assessment Main outcome Main finding
Belfort
2008
Prospective
cohort
1,167 Semi-quantitative
FFQ* in the first
second trimesters, Hb
& MCV** extracted
from electronic
laboratory database
Offspring BP#
at 3 years
Maternal iron
intake
positively
associated with
Offspring BP
Brion
2008
Prospective
cohort
1,255 (Hb)
7,484
(supplement)
7,130 (diet)
FFQ at 32 weeks
Questionnaires at 18
and 32 weeks for
supplements
Hb extracted from
medical records
Offspring BP at
7 years
Maternal
anaemia
associated with
lower offspring
BP in women
not taking
supplements
Law
1991
Historical
cohort
405 Lowest Hb during
pregnancy extracted
from medical records
Offspring BP at
4 years
Maternal
anaemia
associated with
higher
offspring BP
Godfrey
1994
Prospective
cohort
77 Lowest Hb out of up
to 6 measurements
throughout
pregnancy
Offspring BP at
10-12 years
Negative
association
Whincup
1994
Historical
cohort
662 Lowest Hb in
pregnancy and
change in MCV
extracted from
medical records
Offspring BP at
9-11 years
No association
Bergel
2000
Prospective
RCT# follow-up
518 Lowest Hb during
pregnancy recorded
in the trial
Offspring BP at
5-9 years
Positive
association
Lewis
2014
Prospective
cohort,
Mendelian
randomization
11,696 Maternal genotype at
single nucleotide
polymorphisms in the
HFE, TF and TMPRSS6
genes as instrumental
variables
Offspring
cognitive
function
measured by a
shortened
version Of The
Wechsler
Intelligence
Scale For
Children
(WISC-III)
No association
* Food frequency questionnaire
** Mean corpuscular volume
#Blood pressure #Randomised controlled trial
Table 2: Characteristics of epidemiological studies investigating the association of
maternal iron status and long term offspring health outcomes
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2.4 Measures of iron status
The importance of iron status in pregnancy has been discussed earlier in this chapter in
section 2.2. There are several biomarkers used to assess iron status. A nutritional
biomarker is a biological specimen that acts as an indicator of nutritional status with
respect to either intake and/or metabolism of dietary constituents (Potischman and
Freudenheim, 2003). Below is a review of iron status biomarkers used in this thesis
and their pros and cons.
2.4.1 Haemoglobin
The use of functional indices as biomarkers is useful when intake and status are
sufficiently compromised to cause physiological and biochemical disturbances
(Hambidge, 2003). An example is the use of Hb as an indicator of IDA (Zimmermann,
2008, Zimmermann and Hurrell, 2007). Hb is easy to measure and relatively cheap.
Monitoring it is part of routine antenatal care for all pregnant women in most
countries. However, this measure lacks sufficient sensitivity and specificity as there are
other causes of anaemia that may not be related to ID or may coincide with it,
including other nutritional deficiencies such as folic acid and vitamin B12, chronic
inflammation, infections and hereditary causes (Rasmussen, 2001). It is also possible
to be iron-deficient but not to the level of causing anaemia as 20-30% of body iron
could be lost before Hb falls below the specified cut-off for the diagnosis of anaemia
(Cook, 2005) (Figure 2).
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2.4.2 Serum ferritin
The use of body stores as a measure of nutrient status is appropriate to use with iron,
as it is stored when intake in generous and released when intake is less adequate or
demand is increased, as for example in pregnancy. Circulating sF levels have a strong
positive correlation with tissue iron stores (Cook, 2005). sF is the most widely used
biomarker in the assessment of iron status. It is the second line of investigation of
anaemia in pregnancy. Levels under 12 ug/l indicate absent iron stores i.e. iron
depletion. In the presence of anaemia, such a level is diagnostic of IDA (Zimmermann,
2008).
However, ferritin is considered an acute phase protein and can be elevated in
inflammatory conditions independent of body iron stores, thus affecting test
sensitivity. Levels between 12-100 ug/l are difficult to interpret because inflammation
even in the presence of ID can cause elevation of sF (Worwood, 1997). It is considered
unreliable as a test for iron status in conditions of malignancy, heavy alcohol intake,
thyroid and liver disease (Zimmermann, 2008). In the diagnosis of IDA, a practical
approach to minimize this problem is to use a screening test for inflammation such as
C-reactive protein to try and exclude the false negatives (Cook et al., 2003). In
pregnancy, ferritin is considered a marker of infection such as sepsis, which is
associated with premature rupture of membranes leading to preterm birth. This may
limit ferritin’s use as an accurate marker of iron status to use in investigating the
associations between maternal iron status and birth outcomes (Goldenberg et al.,
1998, Scholl, 1998).
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2.4.3 Serum transferrin receptor
Circulating sTfR is a glycoprotein which constitutes the soluble form of the membrane
receptor produced by proteolytic cleavage (Baynes, 1996). It transfers circulating iron
into developing red cells (Zimmermann, 2008). Both the expression of TfR on the cell
surface and the concentration of the soluble TfR are inversely related to the supply of
iron reaching the cell membranes and the level of intracellular iron (Baynes, 1996,
Hambidge, 2003). The advantage of sTfR over sF is that it can distinguish IDA from
anaemia of chronic inflammation and it can identify iron depletion and functional ID in
patients with concurrent inflammation (Allen et al., 1998).
IDE is the most common cause of raised sTfR. Depleted iron stores without IDE is not
associated with raised sTfR, and is best indicated by low sF level. As ID progresses
beyond depletion of iron stores into negative iron status, with inadequate iron supply
from erythropoiesis, sTfR levels begin to rise, and continue to rise as IDE progressively
worsens prior to the development of anaemia (Skikne, 2008).
The use of sTfR as a measure of iron status is limited by the current availability of
several commercial assays that yield different values. There is a pressing need to
calibrate sTfR assays against international reference standards to provide
comparability across studies.
2.4.4 Serum transferrin receptor to serum ferritin ratio (R/F)
R/F ratio quantifies the entire spectrum of iron status from positive iron stores
through to negative iron balance, and is particularly useful in evaluating iron status in
population studies (Skikne, 2008). In the absence of inflammation, it is the most
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sensitive method to assess iron status as it combines the use of sF as a measure of iron
stores and sTfR as a measure of tissue ID (Zimmermann, 2008, Akesson et al., 1998,
Carriaga et al., 1991, Rusia et al., 1999).
A study set out to determine the diagnostic value of R/F ratio against bone marrow
aspirate examination found that it had the best diagnostic efficiency with a sensitivity
of 81% and a specificity of 97%. SF alone with a cut-off of 60 ug/l had the same
specificity but lower sensitivity (76%) (Ruivard et al., 2000). A close linear relationship
was demonstrated between the logarithm of the concentrations, in micrograms per
litre, of R/F ratio with body iron as calculated form the Hb iron after correction for the
absorption of dietary iron (Cook et al., 2003). However, the use of R/F ratio as a gold
standard measure of iron status is still limited by the lack of standardisation of the
different commercial sTfR assays.
2.5 Measures of cardiovascular disease risk
Earlier in this chapter, the evidence around the association between maternal iron
status and offspring cardiovascular risk has been discussed (section 2.3). Several
measures of CVD risk indicators are used as outcomes in the included studies in this
thesis. Below is an evaluation of those indicators and the rationale behind using them.
2.5.1 Pulse wave velocity
Stiff arteries increase the velocity at which the pulse wave travels across the vascular
tree, resulting in earlier return of the reflected wave from peripheral sites. This leads
to suboptimal ventricular-arterial interaction and increased left ventricular afterload
(Cheung, 2010). PWV provides a measure of arterial stiffness which is a convenient,
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precise and reliable. It can be used as an integrated index of vascular pathology over
the life-course (Cruickshank et al., 2009). PWV is the speed at which the forward
pressure of flow wave is transmitted from the aorta through the arterial tree.
Measuring PWV over an arterial segment assesses the stiffness along the length of it or
regional stiffness (Cheung, 2010). PWV is inversely related to arterial distensibility. The
stiffer the artery, the faster is the pulse wave. It is determined by dividing the distance
of the pulse travel, between two arterial sites, by the transit time (Cheung, 2010). .
2.5.1.1 Pulse wave velocity versus pulse wave analysis
The augmentation index is a measure of central pulse wave analysis. It is the difference
between the first and second peaks of the central arterial waveform, expressed as a
percentage of pulse pressure. It is determined by aortic PWV, age, height and diastolic
BP (Laurent et al., 2006). It is negative in healthy young adults but becomes
increasingly positive as arteries stiffen (the lower the AI is the better). PWV, as a
measure of arterial elasticity, discards information about the shape of the pulse wave.
Pulse wave analysis on the other hand, gives information about arterial elasticity and
wave reflection distal to the measurement site and pulse pressure proximal to it. Both
approaches are complementary. PWV as a means of estimating arterial elasticity is
based on a well-understood and tested theoretical model. It does not permit
quantification of functional stiffness per se but provides information about wave
reflection and pulse pressure (Greenwald, 2002).
2.5.1.2 Pulse wave velocity as a predictor of cardiovascular disease
Prediction of CVD morbidity and mortality can be realized through studying arterial
stiffness. Structural vascular abnormalities, in particular increased arterial stiffness,
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have been considered early markers of accelerated vascular aging. Arterial stiffness is a
strong independent cardiovascular risk factor in adults (Meaume et al., 2001).
Vascular dysfunction plays a key role in the pathophysiology of hypertension. Arterial
stiffness, measured non-invasively by PWV in adults, have been associated with
systemic hypertension and left ventricular hypertrophy (Ligi et al., 2010). Therefore,
PWV has been widely used as a predictor of CVD in adults (Weber et al., 2008, Jadhav
and Kadam, 2005), and is associated with higher CVD mortality, coronary heart
disease, and stroke (Vlachopoulos et al., 2010, Sutton-Tyrrell et al., 2005). Age is a
major determinant of PWV, and its influence should be taken into account when using
PWV as a marker of cardiovascular risk (Tomiyama and Yamashina, 2004). However, it
is still not determined whether PWV measured in infancy is a predictor of long term
cardiovascular health.
2.5.1.3 Developmental origins of arterial stiffness
Increased arterial stiffness measured in children, adolescents and young adults, has
been correlated with LBW, which points towards an influence of the fetal
developmental journey on arterial wall structure and function later in life . However,
the relationship seems to be complex, and there is considerable heterogeneity in the
evidence according to which measure of arterial stiffness was used, at which age
arterial stiffness was assessed, and the degree of prematurity and LBW considered.
Oren et al. found an inverse association between gestational age and carotid-femoral
PWV measured in young adults, but a positive association with birth weight, which was
attenuated when excluding offspring of diabetic mothers (Oren et al., 2003). Lurbe et
al. used augmentation index as a measure of pulse wave reflection in 7-18 year old
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children and adolescents and found it to be higher in those born with LBW (Lurbe et
al., 2003). Cheung et al. found that among 8 year old children who were born preterm,
only those with intrauterine growth retardation (IUGR) had increased brachio-radial
PWV (Cheung et al., 2004). In another study, carotid-radial PWV in adolescents was
higher in those born preterm compared to those born at term (Rossi et al., 2011). A
negative correlation was observed between carotid artery stiffness measured by
ultrasound in 9-year old children and birth weight, despite observing no differences in
arterial stiffness index between the normal weight and LBW groups (Martin et al.,
2000). On the other hand, Salvi et al. also found no evidence of a linear relationship
between PWV at 16-19 years of age and birth weight, though there was a positive
relationship with LBW (Salvi et al., 2012). However, in another study there was no
association observed between carotid and aortic arterial stiffness measured by
ultrasound in 7-12 year old children with preterm birth or SGA (Bonamy et al., 2008,
Bonamy et al., 2005). Schack-Nielsen et al. also reported a null association between
aorto-radial and aorto-femoral PWV in 10 year old Danish children and birth weight,
but arterial stiffness was positively associated with duration of breastfeeding (Schack-
Nielsen et al., 2005).
In adults, the evidence is also inconsistent. Some found no evidence of association
between birth weight or LBW and arterial stiffness in adulthood with an age range of
25 years to middle age (Montgomery et al., 2000, Te Velde et al., 2004, Kumaran et al.,
2000), while a study of 55 year olds found that arterial compliance was lower in those
who had been small at birth (Martyn et al., 1995).
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The mechanism of association between LBW and increased arterial stiffness in
childhood and adulthood remains unclear. Endothelial dysfunction in preterm and SGA
babies suggests that functional alterations in arterial tone may contribute to it
(Cheung, 2010). Therefore, this relationship may not be apparent when using
structural methods to assess arterial stiffness such as PWV. Another proposed
mechanism is altered synthesis of elastin in the arterial wall (Cheung, 2010). Arterial
stiffness could be caused by a deficiency of in elastin synthesis in the wall of large
arteries (Martyn and Greenwald, 1997). Elastin normally accumulates in the late
prenatal period and its synthesis falls rapidly after birth (Ligi et al., 2010). Decreased
elastin content in the umbilical arteries, which are direct branches of fetal iliac arteries,
was associated with increased arterial stiffness in one study (Burkhardt et al., 2009).
Gestational age was observed to be correlated with elastin content. Reduction in the
elastin content of umbilical cord arteries has been shown to be associated with both
preterm and SGA infants (Ligi et al., 2010).
In summary, there is some evidence linking size at birth and prematurity with arterial
stiffness later in life. However, the methods used to assess arterial stiffness in these
studies vary significantly, as does the age at which arterial stiffness was assessed.
These issues render the studies quite heterogeneous and therefore difficult to draw
solid conclusions about the magnitude of the association and potential thresholds in
birth weight or gestational age at which adverse programming is likely.
73
2.5.1.4 Association between arterial stiffness and other cardiovascular
markers in children
In the Lifestyle of Our Kids Study, carotid-femoral PWV was positively correlated with
BMI, percentage body fat and WC in children with an average age of 10 years (Sakuragi
et al., 2009). Brachial-ankle PWV in healthy adolescents was found to be associated
with BP, BMI, percent body fat, waist-to-height ratio, sex, homocysteine levels, and
metabolic risk variables (triglycerides, high-density lipoprotein cholesterol, atherogenic
index, glucose, insulin, and insulin resistance) (Miyai et al., 2009, Im et al., 2007). PWV
was associated with physical activity and dietary fat energy percentage in 10 year old
Danish children. (Schack-Nielsen et al., 2005). A study which measured carotid-radial
PWV in 33 obese adolescents and 18 lean controls (average age 14 years) found lower
PWV in the obese group which might reflect general vasodilatation (Dangardt et al.,
2008).
2.5.1.5 Studies of arterial stiffness in infants
Few studies measured arterial stiffness in infants. Akira et al. assessed aortic stiffness
in infants using an index measured by ultrasound to estimate the aortic systolic and
diastolic diameters and their correlation with BP, and found that it increased with
gestational age at birth (Akira and Yoshiyuki, 2006). Using pulse pressure
measurement (distensibility coefficient, and whole body arterial compliance measured
by ultrasound and recording of aortic pulse pressure), increased arterial stiffness was
observed as early as the fifth day of life in very LBW premature infants, and persisted
at least until the 7th week of life (Tauzin et al., 2006). Skilton et al. observed an
increased aortic wall thickness, a marker of atherosclerosis, in SGA infants (Skilton et
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al., 2005). Sehgal et al. calculated arterial wall stiffness index in appropriate for
gestational age (AGA) and SGA infants, and found an increase with very SGA (<3rd
centile) (Sehgal et al., 2014).
Very few population studies to date have examined arterial stiffness using PWV in the
first weeks of life. Koudsi et al. measured aortic PWV in 30 babies in Manchester within
3 days of birth. They found an inverse association between maternal systolic BP at 28
weeks gestation and neonatal PWV, contrary to their hypothesis of a positive
association between the two. Neonatal PWV was positively correlated with birth
weight, birth length and neonatal systolic BP (Koudsi et al., 2007).
2.5.1.6 Maternal/early life nutrition and offspring PWV
Few studies have examined the relationship between maternal nutritional exposures
and arterial stiffness in the offspring. One study examined the association of maternal
vitamin D status during late pregnancy and arterial compliance measured by PWV at 9
years of age and found no evidence of association (Gale et al., 2007). Brachial PWV and
augmentation index were used to evaluate arterial structure and function in 8 year old
children who had participated in a RCT of dietary n-3 and n-6 fatty acid modification
over the first 5 years of life (Ayer et al., 2009). This study also found no evidence of
association between the dietary intervention and arterial stiffness in children.
Another study investigated whether fish oil supplementation versus olive oil
supplementation of lactating mothers could modify PWV in their children after 2.5
years and found no association (Larnkjaer et al., 2006). Adolescent children of women
who have received daily balanced protein-calorie supplements during pregnancy as
part of a community trial in South India had a more favourable lower augmentation
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index as a measure of arterial stiffness than children of women who did not receive
the supplements (Kinra et al., 2008).
However, to date there are no published comparable studies assessing the relationship
between maternal dietary exposures or nutritional status during pregnancy and infant
arterial stiffness within the first few weeks of life. In chapter 4 of this thesis, the first
research study to address this important question is presented.
2.5.2 Blood pressure
BP is strongly and directly linked to the risk of coronary and cerebrovascular events
(Psaty et al., 2001). Almost 30% of coronary heart events can be attributed to high BP
(Wilson et al., 1998). From middle age onwards, BP is strongly and directly related to
vascular and overall mortality, without any evidence of a threshold down to at least
115/75 mm Hg (Prospective Studies Collaboration 2002). Lowering population-wide
diastolic BP by only 2 mm Hg can reduce the prevalence of hypertension by 17 %, the
risk of coronary heart disease by 6 % and the risk of stroke/transient ischaemic attacks
by 15 % (Cook et al., 1995).
2.5.2.1 Developmental origins of hypertension
Adult BP has been inversely linked to birth weight (Barker et al., 2007). However,
changes that occur in utero during fetal development that contribute to the
developmental origins of CVD, including high BP, do not necessarily result in fetal
growth restriction or LBW. There is evidence that children from deprived
backgrounds, those whose mothers experience pregnancy-induced hypertension,
those whose mothers smoke throughout pregnancy, those with LBW, who are not
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breast-fed, who have high sodium diets in infancy and who are obese in childhood or
adolescence tend to have higher BP as adults (Lawlor and Davey Smith, 2005).
Postulated mechanisms for the developmental origins of high BP include fetal
exposure to increased glucocorticoids, attenuation in kidney structure and function by
permanently reducing nephron number, reduced elastin content of arterial walls, and
epigenetic mechanisms involving changes in telomere length and sympathetic over-
activity (Adair and Dahly, 2005). Maternal nutritional status prior to conception and
during pregnancy is likely to be one of the important contributors to the origins of
offspring adult hypertension.
2.5.2.2 Maternal nutrition in pregnancy and offspring BP
In animal studies, there is strong evidence of association between hypertension in the
offspring and sub-optimal maternal nutritional statuses, including general under-
nutrition, low-protein, and vitamin deficient diets (Woodall et al., 1996, Langley and
Jackson, 1994, Sinclair et al., 2007). Earlier in this chapter, the evidence generated by
animal studies of the effect of a maternal diet deficient in iron on offspring’s BP was
reviewed (section 2.3.1).
In humans, there is observational evidence of association between protein-
carbohydrate balance and fat intake during pregnancy with adult and adolescent
offspring BP (Campbell et al., 1996, Adair et al., 2001). Natural experiments, such as
the Dutch Hunger Winter, revealed links between starvation of pregnant women in the
first trimester of pregnancy and offspring hypertension (Schulz, 2010). There is also
evidence of effect on child BP from follow-up RCTs of supplementation during
pregnancy, such as calcium (Belizán et al., 1997), prebiotics (Aaltonen et al., 2008) and
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multiple micronutrient supplements (Vaidya et al., 2008). Epidemiological evidence
linking maternal iron intake in pregnancy and offspring BP in childhood was explored
earlier in this chapter in section 2.3.3.
2.5.3 Obesity
Obesity is an important cardiovascular risk indicator in the offspring when considering
the influence of lifecourse exposures on this risk. The prevalence of obesity has been
on the rise since the early 1980s. Worldwide, at least 2.6 million people died of causes
attributable to obesity in the year 2000 (Ezzati M et al, 2004). Being obese or
overweight can increase the risk of developing chronic diseases such as type 2
diabetes, hypertension, CVD, cancer and all-cause mortality (Pi‐Sunyer, 2012). It can
also have a major impact on the individual’s self-esteem, quality of life and educational
attainment. Tackling obesity is now the concern of most Western governments who
accept its major public health significance. The Foresight report states that, by 2050
over half of the UK adult population could be obese and the NHS costs attributable to
overweight and obesity are projected to double to £10 billion per year. The wider costs
to society and business are estimated to reach £50 billion per year (Foresight Report,
2007).
2.5.3.1 Measures of adiposity
BMI is calculated by dividing the weight in kilograms by the height in metres squared.
It is accepted by the WHO as the appropriate method of classifying overweight and
obesity in adults with cut-offs of 25 kg/m2 for overweight and 20 kg/m2 for obese
(WHO, 1995). However, it is argued that different populations need different cut-offs
due to population-specific differences in disease risk. Indians have a marked tendency
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for abdominal obesity and insulin resistance and perhaps the greatest amplification of
risk as weight increases. Lower BMI cut-offs of 23 kg/m2 in Asia and 24 kg/m2 in
Hispanic countries are conventionally used (Sanchez-Castillo et al., 2006). However,
deriving population-specific BMI cut-off points is difficult as the increase in observed
risk varies from 22 to 25 kg/m2 in different populations. WHO therefore recommends
that the current BMI cut-off points should be retained as the international
classification and additional points are to be used for public health action reporting
(WHO expert consultation, 2004).
WC and waist-to-hip ratio are considered as measures of abdominal or central obesity.
They have been linked to CVD incidence (de Koning et al., 2007). In the elderly, a U-
shaped relationship was shown between WC and mortality (de Hollander et al., 2012).
There are conflicting results regarding the association between this measure in
adulthood and birth weight (Tian et al., 2006, Schooling et al., 2010). So far, the WHO
has not specified cut-off points for WC and waist-to-hip ratio with regards to CVD risk
prediction, as it did with BMI (Nishida et al., 2009). Some suggest a cut-off point for
WC of 90 cm in men and 80 cm in women to mark increased CVD risk (Dobbelsteyn
et al., 2001).
2.5.3.2 Developmental origins of obesity
There is now substantial evidence that early fetal and childhood ‘programming’
influences the development of obesity and its associated chronic diseases such as
diabetes and hypertension in later life. This evidence started to emerge when Barker
and colleagues observed that LBW was associated with a greater risk of developing
abdominal obesity, diabetes and hypertension in late middle-age (Barker, 1998). The
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life-course influences are now thought to be much more complex than the association
with the crude measure of birth weight. Possible mechanisms could be through
epigenetic and transcriptional regulation of key metabolic genes in response to
nutritional stimuli during pregnancy that mediate persistent changes leading to an
adult metabolic syndrome phenotype (Bruce and Hanson, 2010).
The concept of life-course influences on obesity and risk of chronic diseases and the
complex interactions involved is illustrated in Figure 6.
Source: Ending malnutrition by 2020: an agenda for change in the millennium (James et al., 2000).
Figure 6: Life-course influences on obesity and chronic disease risk
2.5.3.3 Maternal nutrition in pregnancy and offspring obesity
Experimental evidence in animal studies supports a role of maternal nutritional quality
in pregnancy on the development of obesity in the offspring (Howie et al., 2009, Bayol
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et al., 2007, Remacle et al., 2011). The evidence specifically linking maternal ID with
offspring adiposity in animal studies was reviewed earlier in this chapter in section
2.3.1.
Higher risk of obesity was observed among children of women who experienced the
Dutch Famine (Painter et al., 2005), which extended to the second generation (Painter
et al., 2008). However, despite the ample evidence from animal studies,
epidemiological studies that characterise the relationship of maternal dietary patterns
and components during pregnancy with offspring obesity later in life, as well the
potential long-term effects of dietary interventions in the mother on offspring obesity,
are almost lacking.
2.6 Significance of this thesis
2.6.1 How is this research scientifically novel?
This thesis is uniquely placed to contribute to the developmental origins of CVD
research by analysing dietary exposures, biomarkers and clinical outcome data from
large cohort studies (CARE, ALSPAC, UKWCS), as well as including a new study which
utilises novel ways of exposure and outcome assessment (Baby VIP).
Data specifically collected for this thesis:
1. New data on the offspring of a sub-sample of the UKWCS
2. The Baby VIP study
Existing data analysed in this thesis come from the following cohorts:
1. The CARE study
81
2. ALSPAC study
3. HFE genotype data from the UKWCS
This programme of research is novel in several aspects:
 Maternal iron intake from the diet as well as supplements is assessed as a
predictor of birth outcomes, including stratifying by type of iron (haem and non-
haem) and testing for effect modification by vitamin C (chapters 3 & 5)
 The Baby VIP study (chapter 4) is the first study to examine the relationship
between a measure of maternal nutritional status during pregnancy and infant
PWV as a proxy for later cardiovascular risk.
 The best available measure of body iron status is used in the Baby VIP study:
the R/F ratio.
 Infant PWV has not been assessed before in a population study with a sample
size in hundreds. This is a novel measure which could provide a non-invasive
predictor of later cardiovascular health that is easier to perform in infants than BP.
 Chapter 5 builds on the previous analysis performed in ALSPAC by Brion et al,
by analysing additional offspring CVD markers as well as BP, including arterial
stiffness, endothelial function and BMI. The sample included is bigger than the
previous analysis, the outcome measurements are taken at a later offspring age,
and include arterial stiffness and endothelial function and adiposity, which were
not analysed in the Brion study.
 The UKWCS-IBPS element of the thesis (chapter 6) is the first study that uses a
MR design to examine a transgenerational relationship between maternal
micronutrient status and adult health indicators.
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 All the above elements exploring the hypothesis of interest at different stages
in the lifecourse are pulled together in this thesis for the first time
2.6.2 Relevance to public health
Any intervention that could result even in a modest reduction in BP, obesity and/or
arterial stiffness at a population level, would have a significant public health impact on
CVD morbidity and mortality. Maternal iron supplementation and/or optimising
dietary iron intake during pregnancy could be such intervention. The outcome of this
study will inform the debate on whether there is benefit to the offspring from
recommending increased iron intake universally through diet and/or supplements
during pregnancy, restricting this to mothers with IDA, or those who have ID even
without anaemia. Positive results would suggest increasing iron intake during
pregnancy is beneficial to the offspring’s health in the long term. Negative results
would suggest a different relationship between maternal iron status and offspring CVD
risk in humans compared to that which has been observed in animal studies.
83
2.7 Conclusion
Maternal ID and IDA during pregnancy is a common problem if women start their
pregnancy with inadequate iron stores. It is potentially associated with adverse
consequences for the baby in the short term, including LBW, prematurity and infant
IDA, particularly if the deficiency is present early in pregnancy. Methods to optimise
iron intake during pregnancy include dietary optimisation of iron intake from natural
sources, iron fortification of certain elements of the diet such as flour, and iron
supplementation. The benefit of such interventions with regards to infant outcomes is
not consistent, particularly in high income country settings.
Maternal ID in pregnancy has been shown to be causally associated with higher risk of
offspring hypertension and obesity in animal studies. However, the available
epidemiological evidence is insufficient to make any conclusions regarding the
presence and direction of such associations. This thesis will test in humans the
hypothesis generated by animal studies using epidemiological study designs. It will
contribute to the evidence-base on whether a mother’s iron intake and status during
pregnancy are important predictors of later cardiovascular risk in her children. Each
study included in this project addresses at least one aspect of the research question of
whether maternal ID during pregnancy is associated with increased offspring’s
cardiovascular risk later in life.
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3 Associations of dietary iron and
supplement intake in pregnancy with birth
outcomes in a cohort of British women: the
CARE study
This chapter commences the investigation of the relationship between markers of
maternal iron status during pregnancy, including intake from the diet and
supplements, and Hb and MCV, with short-term birth outcomes including size at birth
and duration of gestation.
Work from this chapter has formed the basis of two peer-reviewed papers (Alwan et
al., 2011, Alwan et al., 2010), and three conference presentations.
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3.1 Chapter summary
The aim of this study was to investigate the associations between dietary supplements
and iron intake in pregnancy with size at birth and preterm birth using data from a
prospective cohort of 1274 pregnant women aged 18-45 years in Leeds, UK, The
Caffeine and Reproductive Health study (CARE). Dietary intake was reported in a 24-
hour recall administered by a research midwife at 12-week gestation. Dietary
supplement intake was ascertained using dietary recall and three questionnaires (first,
second and third trimesters). Information on delivery details and antenatal pregnancy
complications was obtained from the hospital maternity records.
Reported dietary supplement use declined from 82% of women in the first trimester of
pregnancy to 22% in the second trimester and 33% in the third trimester. Folic acid
was the most commonly reported supplement taken. 24%, 15% and 8% reported
taking iron-containing supplements in the first, second and third trimesters
respectively.
Eighty percent of women reported dietary iron intake below the UK RNI of 14.8
mg/day. Women with dietary iron intake >14.8 mg/day were more likely to be older,
have a higher energy intake, have higher education and take daily supplements during
the first trimester. They were less likely to be smokers, live in a deprived area, or
report a chronic illness.
Vegetarian participants were less likely to have low dietary iron intake (OR=0.5, 95% CI
0.4, 0.8) and more likely to take iron-containing supplements during the first and
second trimesters. Total iron intake, from food and supplements, was positively
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associated with birth weight centile (adjusted change=2.5 centiles per 10 mg increase
in iron, 95% CI 0.4, 4.6). Taking any type of daily supplement during any trimester was
not significantly associated with size at birth taking into account known relevant
confounders. Women taking MVM supplements in the third trimester were more likely
to experience preterm birth (adjusted OR=3.4, 95% CI 1.2, 9.6, P=0.02). Hb at 28 weeks
was associated with increased risk of SGA (adjusted OR per g/dl increase in Hb 1.4,
95% CI 1, 1.8, P=0.03).
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3.2 Background
3.2.1 Dietary iron intake during pregnancy
Dietary recommendations and population levels of intake of iron from the diet during
pregnancy have been reviewed earlier in chapter 2 (section 2.2.7). Results of studies
investigating the relationship between dietary maternal iron intake during pregnancy
and size at birth and/or gestational age are conflicting (Doyle et al., 1990, Godfrey et
al., 1996, Scholl and Hediger, 1994, Mathews et al., 2004, Scholl et al., 1992, Lagiou et
al., 2005, Al-Shoshan, 2007, Baker et al., 2009, Mitchell et al., 2004, Haste et al., 1991,
Mathews et al., 1999). These have been reviewed in section 2.2.7.4 and summarised in
Table 1. Many studies that assessed total iron intake did not model the relationships
separately for iron from food and that from dietary supplements. Neither did they
consider the potential differential effects of haem and non-haem iron. One study
assessed the relationship between ascorbic acid and anaemia and well as vitamin C
intake and iron status (Baker et al., 2009). However the potential interaction between
iron intake and the vitamin C intake and other micronutrients has not been explored
(Gibney et al., 2004).
3.2.2 Dietary supplement intake during pregnancy
Dietary supplements during pregnancy are becoming an attractive option considered
by international agencies to improve the nutritional status of pregnant women in
developing countries. Multivitamin-mineral supplements (MVM) supplements have
been routinely recommended for pregnant women and those who might become
pregnant in some developed countries such as the United States (Willett and Stampfer,
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2001). They are not routinely recommended during pregnancy by the WHO, or in other
developed countries such as the UK. These preparations are readily available over-the-
counter, and heavily advertised and promoted to expectant mothers especially in
Western countries. They are considered relatively cheap, feasible and have the
potential to improve maternal nutrition when administered through national antenatal
programmes. However, dietary supplements are not subject to the same rigorous
safety and efficacy standards as prescription medications (Gardiner et al., 2008). Their
proposed use during pregnancy is supported by findings from several RCTs in low and
middle income country settings, where deficiency in micronutrients is more prevalent
and more pronounced than high income countries.
3.2.2.1 Multivitamin-mineral supplements and birth outcomes
Multiple-micronutrient deficiency is common among pregnant women in low-income
countries (Lumbiganon, 2007). However, pregnant women in developed countries are
expected to have better baseline nutrient status compared to pregnant women in
developing countries, and nutritional deficiencies are more likely to be restricted to
specific micronutrients such as iron. Therefore, the effect of supplementation
programmes in terms of birth outcomes may vary between the two settings.
3.2.2.1.1 Evidence from low and middle income countries
Studies in Nepal, India, Indonesia, Guinea-Bissau and Tanzania have shown positive
effects on adverse birth outcomes such as infant mortality and LBW (Osrin et al., 2005,
Gupta et al., 2007, The supplementation with Multiple Micronutrients Intervention
Trial (SUMMIT) Study Group, 2008, Kaestel et al., 2005, Fawzi et al., 2007). However,
other trials in Nepal, Mexico and Zimbabwe have failed to demonstrate a significant
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effect on the incidence of LBW (Christian et al., 2003, Friis et al., 2004, Ramakrishnan
et al., 2003, Christian et al., 2008), and some have even demonstrated an increased
risk of adverse outcomes (Roberfroid et al., 2008, Christian et al., 2008) . In relation to
the incidence of neural tube defects (NTD), a direct comparison of folate versus
multivitamin supplementation indicated a significant reduction in the folate group
suggesting that folate supplementation may be more useful that MVM considering this
outcome (Lumley et al., 2002).
According to a Cochrane systematic review, there was a favourable effect of MVM
supplementation on the incidence of LBW and SGA compared to none or placebo
supplementation. However, there was insufficient evidence to suggest replacement of
iron and folate supplementation with multiple micronutrient supplements. The review,
which included 9 trials and around 15,000 women, recommended further research to
quantify the degree of maternal or fetal benefit and to assess the risk of excess
supplementation and the potential for adverse interactions between micronutrients.
All the trials included in this review were conducted in low income countries (Haider
and Bhutta, 2006).
An updated review by the same authors, including data from 17 studies all conducted
in developing countries, showed a significant reduction of 9% in the risk of SGA
compared to iron-folate supplementation (Haider et al., 2011). Also, a recent meta-
analysis by Shah et al. of 13 RCTs on the effect of MVM supplements on infant
outcomes showed a significant reduction in the risk of LBW in women who received
these supplements during pregnancy compared to placebo (RR=0.8, 95% CI 0.7, 0.9).
Mean birth weight was also higher as compared to women who took combined iron
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and folic acid supplementation (Shah et al., 2009). There were no differences in the
risk of preterm birth or SGA. One third of the women included were in the first
trimester, half were in the second trimester and the rest in the third trimester during
the trials. All, but one, of the included trials were conducted in a developing country.
This review included a trial of HIV positive women, which the Cochrane review did not
include.
3.2.2.1.2 Evidence from high income countries
Although multivitamin supplements have been recommended for women who might
become pregnant in some high income countries such as the United States (Willett and
Stampfer, 2001), there are few studies examining their effect on birth outcomes in
developed countries, where there is likely to be a significant difference in women’s
baseline nutrient status compared to low income countries. A RCT in France showed
significant positive effects for micronutrient supplementation versus placebo on the
incidence of LBW (Hininger et al., 2004). However, this study had a relatively small
sample size of 100 women and a very small number of babies born with LBW. The
supplements given in this study were iron-free, and thus differ from currently available
over the counter MVM preparations for pregnant women. There was no difference
detected in the oxidative stress parameters measured in the study between
supplemented and unsupplemented women.
The Camden study which examined the association of multivitamin supplementation
intake in pregnancy with birth outcomes was conducted in a disadvantaged urban
setting in the USA (Scholl et al., 1997). Reduced risks of both LBW and preterm delivery
were associated with supplement use in the first and second trimester. Analysis was
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restricted to data obtained by 28 weeks of pregnancy and did not report on the
relationship between infant outcomes and supplement use in the third trimester of
pregnancy.
In summary, MVM supplements are likely to improve infant outcomes in low income
countries. There is a possibility in well-nourished women however of reduced
bioavailability of micronutrients due to interactions, and there is no strong evidence of
benefit of regular intake during pregnancy in high income country settings.
3.3 Hypothesis and objectives
It is hypothesised that women with adequate iron intake and those who take dietary
supplements during pregnancy have, on average, bigger babies.
The objectives of this study were to:
1. Investigate the association between maternal iron intake during early
pregnancy with both birth weight/SGA and preterm birth
2. Assess whether any relationships differ by source of iron (food versus dietary
supplements) or by type of iron (haem versus non-haem)
3. Explore the role of vitamin C intake as an effect modifier in the association
investigated by objective 1
4. Examine the relationship between supplement use during the first, second and
third trimesters of pregnancy with birth weight and preterm delivery
5. Examine the relationship of maternal Hb during pregnancy with birth
weight/SGA
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3.4 Methods
3.4.1 Study design and participants
The CARE study is a prospective birth cohort in which low-risk pregnant women aged
18-45 years with singleton pregnancies were prospectively recruited at 8 to 12 weeks
gestation from the Leeds Teaching Hospitals maternity units between 2003 and 2006
(CARE Study Group, 2008, Boylan et al., 2008). This was part of a multicentre study into
maternal diet and birth outcomes. Women with concurrent medical disorders,
psychiatric illness, HIV infection, or hepatitis B infection were excluded.
Eligible women were identified by screening their pre-booking maternity notes. They
were contacted then sent detailed information about the study and were asked to
return a reply slip to state whether they were willing to take part. A total of 4571
eligible women were approached in Leeds. Of these, 1374 consented. Those who
agreed to participate were then interviewed. This interview was conducted either at
the hospital, the participant’s general practice, or her home by a research midwife.
Demographic details were obtained using a self-reported questionnaire. Figure 7
illustrates the study’s data collection points.
As part of the original study of caffeine and birth outcomes, it was planned to follow-
up women several weeks after delivery to investigate how their caffeine metabolism
had returned to normal, using a caffeine challenge. To reduce costs without
introducing selection bias, follow up was aimed at all cases defined as women with
LBW or SGA babies (< 2500 grams) but only a sample of controls, taken to be the two
closest births either side of the case, following a nested case-control design. The
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interviews for the third trimester data were performed retrospectively on this sub-
sample of the cohort (n=425) with a ratio of 2 controls for every case. Almost all of the
sampled women who were approached returned data for the third trimester of
pregnancy.
Figure 7: CARE study data collection points
3.4.2 Exposure assessment
3.4.2.1 Questionnaire assessment of supplement use
Supplement use was ascertained throughout pregnancy using questionnaires in the
first, second and third trimesters. The questionnaires were interviewer-administered
during the first and third trimesters and self-administered during the second trimester.
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The respondents were asked to report the type/brand, frequency and the amount of
all the dietary supplements they were using during each trimester. The questions were
free text rather than multiple choice questions, asking participants to tick the type of
supplements they were using to ensure all sources were covered. The supplements’
types were then coded during data entry.
3.4.2.2 Recall dietary assessment
Dietary and supplement intake was reported through a 24-hour dietary recall
administered by a research midwife at 8-12 weeks gestation (appendix 10.2). Values
for the proportion of haem iron in each type of meat were used to derive haem values
for each of the food codes. These values were derived by recording the meat content
of each product, together with food tables values (McCance, 1990), to calculate a
weighted mean meat content of each food item consumed. A literature search was
carried out to arrive at ‘haem factors’ for different animal products that reflect the
haem iron content of these foods. Values derived from the Schricker and modified
Schricker methods, and the Hornsey method were used to calculate mean values for
haem iron (Schricker and Stouffer, 1982, Hornsey, 1956). These values were then used
to generate total iron values for each relevant food (O'Hara, 2004). The non-haem iron
values were derived as the difference between total iron from food tables (McCance,
1990) and calculated haem values. Total iron was derived from adding dietary intake
and supplement intake as reported in the recall. Iron content of each supplement
reported was added to the dietary intake multiplied by total number of supplement
tablets/capsules taken during the 24-hour recall. Vitamin C intake from the diet was
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reported in the 24-hour recall and categorized into above or equal to/below the RNI of
50 mg/day in the analysis.
3.4.2.3 Haemoglobin
Data on Hb concentrations and MCV at 12 weeks (n=558) and 28 weeks (n=572) were
extracted from the electronic antenatal laboratory records for a sub-sample of the
cohort which was selected randomly from the main sample using study identification
numbers.
3.4.3 Outcome assessment
The two primary outcome measures were birth weight and preterm birth. Birth weight
and gestational age were extracted from the medical delivery notes. Birth weight was
measured in grams, and as expressed as customised birth weight centile using charts
which take into account gestational age, maternal height, weight, ethnicity and parity,
and neonatal birth weight and sex (Gardosi, 2004). Duration of gestation was
calculated from the date of the last menstrual period, and confirmed by ultrasound
scans dating at around 12 and 20 weeks gestation. SGA was defined as <10th
customised birth weight centile. Preterm birth was defined as delivery at <37 weeks
(259 days) gestation. Information was obtained from the hospital maternity records on
pregnancy and delivery complications.
3.4.4 Assessment of participants characteristics
Socioeconomic status was assessed using the Index of Multiple Deprivation (IMD)
score. The IMD combines a number of indicators, chosen to cover a range of
economic, social and housing issues into a single deprivation score for each small area
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in England. This allows each area to be ranked relative to one another according to
their level of deprivation (Department for Communities and Local Government, 2009).
IMD however, is an area, not an individual, deprivation measure.
Mothers’ educational level, smoking status, alcohol intake, parity, ethnicity, pre-
pregnancy weight, past history of miscarriage, long-term chronic illness and vegetarian
diet were self-reported in a first-trimester questionnaire. Salivary cotinine levels were
measured using an enzyme-linked immunosorbent assay (ELISA) (Cozart Bioscience,
Oxfordshire, UK). Participants were classified on the basis of these cotinine
concentrations as active smokers (>5 ng/ml), passive/occasional smokers (1-5 ng/ml),
or non-smokers (<1 ng/ml) (CARE Study Group, 2008).
3.4.5 Statistical power calculations
Comparing birth weights between mothers with dietary iron intake of >14.8 mg/day
(the recommended UK RNI for women of childbearing age) to those with ≤ 14.8 
mg/day during the first trimester of pregnancy, using the ratios of the low-intake to
the high-intake group and the standard deviation (SD) for birth weight measured in
this study (SD 577 g), this analysis had 85% power to detect a difference of 120 g in
birth weight between the two groups for P <0.05 and a two-sided test.
Comparing birth weights between supplement users and non-users within the first
trimester, using the ratios of users to non-users and standard deviations identified in
the study, this analysis had 80% power to detect a difference of 120 g and 90% power
to detect a difference of 140 g, for P<0.05. Within trimester two, this study had 80%
power to detect a difference of less than 115 g and 90% power to detect a difference
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of 130 g. Within trimester 3, this study had 85% power to detect a doubling of the
prevalence of SGA (from 13% to 26%), and to detect a tripling of the preterm birth rate
(from 5% to 15%) for a two-sided test at P<0.05.
3.4.6 Statistical methods
Univariable comparisons were made using two-sample Student’s t-test for continuous
variables and chi-square test for categorical variables. Multiple linear regression using
birth weight and customised birth weight centile as continuous outcomes, and
unconditional logistic regression with preterm birth and SGA as binary outcomes were
performed using STATA version 11 (College Station, TX, 2009).
Analysis was undertaken using dietary iron intake as a continuous variable and a binary
variable using the UK RNI cut-off of 14.8 mg/day. Total iron from diet and
supplements, assessed by the 24-hour recall, was analysed as a continuous variable.
Intake of iron-containing supplements was analysed as a binary variable. With regards
to supplement intake, analysis was performed using two groups; women who reported
taking any type of daily supplements and those who specifically reported taking MVM
supplements during pregnancy.
Maternal height, weight, ethnicity, parity, neonatal gestation at delivery and baby’s sex
were taken into account in the definition for customised birth centile, and were
adjusted for in the model for birth weight. Statistical adjustment was also made for
salivary cotinine levels, self-reported alcohol consumption, maternal age, maternal
vegetarian diet, IMD, the mother having a university degree, past history of
miscarriage and long-term chronic illness in all models.
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Sensitivity analyses for the linear iron intake model were performed by excluding
vegetarians from the model, and adding an interaction term for daily vitamin C intake
in the model. Sensitivity analyses for the multivitamin models were performed taking
into account clinical diagnosis of IUGR. Subgroup analysis using the multiple linear iron
intake model was performed using type of dietary iron (haem versus non-haem).
Multiple linear regression was also used to explore the association between Hb and
MCV levels at 12 and 28 weeks of pregnancy with iron intake and birth weight/SGA.
3.4.7 Ethical approval
All women participating in the study gave informed written consent and the study was
approved by the Leeds West Local Research Ethics Committee (reference number
03/054). All procedures were in accordance with the Helsinki Declaration of 1975 as
revised in 1983.
3.4.8 Funding
The work included in this chapter was supported by the Wellcome Trust [Grant
number WT87789 to N.A.A.] and the Food Standards Agency, United Kingdom [Grant
number T01033]. The funders had no influence on the design or analysis of the study.
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3.5 Results
3.5.1 Birth outcomes
There were 1259 babies with information on birth weight. Mean birth weight was 3439
g (SD 577 g) with 4.4% babies weighing less than 2500 g (n=55). 13% (n=166) were SGA
(<10th centile), 8% (n=99) weighed less than the 5th centile, and 5% (n=65) less than the
3rd centile. 9% of babies (n=118) weighed more than the 90th centile. Out of the 1234
pregnancies with information on gestational age, 55 (4.5%) delivered their babies
before 37 weeks gestation.
3.5.2 Dietary recall
Based on midwife-administered 24-hour recall dietary assessment at 8 to 12 weeks
gestation, women in the CARE study had average dietary intakes from food above the
RNI values for most vitamins and minerals (The Panel on Dietary Reference Values of
the Committee on Medical Aspects of Food Policy, 1991) except vitamin D, iron, folate,
selenium and iodine.
Table 3 shows the mean intake in the cohort, the nutrient requirements for adult
women plus the additional requirement recommended for consumption during
pregnancy, and the proportion of the women with dietary intakes above the
recommended RNI in pregnancy. The mean total energy intake was 2125 kcal/ day
(95% CI 2084, 2166).
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Micronutrient Mean (SD) RNI* Increment**
% with intakes
>pregnancy RNI
(95% CI)
Thiamin (mg/d) 2.4 (7.7) 0.8 +0.1 85 (83,87)
Riboflavin (mg/d) 1.7 (0.8) 1.1 +0.3 58 (55,61)
Niacin (mg/d) 20 (10) 13 *** 75 (72,77)
Vitamin B6 (mg/d) 2.1 (1.0) 1.2 *** 85 (82,86)
Vitamin B12 (ug/d) 3.9 (3.7) 1.5 *** 79 (77,82)
Folate (ug/d) 257 (119) 200 +100 32 (29,35)
Vitamin C (mg/d) 143 (129) 40 +10 75 (73,78)
Vitamin A (ug retinol
equivalent/d) 803 (665) 600 +100 45 (42,48)
Vitamin D (ug/d) 2.5 (2.7) - 10 2 (1,3)
Vitamin E (mg/d) 7.9 (5.4) - # -
Calcium (mg/d) 938 (471) 700 *** 65 (62,68)
Phosphorus (mg/d) 1344 (501) 550 *** 98 (97,99)
Magnesium (mg/d) 283 (112) 270 *** 49 (46,52)
Iron (mg/d) 11.5 (5.3) 14.8 *** 20 (18,23)
Zinc (mg/d) 8.6 (4.3) 7 *** 59 (56,62)
Copper (mg/d) 1.1 (0.6) 1.2 *** 32 (29,35)
Selenium (ug/d) 58 (37) 60 *** 40 (38,43)
Iodine (ug/d) 118 (82) 140 *** 28 (24,29)
* Reference nutrient intakes for women aged 19-50 years in the UK
**Recommended Increment to RNI during pregnancy ***No increment is recommended
#Safe intake – above 3mg/day for women (The Panel on Dietary Reference Values of the Committee on
Medical Aspects of Food Policy, 1991)
Table 3: Average daily intakes of vitamins and minerals (from diet alone) based on
24-hour dietary recall at 8-12 weeks of pregnancy in the CARE study (n=1257)
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3.5.3 Iron intake
3.5.3.1 Iron intake from diet
1257 women had dietary recall information in the first trimester. The mean dietary
iron intake from food was 11.5 mg/day (SD 5.3) with only 20% (n=257) of women
reporting intake >14.8 mg/day (95% CI 18, 23%). 24% of women reported iron intake
equal or less than the UK LRNI of 8 mg/day (95% CI 22, 27%). Only 4% reported a
dietary iron intake of more than the US recommended intake during pregnancy of 27
mg/day (95% CI: 3, 5%). Mean haem iron intake was 0.6 mg/day (SD 0.8). This estimate
for haem iron changed little after excluding the 114 reported vegetarian participants
(with a haem iron intake of zero). Mean non-haem iron intake was 10.9 mg/day (SD
5.2) (Table 4).
Mean
(mg/day)
Standard
deviation
Median
(mg/day)
Interquartile
range
Iron intake from food 11.5 5.3 10.5 8.1 , 13.7
Haem iron intake 0.6 0.8 0.3 0.1, 0.8
Non-haem iron 10.9 5.2 10 7.6, 13.0
Total iron from food and supplements 16.5 21.1 11.8 8.6, 19.1
Total iron from food and supplements
excluding therapeutic iron
preparations (≥ 65 mg/dose)  
14.3 8.4 11.6 8.5, 18.6
Table 4: Average iron intake from food and dietary supplements as reported in first
trimester 24-hour dietary recall in the CARE study (n=1257)
3.5.3.1.1 Characteristics of women with high versus low iron intake
Women with dietary iron intake >14.8 mg/day were more likely to be older, report a
higher total energy intake, have a university degree, be vegetarian, and take daily
supplements during the first trimester including iron-containing supplements. They
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were less likely to be smokers, live in an area with the worst IMD quartile, or have a
long-term illness (Table 5). Vegetarian participants were less likely to have dietary iron
intake ≤14.8 mg/day (unadjusted odds ratio (OR) 0.5, 95% CI 0.4, 0.8, P=0.004).
Vegetarians were also more likely to take iron-containing supplements during the first
and second trimester (OR 2.9, 95% CI 2.0, 4.3, P<0.0001 for the 1st trimester, OR 2.9,
95% CI 1.9, 4.4, P<0.0001 for the 2nd trimester).
>14.8 mg/day#
(n=257)
≤14.8 mg/day 
(n=1000) P*
Dietary iron intake (mg/day) (mean, 95% CI) 19.6 (15.0, 31.7) 9.4 (4.5, 13.8) -
Age of mother (years) (mean, 95% CI) 31 (30, 31) 30 (29, 30) 0.004
Pre-pregnancy weight (kg) (mean, 95% CI) 66 (64, 68) 68 (67, 68) 0.1
Total energy intake (kcal) (mean, 95% CI) 2777(2657,2897) 1958(1924,1991) <0.0001
Active smoker at 12 weeks (%, 95% CI) 8 (5, 12) 20 (17, 23) <0.0001
IMD** most deprived quartile (%, 95% CI) 25 (20, 31) 32 (29, 35) 0.03
Caucasian (%, 95% CI) 91 (87, 95) 94 (92, 95) 0.2
Higher education (%, 95% CI) 52 (49, 58) 35 (32, 39) <0.0001
Vegetarian (ovo-lacto) (%, 95% CI) 13 (10, 18) 8 (6, 10) 0.004
Primigravida (%, 95% CI) 47 (41, 54) 46 (43, 49) 0.7
History of long term illness (%, 95% CI) 9 (6, 13) 14 (12, 16) 0.04
Average alcohol consumption more than 0.5
units/day throughout pregnancy (%, 95% CI) 30 (24, 36) 26 (23, 29) 0.2
Past history of miscarriage (%, 95% CI) 20 (16, 26) 25 (22, 27) 0.08
Report taking any form of daily supplements in the
1st trimester questionnaire (%, 95% CI) 87 (82, 91) 81 (78, 83) 0.01
Report taking daily iron-containing supplements in
the first trimester (questionnaire) (%, 95% CI) 29 (23, 35) 23 (20, 25) 0.04
# Reference nutrient intake (RNI) for iron for women aged 19-50 years in the UK
* P-value using two-sample t-test for continuous variables, chi-squared test for categorical variable
**Index of multiple deprivation
Table 5: Characteristics of women by dietary iron intake above versus equal to or
below RNI during the first trimester as reported in a 24-hour dietary recall (n=1257)
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3.5.3.2 Iron intake from supplements
20% of participants (95% CI 18, 22) reported taking iron-containing supplements in the
recall compared to 24% (95% CI: 22, 26) in the first trimester questionnaire (Kappa
agreement = 0.85). 15% (95% CI 13, 18) and 8% (95% CI 7, 10) reported taking iron-
containing supplements in the second and third trimester questionnaires respectively.
Median total iron intake from diet and supplements, as recorded in the recall, was 11.8
mg/day (IQR 8.6, 19.1). 34% (95% CI: 32, 37) of women had an iron intake
>14.8mg/day from diet and supplements. Only 11 participants reported taking iron-
only preparations in the recall, which were assumed to be the conventional
therapeutic preparation with a dose of 65 mg iron/tablet, and 5 reported taking a
preparation of iron and folic acid which contains 100 mg iron per dose. 8, 21 and 29
participants reported taking iron-only supplements in the first, second and third
trimester questionnaires respectively. Median total iron excluding these 16
participants who reported taking iron-only supplements in the recall was 11.6 mg/day
(IQR 8.5, 18.6).
3.5.3.3 Relationship between iron intake and birth weight
Dietary iron intake from food was significantly related to birth weight measured on the
customised birth centile. The unadjusted change in birth weight centile per 10 mg/day
increase in dietary iron intake during the first trimester was 5.2 centile points (95% CI
2.2, 8.2, P=0.001). Adjusting for maternal age, salivary cotinine levels and alcohol
intake attenuated this relationship (adjusted change 3.1 centile points, 95% CI -0.2,
6.3, P=0.07) (Table 6). The estimate changed little when excluding vegetarians, or
including calcium or zinc intake as interaction terms with iron intake (data not shown).
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Considering birth weight in grams as an outcome, the unadjusted difference per 10
mg/day increase in dietary iron intake was 70 g (95% CI: 10, 130, P=0.02). When
adjusting for maternal age, cotinine levels, alcohol intake, maternal weight, height,
parity, ethnicity, gestational age and baby’s sex, the difference was 34 g (95% CI: -13,
80, P=0.2).
There was no evidence of a relationship between haem iron intake and customised
birth centile. Unadjusted difference per 1 mg/day increase in haem iron intake was -
1.2 centile points (95% CI -3.3, 0.8, P=0.2). Birth weight centile was positively
associated with non-haem iron intake (unadjusted change in birth weight centile per 1
mg/day increase in non-haem iron intake 0.6, 95% CI 0.3, 0.9, P<0.0001; adjusted
change 0.3, 95% CI 0, 0.9, P=0.05).
There was a positive relationship between total iron intake, from food and
supplements, with customised birth weight centile (unadjusted change in centile
points per 10 mg/day increase in total iron intake 4.3, 95% CI 2.4, 6.3, P<0.0001,
adjusted change 2.5, 95% CI 0.4, 4.6, P=0.02) (Table 6).
3.5.3.4 Relationship between iron intake and small for gestational age
Participants with dietary iron intake equal to or less than 14.8 mg/day were 1.6 times
more likely to have a SGA baby (95% CI 1.0, 2.5, P=0.05). However, the adjusted
relationship was not significant (1.4, 95% CI 0.9, 2.3, P=0.2). This association is similar
for total iron intake from diet and supplements (Table 6).
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3.5.3.5 Relationship between iron intake and preterm birth
There was no evidence of an association between iron intake from food only, or total
iron intake from diet and supplements as recorded in the recall diary in the first
trimester, with preterm birth (Table 6).
3.5.3.6 Role of vitamin C intake
The relationship between dietary iron intake from food and customised birth weight
centile was significant in participants with vitamin C intake above the RNI of 50 mg/day
(adjusted change in centile points per 10 mg/day increase in dietary iron intake 3.7,
95% CI 0.1, 7.3, P= 0.04), compared to -1.9 percentile units (95% CI -11.1, 7.5, P=0.7)
for those with vitamin C intake ≤50 mg/day (n=253).  However, the interaction 
between iron and vitamin C intakes on the outcome was not statistically significant
(P=0.3). Similar relationships were observed for non-haem iron and total iron intake
from diet and supplements using an interaction term between iron intake and vitamin
C intake in the models (Table 6)
3.5.3.7 Relationship between intake of iron-containing supplements
and birth outcomes
There was no association between daily intake of iron-containing supplements in the
first and second trimester and customised birth centile. There was an inverse
association between taking iron-containing supplements in the third trimester (73% of
which as part of MVM preparations) and customised birth weight centile adjusted for
salivary cotinine levels, alcohol intake and maternal age (adjusted difference -10.7,
95% CI -16.7, -4.8, P <0.0001). When looking at the relationship between taking any
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iron-containing supplement (mainly as part of a MVM supplement) and preterm birth,
there was an increased risk of preterm birth if taken in the third trimester (adjusted OR
3.0, 95% CI 1.2, 7.6, P=0.02).
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Customised birth centile#
Unadjusted
change
95% CI P
Adjusted
change*
95% CI P
Dietary iron intake † 5.2 2.2, 8.2 0.001 3.1 -0.2,6.3 0.07
Dietary iron intake in participants
with vitamin C intake > 50 mg/day
†
5.3 1.9, 8.6 0.002 3.9 0.4, 7.5 0.03
Non-haem iron intake † 5.7 2.6, 8.8 <0.0001 3.4 0.0, 8.8 0.05
Non-haem iron intake in
participants
with vitamin C intake > 50 mg/day
†
5.9 2.5, 9.3 0.001 4.4 0.7, 8.0 0.02
Haem iron intake †† -1.2 -3.3, 0.8 0.2 -0.7 -2.8,1.4 0.6
Total iron intake *** † 4.3 2.4, 6.3 <0.0001 2.5 0.4, 4.6 0.02
Total iron intake *** in
participants with vitamin C intake
> 50 mg/day †
4.4 2.2, 6.5 <0.0001 3.0 0.7, 5.4 0.01
Small for gestational age (<10th centile)
Unadjusted
OR **
95% CI P Adjusted
OR*
95% CI P
Dietary iron intake (≤14.8 mg/day) 
1.6 1.0, 2.5 0.05 1.4 0.9, 2.3 0.2
Total iron intake *** (≤14.8 
mg/day)
1.5 1.0, 2.1 0.04 1.2 0.8, 1.8 0.3
Preterm birth (<37 weeks gestation)
Unadjusted
OR **
95% CI P Adjusted
OR*
95% CI P
Dietary iron intake (≤14.8 mg/day) 1.1 0.7, 2.3 0.7 1.0 0.5, 2.3 0.8
Total iron intake *** (≤14.8 
mg/day)
1.5 0.8, 2.7 0.2 1.3 0.7, 2.5 0.4
#Takes into account: maternal pre-pregnancy weight, height, parity, ethnicity, gestation and baby’s sex
*Adjusted for maternal age, salivary cotinine levels and alcohol intake in a multiple linear regression
model, with an interaction term between iron and vitamin C intakes where the estimates are reported in
the table to be for iron intake in the group with vitamin C intake >50 mg/day
**Odds ratio with dietary iron intake >14.8 mg/day as the reference group
†Percentage point change in birth weight centile per 10 mg/day increase in iron intake
†† Percentage point change in birth weight centile per 1 mg/day increase in haem iron intake
*** From food and supplements excluding therapeutic iron supplement takers (≥ 65mg/dose) 
Table 6: The Relationship between maternal dietary iron intake (mg/day) during
pregnancy and birth outcomes in the CARE study
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3.5.4 Dietary supplement intake
All 1274 participants had information on supplement intake in the first and second
trimester. 425 women had information on supplement intake in the third trimester.
The proportion of pregnant women taking any form of daily supplements was 82%,
22% and 33% for the first, second and third trimester respectively (Table 8).
Out of the women who took daily supplements in the third trimester (n=139), 94%
(n=131) also reported taking daily supplements in the first trimester of their
pregnancy, and 66% (n=91) took daily supplements in their second trimester. Only five
women, who reported taking daily supplements in the third trimester, had not taken
supplements in the first or second trimester.
3.5.4.1 Characteristics of women in supplement-taking and non-
supplement-taking groups
Women who reported taking supplements at any stage of pregnancy were more likely
to have a university degree and be vegetarian, and less likely to be smokers. They were
less likely to be living in an area with an IMD score in the most deprived quartile.
Women who reported taking daily supplements in the first and second trimester were
more likely to be primiparous. However, there was no difference between primiparous
and multiparous women in their use of supplements in the third trimester. There were
also no differences between women who reported taking daily supplements at any
stage in pregnancy with those who did not with regards to pre-pregnancy weight,
ethnic origin or history of long term illness (Table 7).
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Characteristic 1st trimester 2nd trimester 3rd trimester
Taking any daily
supplements (n)
Yes
(1043)
No
(231) P*
Yes
(274)
No
(1000) P
Yes
(139)
No
(286) P
Age of mother (years)
(m#, 95% CI**)
30
(30,31)
29
(28,29) <0.001
31
(31,32)
30
(29,30) <0.001
31
(30,32)
29
(28,30) <0.001
Pre-pregnancy weight
(kg)(m, 95% CI)
67
(66,68)
66
(65,68) 0.4
66
(65,68)
68
(67,68) 0.2
67
(64,69)
68
(66,70) 0.4
Total energy intake (kcal)
(m, 95% CI)
2148
(2103, 2193)
2019
(1921, 2117) 0.02
2167
(2075, 2258)
2113
(2068, 2158) 0.3
2095
(1983, 2205)
2214
(2118, 2311) 0.1
Smoker at 12 weeks
(%, 95% CI)
16
(14,18)
28
(21,37) <0.001
11
(7,15)
19
(17,22) 0.002
15
(10,23)
24
(19,29) 0.04
IMD*** worst quartile
(%, 95% CI)
28
(25,31)
41
(35,48) <0.001
21
(16,26)
33
(30,36) <0.001
18
(12,25)
34
(29,40) 0.002
European origin
(%, 95% CI)
94
(92,95)
92
(88,95) 0.9
95
(91,97)
93
(91,95) 0.5
96
(91,98)
96
(93,98) 0.8
University degree
(%, 95% CI)
43
(40,46)
20
(15,25) <0.001
54
(48,60)
35
(32,38) <0.001
51
(43,60)
31
(26,37) <0.001
Vegetarian
(%, 95% CI)
9
(7,11)
7
(4,12) 0.08
16
(12,21)
7
(5,9) <0.001
15
(10,22)
5
(2,9) 0.003
Primigravida
(%, 95% CI)
47
(44,50)
40
(34,47) 0.04
55
(49,61)
44
(41,47) 0.002
53
(45,62)
50
(44,56) 0.5
History of long term
illness (%, 95% CI)
13
(11,15)
10
(6,15) 0.1
13
(9,18)
13
(11,15) 0.9
15
(10,22)
16
(12,21) 0.7
Average alcohol
consumption >0.5
units/day (%, 95% CI)
28
(25,31)
20
(14,27) 0.03
28
(23,34)
27
(24,30) 0.7
27
(19,35)
25
(20,31) 0.09
Miscarriage history (%,
95% CI)
23
(21,33)
27
(21, 33) 0.3
27
(22,32)
23
(20,26) 0.2
21
(14,29)
23
(18,28) 0.8
#Mean * two-sample t-test for continuous variables, chi-squared test for categorical variables ** Confidence interval *** Index of Multiple Deprivation
Table 7: Characteristics of women by whether they have reported taking any daily supplements in the first, second and third
trimester in the CARE study (n=1274 for first & second trimesters, n=425 for third trimester)
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3.5.4.2 Type of supplements
Women reported taking 22 different types of supplements including folic acid, iron,
combined folic acid-iron preparations, MVM preparations (6 brands), evening
primrose, cod liver oil, omega 3, vitamin C, vitamin B, vitamin D, vitamin E, vitamin A,
calcium, zinc, magnesium and selenium preparations (Table 8). Folic acid was the most
frequently reported daily supplement in the first trimester. MVM supplements were
the most frequently reported daily supplements in the third trimester.
Supplement First trimester Second trimester Third trimester
Folic acid 845 51 2
Iron 8 21 29
Folic acid/iron 2 1 1
Multivitamin-mineral 293 177 79
Evening primrose 6 2 2
Cod liver oil 10 2 3
Omega 3 fish oil 11 12 9
Vitamin C 18 8 15
Vitamin B 7 0 2
Vitamin E 1 3 1
Vitamin A 0 0 1
Calcium 14 8 3
Zinc 7 1 1
Magnesium 2 0 0
Selenium 2 0 0
Table 8: Number of women taking different types of supplements during pregnancy
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3.5.4.3 Relationship between supplement taking and birth weight
Using a multiple linear regression model, taking any type of daily supplement during
the first, second or the third trimester of pregnancy was not associated with the
customised birth weight centile as a measure of birth size (adjusted change in centile
points 2.7, 95% CI -2.5, 7.8, P=0.3 for the first trimester; 3.2, 95% CI -0.9, 7.4, P=0.1 for
the second trimester and 0.5, 95% CI -6.0, 7.0, P=0.9 for the third trimester). These
estimates are based on models adjusted for cotinine levels, self-reported alcohol
intake, IMD group, having a university degree, mother being a vegetarian, history of
long-term chronic illness and past history of miscarriage.
Using birth weight in grams as an outcome, and adjusting for the above factors as well
as maternal age, height, ethnicity, pre-pregnancy weight, parity, gestational age and
baby’s sex, there was also no relationship between taking daily supplements at any
stage in pregnancy and birth weight (adjusted change 6 g , 95% CI -70, 82, P=0.9 for the
first trimester, 24 g , 95% CI -36, 83, P=0.4 for the second trimester, and -7 g , 95% CI -
106, 91, P=0.9 for the third trimester ).
When looking at taking particular types of supplements, taking a daily MVM
preparations at any stage in pregnancy was not associated with size at birth using the
continuous outcomes of birth weight in grams and customised birth weight centile, as
well as the binary outcome of SGA (adjusted OR 1.3, 95% CI 0.8, 1.9, P=0.3 for the first
trimester, 1.1, 95% CI 0.7, 1.9, P=0.7 for the second trimester, 0.9, 95% CI 0.5, 1.7,
P=0.8 for the third trimester) (Table 9). It was not associated with having a baby
weighing less than 3rd centile (adjusted OR 1.5, 95% CI 0.8, 2.7, P=0.3 for the first
trimester, 1.2, 95% CI 0.5, 2.6, P=0.7 for the second trimester, 1.6, 95% CI 0.7, 3.7,
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P=0.3 for the third trimester). There was no evidence of association observed between
maternal MVM supplement intake with having a baby weighing less than 5th centile or
more than 90th centile (data not shown).
3.5.4.4 Relationship between supplement use and preterm birth
A logistic regression model was used to examine the relationship between the risk of
preterm birth and patterns of supplement taking during pregnancy adjusting for
salivary cotinine levels, self-reported alcohol intake, vegetarian diet, ethnicity,
maternal age, baby’s sex, parity, IMD score, having a university degree, past history of
miscarriage and long-term chronic illness. Any type of daily supplement-taking during
the third trimester was associated with an increase in the risk of preterm birth
(adjusted OR=3.0, 95% CI 1.2, 7.4, P=0.02). This relationship was not statistically
significant for supplement-taking in the second trimester (adjusted OR 1.6, 95% CI 0.8,
3.2, P=0.2), and marginally significant in the first trimester though confidence intervals
were wide (adjusted OR 4.3, 95% CI 1.0, 18.2, P=0.05).
Taking MVM supplement preparations during the third trimester was also associated
with an increased risk of preterm birth (adjusted OR 3.4, 95% CI 1.2, 9.6, P=0.02). This
relationship was not statistically significant in the first or second trimester (Table 9).
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Birth weight (grams)
Daily multivitamin
supplements
1st trimester
2nd trimester
3rd trimester
Unadjusted difference
(95% CI#) P
Adjusted difference* (95%
CI) P
30.0 (-45.7, 105.7)
38.4 (-53.6, 130.5)
-29.1 (-179.9, 121.6)
0.5
0.4
0.7
16.9 (-42.3, 75.8)
29.4 (-43.0, 101.5)
-50.4 (-168.7, 67.9)
0.7
0.3
0.4
Customised birth centile##
1st trimester
2nd trimester
3rd trimester
Unadjusted difference
(95% CI) P
Adjusted difference**
(95% CI) P
3.6 (-0.2, 7.5)
5.1 (0.4, 9.7)
1.2 (-6.5, 8.8)
0.06
0.04
0.8
1.8 (-2.3, 5.9)
3.3 (-1.8, 8.3)
-2.3 (-10.3, 5.7)
0.4
0.3
0.8
Small for gestational age (<10th centile)
1st trimester
2nd trimester
3rd trimester
Unadjusted odds ratio
(OR) (95% CI)
P Adjusted OR **
(95% CI) P
1.0 (0.6, 1.4)
0.9 (0.5, 1.4)
0.7 (0.4, 1.3)
0.8
0.6
0.3
1.3 (0.8, 1.9)
1.1 (0.7, 1.9)
0.9 (0.5, 1.7)
0.3
0.7
0.8
Preterm birth (<37 weeks)
1st trimester
2nd trimester
3rd trimester
Unadjusted odds ratio
(OR) (95% CI) P
Adjusted OR ***
(95% CI) P
0.9 (0.5, 1.8)
1.0 (0.5, 2.2)
1.8 (0.8, 4.4)
0.8
0.9
0.2
1.3 (0.6, 2.7)
1.8 (0.8, 4.1)
3.4 (1.2, 9.6)
0.5
0.2
0.02
# Confidence intervals
## Takes into account: maternal pre-pregnancy weight, height, parity, ethnicity, gestation and baby’s sex
* Adjusted for gestational age, baby’s sex, maternal age, height, pre-pregnancy weight, ethnicity, parity, salivary
cotinine levels, self-reported alcohol intake, past history of miscarriage, long-term chronic illness, IMD score,
educational attainment and maternal vegetarian diet in a multiple linear regression model
** Adjusted for salivary cotinine levels, self-reported alcohol intake, past history of miscarriage, long-term chronic
illness, IMD score, educational attainment and maternal vegetarian diet in a multiple linear regression model
*** Adjusted for salivary cotinine levels, self-reported alcohol intake, maternal age, maternal vegetarian diet,
ethnicity, baby’s sex, parity, IMD score, educational attainment, past history of miscarriage and long-term chronic
illness in an unconditional logistic regression model
Table 9: The relationship between maternal multivitamin-mineral supplement use
during pregnancy and birth outcomes in the CARE study
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3.5.4.5 Sensitivity analyses
A sensitivity analysis adjusted for the clinical diagnosis of IUGR detected by ultrasound
scan during pregnancy and documented in the maternity notes, in the relationship
between taking a MVM supplement preparation and both birth weight and preterm
birth. The risk of preterm birth when taking supplements in the third trimester
(adjusted OR 3.5, 95% CI 1.2, 10.0, P=0.02) remained broadly unchanged.
To take into account the possibility that the pattern of multivitamin-mineral
supplement use is influenced by previous adverse birth outcomes, the same analysis
was performed separately by parity. In primiparous women, the adjusted OR for the
relationship between taking MVM supplement in the third trimester and preterm birth
was 5.4 (95% CI 1.3, 22.7, P=0.02). In multiparous women, the adjusted OR was 3.7
(95% CI 0.5, 29.4, P=0.2). However, numbers were small resulting in wide confidence
intervals.
3.5.5 Haemoglobin and mean corpuscular volume
558 and 572 participants had information on Hb and MCV at 12 and 28 weeks
gestation respectively. Mean Hb was 12.7 g/dl (SD 0.9 g/dl) at 12 weeks and 11.5 g/dl
(SD 1.0 g/dl) at 28 weeks. The proportion of participants with Hb <11 g/dl was 3% at 12
week and 23% at 28 weeks. Mean MCV was 90 fl (SD 5.0 fl) at 12 weeks and 89 fl (SD
5.5 fl) at 28 weeks.
3.5.5.1 Relationship between blood indices and birth outcomes
There was no relationship between customised birth centile or birth weight in grams
and Hb/MCV at 12 or 28 weeks pregnancy in this study. Hb at 28 weeks was associated
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with SGA (unadjusted OR per g/dl increase in Hb =1.4, 95% CI 1.1, 1.8, P=0.02; OR
adjusted for maternal age, salivary cotinine levels and alcohol intake 1.4, 95% CI 1, 1.8,
P=0.03). Adjusting for dietary iron intake did not alter this relationship.
3.5.5.2 Relationship between blood indices and dietary iron intake
There was no relationship between maternal Hb/MCV at 12 or 28 weeks pregnancy
with dietary iron intake in the first trimester. However, there was a positive
relationship between taking iron-containing supplements as reported in the first
trimester questionnaire and Hb at 12 and 28 weeks, and MCV at 28 weeks in
univariable analyses. The relationship remained significant for Hb at 12 and 28 weeks
after adjusting for maternal age, ethnicity, parity, educational attainment, vegetarian
diet, and IMD score in multiple linear regression model. Taking iron-containing
supplements in the second trimester was also positively associated with maternal Hb
at 28 weeks with marginal statistical significance in the multivariable model (Table 10).
116
Unadjusted
change 95% CI
# P Adjustedchange* 95% CI P value
Dietary iron intake = <14.8 mg/day in the first trimester
Hb at 12 weeks (g/dl) 0.1 -0.1, 0.3 0.2 0.09 -0.1, 0.3 0.4
Hb at 28 weeks (g/dl) -0.1 -0.3, 0.1 0.3 -0.1 -0.3, 0.1 0.4
MCV at 12 weeks (fl**) 0.2 -0.1, 1.2 0.7 0.3 -0.7, 1.3 0.6
MCV at 28 weeks (fl) -0.9 -2.0, 0.2 0.1 -0.8 -1.9, 0.3 0.2
Daily intake of iron-containing supplements in the first trimester
Hb at 12 weeks (g/dl) 0.3 0.1, 0.4 0.005 0.2 0.05, 0.4 0.01
Hb at 28 weeks (g/dl) 0.4 0.2, 0.6 <0.0001 0.3 0.2, 0.5 <0.0001
MCV at 12 weeks (fl**) 0.6 -0.4, 1.5 0.2 0.1 -0.8, 1.1 0.8
MCV at 28 weeks (fl) 1.3 0.4, 2.4 0.008 0.8 -0.2, 1.8 0.1
Daily intake of iron-containing supplements in the second trimester
Hb at 28 weeks (g/dl) 0.3 0.1, 0.6 0.002 0.2 0.0, 0.5 0.05
MCV at 28 weeks (fl) 1.5 0.4, 2.8 0.01 0.7 -0.05, 2.0 0.3
#Confidence intervals
*Adjusted for: maternal age, ethnicity, chronic illness, Index of multiple deprivation score, educational attainment,
parity and vegetarian diet in a linear regression model
Table 10: The Relationship between dietary and supplemental iron intake and
maternal blood indices (Hb and MCV) during pregnancy in the CARE study
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3.6 Discussion
3.6.1 Iron intake in pregnancy
This analysis shows a positive relationship between both total iron intake (from food
and supplements) and non-haem iron intake, derived from 24-hour dietary recall in the
first trimester of pregnancy, and birth weight. There was no association between
maternal iron intake in pregnancy and preterm birth.
3.6.1.1 Confounding
In this dataset, non-haem, rather than haem iron, was positively related to size at
birth. This raises the possibility that the observed relationship is due to residual
confounding by an unmeasured factor associated with both non-haem iron intake and
size at birth. Therefore a sensitivity analysis was carried out by excluding vegetarians
as vegetarian status may be associated with a generally healthier diet & lifestyle. This
did not change the regression estimates. It could be that participants with higher
intake of haem iron are more likely to have adverse birth outcomes due to lifestyle and
socioeconomic factors associated with high meat intake (Hulshof et al., 2003), thus
counteracting any positive effect of haem iron. However, adjusting for educational
status and IMD group did not change the results. Findings from the Motherwell cohort
study suggest that a diet high in low-quality meat might itself reduce fetal growth,
perhaps through stimulating a stress response in the mother (Herrick et al., 2003).
Adjustment for total energy intake is recommended if it is a confounder of the
relationship being examined (Willett et al., 1997). However, we did not adjust for it
here because it did not fulfil the definition of a “true” confounder. Confounding can
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result if total energy intake is associated with both the exposure of interest and the
main outcome (Pearl, 2000), which is not the case in this study as total energy intake
was not associated with birth weight (data not shown).
3.6.1.2 Effect modification
Although effect modification was not statistically significant for vitamin C, the stronger
association between iron intake and birth weight in participants whose vitamin C
intake was more than 50 mg/day is of interest, as vitamin C is the best known
enhancer of iron absorption (Gibney et al., 2004). We used a cut-off of the pregnancy
RNI of 50 mg/day for vitamin C, but the threshold where daily vitamin C intake starts to
have an effect on iron absorption in vivo is not exactly known.
3.6.1.3 Relationship of iron intake with blood indices
Hb and MCV were used as proxies for iron status to assess the extent of agreement
with iron intake levels. However, there are major limitations for the use of Hb and
MCV levels as indicators of iron status as they do not represent specific or sensitive
measures of body iron stores (Milman, 2006a). These limitations were discussed earlier
in section 2.4.1. There was no evidence of association between dietary iron intake and
Hb or MCV levels. This is not a surprising finding as these blood indices are only
affected when ID is pronounced. It is difficult to determine the direction of the
relationship between iron-containing supplements and Hb. In this analysis, it was
positive. However, anaemic participants are more likely to take iron-containing
supplements. This is supported by the stronger positive relationship between taking
iron-containing supplements in the first trimester and Hb at 28 weeks compared to
that at 12 weeks gestation.
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3.6.2 Supplement intake in pregnancy
This study has shown that taking daily MVM supplements (mostly iron-containing)
during any stage in pregnancy was not associated with birth weight. However, taking
MVM supplements, or any supplements, in the third trimester was associated with a
three-fold increase in risk of preterm birth after adjustment for smoking, alcohol
intake and other relevant maternal and socioeconomic factors. Preterm birth is a
leading cause of perinatal morbidity and mortality with a frequency of about 12-13% of
births is the US and 5-9% in many other developed countries (Goldenberg et al., 2008).
The relationship between preterm birth and any supplement intake in the third
trimester of pregnancy is likely to be driven by MVM supplements as they were the
most common supplements to be taken in the CARE cohort (Table 8). This negative
effect seems more pronounced in primiparous women. The mechanism for this is
unclear and this study’s findings need confirming by other cohorts and/or trials in high
income countries, where pregnant women are predominantly micronutrient-replete.
3.6.2.1 Confounding
Although the number of supplement-taking women in the third trimester was
considerably less than that for the first two trimesters, there was enough statistical
power with the nested case-control design to detect an OR of 3 for the preterm birth
outcome. However, this study is observational so causality cannot be inferred from the
findings. As information on iatrogenic preterm birth was not available, it is possible
that some women knew that they were at risk of preterm birth and that this
knowledge initiated physician or patient-led supplementation. However, in this study,
only 5 women who reported taking daily supplements only in the third trimester, did
120
not take supplements in the first and second trimester. None of these 5 women had a
preterm birth. This means that most women have continued taking MVM supplements
from the first or second trimester and have not stopped until the end of pregnancy.
Because this is not a RCT, there is a possibility that residual confounding may be
contributing to this apparent association. There may be unmeasured or uncontrolled
confounders resulting in the apparent negative relationship between multivitamin
supplement taking in the third trimester and preterm birth. However, most factors
known to confound this relationship were taken into account. The possibility that
supplement use may be influenced by a woman knowing that the baby is not growing
as it is expected to do is also taken into account by adjusting for the clinical diagnosis
of IUGR as extracted from the pregnancy medical notes in a sensitivity analysis.
The potential for previous poor pregnancy outcomes influencing the mother’s decision
to take supplements in subsequent pregnancies was also considered. Therefore, past
history of miscarriage was adjusted for in the main models, and a sensitivity analysis
was performed separately for primiparous and multiparous women. The hypothesis is
that women with previous adverse pregnancy outcomes would be more likely to take
supplements as well as experience adverse outcomes in their subsequent pregnancies.
This would confound the relationship between supplement-taking in the third
trimester and preterm birth. However, in contrast to this hypothesis, this relationship
was more pronounced in primiparous women. This means that the effect is not
influenced by previous birth outcomes.
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3.6.2.2 Interpretation of the observed association between maternal
multivitamin-mineral supplement intake and preterm birth
The use of MVM supplements in the CARE cohort was restricted mainly to two
pregnancy-specific brands. Both brands included folate and vitamin C exceeding the
current recommended minimum during pregnancy. One of the brands had the
additional components of B-carotene, vitamin K, selenium and iodine as well as higher
doses of vitamins E, B1, B6, B12 and zinc (at least double) compared with the other
main brand. Women in our cohort were having adequate amounts of these
micronutrients from their diet alone as assessed by the 24 hour dietary recall (Table 3).
This confirms the inverse supplement hypothesis that women who least need
supplements are most likely to take them (Conner et al., 2003).
Some observational studies report a favourable effect of periconceptional use of MVM
supplements on preterm birth and SGA (Catov et al., 2007, Catov et al., 2011). Other
studies have suggested potential adverse effects of some supplements, specifically
those containing antioxidant vitamins such as vitamins C and E, on pregnancy outcome
when taken in women with adequate dietary micronutrient intake. Smedts et al., in a
case control study of offspring with congenital heart disease, found that
periconceptional use of vitamin E supplements with high dietary intake of the same
vitamin was associated with up to nine-fold increase in the risk of congenital heart
disease (Smedts et al., 2009). Another study found that use of vitamins C and E
supplements was associated with an increased risk of premature rupture of
membranes (Spinnato Ii et al., 2008). Unfortunately, this information was not recorded
in the CARE study. In a RCT to assess the effect of vitamins E and C supplementation
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during pregnancy on the incidence of pre-eclampsia, Poston et al. found that more low
birth weight babies were born to women who took these antioxidants than to controls
(Poston et al., 2006). A recent meta-analysis of seven studies concluded that combined
vitamin C and E supplementation had no potential benefit in improvement of maternal
and neonatal outcome and increased the risk of gestational hypertension in women at
risk of pre-eclampsia (Rahimi et al., 2009).
It is well established that there are significant interactions between micronutrients and
their metabolism. It has been shown in rats, for example, that copper deficiency during
pregnancy can result in reduced iron status and vice versa, and that copper overload
induces iron overload, by interfering with the iron regulatory mechanism (Fosset et al.,
2009, Gambling et al., 2008). Others have demonstrated interactions between iron and
zinc (Kelleher and Lönnerdal, 2006). During the third trimester, fetal growth is at its
most rapid. The fetus not only needs minerals to sustain its growth, it is also a stage
when the fetal liver builds up stores for the immediate post-natal period. A reduction
in availability, by interactions between the nutrients in the maternal gut, liver or in the
placenta itself may result in adverse outcomes for the baby.
The pattern of dietary supplement use in the CARE cohort, with most women taking
supplements (mainly folic acid) in the first trimester, is expected as there is no national
recommendation in England for routine supplement-taking during pregnancy apart
from folic acid in the first trimester and vitamin D for pregnant women in “high-risk”
groups (National Institute for Clinical Excellence (NICE), 2008). There is no national
recommendation to take MVM supplements at any stage during pregnancy. However,
they are readily available over-the-counter and are heavily promoted to expectant
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mothers. Health value and susceptibility to illness are major predictors of supplement
use by women, with dietary supplements acting as an insurance against possible ill
health (Conner et al., 2001).
3.6.3 Strengths and limitations of the study
3.6.3.1 Study sample
This was a large prospective cohort study. Although a RCT is the gold standard study
design to investigate causality, this design would be difficult to execute especially
when the exposure is dietary intake. The response rate to take part in the study was
30% out of all the women who were invited. The percentage of LBW babies (<2500 g)
in this study (4.4%) was less than the National UK (7.2%) and the Yorkshire & Humber
region average (7.8%) for 2007 (Office for National Statistics). This raises the possibility
that women who are more likely to have LBW babies were less likely to participate in
this study.
3.6.3.2 Outcome measures
Customised birth weight centile, which takes into account gestational age, maternal
height, weight, ethnicity and parity, and neonatal birth weight and sex was used in this
chapter’s analyses. However, it does not take into account paternal height, which has
been shown to be related to birth weight (Morrison et al., 1991, Nahum and Stanislaw,
2003).
3.6.3.3 Exposure measures
Dietary iron intake was ascertained using 24-hour dietary recall recorded by a midwife-
administered interview at around 12 weeks gestation. This method has been validated,
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and found to be comparable to other dietary assessment methods such as FFQs and
food diaries in estimating iron intake (Bingham et al., 1997). However, the 24-hour
recall has its limitations such as failure to recall diet accurately and the chance of
consuming non-typical diet during the day prior to the assessment. Whilst the study
has a large sample size and hence good probable estimates of mean daily intake, these
may be more widely dispersed than in reality due to the use of this dietary assessment
method. It therefore may over-estimate the proportion of mothers with extremely
high or low iron intakes, for example the proportion with daily iron intake <UK LRNI
(24% in our sample). However, there is evidence, when validating 24-hour recalls
against other methods of dietary assessment, that recall is prone to over-reporting low
intakes and under-reporting high intakes (Gersovitz et al., 1978). The estimation of
haem iron intake may have been subject to greater error than the estimation of non-
haem intake, given that it constitutes a smaller proportion of total dietary iron.
The use of supplements was recorded both in the 24-hour recall and the interviewer-
administered and self-reported questionnaires. The extent of agreement was high
between the two methods in this study for reporting iron-containing supplements
intake, however there is potential for measurement error using both methods. It is
unlikely that women with adverse outcomes would have reported their supplement-
use pattern or dietary intake differently to other women since it is a prospective study,
therefore reducing the chance of differential bias. The supplements reported in the
recall, rather than the questionnaire, were used to add up to the dietary iron in order
to derive the total iron intake variable as they were both reported in the same recall
i.e. came from the same source, hence less chance of reporting bias.
125
Lastly, iron intake is used in this study as a proxy for maternal iron status in pregnancy.
Absorption of iron is influenced by several factors including the individual’s iron status
as discussed earlier in section 2.2. Therefore, maternal iron status in early pregnancy
was assessed using biomarkers including sF and sTfR to investigate its association with
birth outcomes in chapter 4 of this thesis.
3.6.4 Implications for research and practice
3.6.4.1 Iron intake in pregnancy
Further research is needed to explore the role of vitamin C intake in the relationship
between dietary and supplementary iron intake and birth outcomes. A RCT of high
dietary iron intake combined with vitamin C at mealtimes during early pregnancy can
provide some important insights, as there are problems with just relying on
supplement intake, as pointed out in this chapter, and earlier in sections 2.2.8.2 and
2.2.8.3. Public health messages about increasing iron intake during early pregnancy
and ways to optimise its absorption need to be promoted.
3.6.4.2 Multivitamin-mineral intake in pregnancy
Most previous trials and observational studies in developed country settings have
looked at the effect of taking multivitamin supplementation in early pregnancy on
maternal and birth outcomes. More research is needed into the effect of taking MVM
supplements in late pregnancy on birth outcomes in relatively well-nourished
populations. Larger cohort studies are required to examine this association in detail
and to validate the findings of this study. Results from our cohort also suggest that a
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trial, in a high income country setting, is needed to weigh the possible benefits and
harms of policies recommending supplementation or restriction of supplementation.
The study findings suggest that clinicians and midwives should be cautious when
recommending over-the-counter MVM supplements to women in their late pregnancy.
As in any clinical situation, they should weigh the potential risks and benefits when
considering prescribing such supplements during late pregnancy. The type of
supplement recommended or prescribed should be more focussed on the specific
vitamin or mineral deficiency the woman has. Although the negative relationship
between MVM in the third trimester and preterm birth needs to be investigated
further, this study did not show any positive effect on birth weight and gestational age
when these supplements are taken in any stage in pregnancy.
Conclusive evidence is provided solely for periconceptional folate supplementation in
the prevention of neural tube defects. A Lancet review in 2005 recommended 16
interventions to improve neonatal survival, out of which two were supplementation
programmes: folic acid to reduce neural tube defects incidence and calcium to reduce
pre-eclampsia and eclampsia incidence (Darmstadt et al., 2005). MVM supplements
may be beneficial in women with poor nutrition and multiple micronutrient
deficiencies. Adverse effects seen in some studies associated with MVM
supplementation may be due to the detrimental effects of certain components such as
vitamins C and E, and/or to the interaction between the multiple ingredients of the
preparation. In summary, there is much less evidence on the need for
supplementation in general during pregnancy in high income compared to low income
countries.
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3.7 Conclusion
In this chapter, a positive association between total iron intake from food and
supplements in the first trimester of pregnancy and customised birth weight centile
was demonstrated. This association was stronger in the high vitamin C intake group,
however effect modification was not significant. Although iron intake from food alone
was not significantly associated with birth weight after adjustment, intake of non-
haem iron was more strongly associated with birth weight than haem iron. Iron intake
during the first trimester of pregnancy, both from diet and supplements, was higher in
vegetarians and women with better socioeconomic profile.
In this study, the use of MVM supplement preparations during the third trimester in
pregnancy was associated with an increased risk of preterm delivery, and was not
associated with birth weight or SGA at any stage in pregnancy. These findings suggest
that, at least in micronutrient-replete mothers, caution must be exercised when
recommending MVM supplements in late pregnancy. This is an observational
prospective study offering weaker causal evidence than a RCT. However, in the
absence of a trial in a developed country setting, this study makes a useful
contribution to the research evidence in this area. The findings generate a concern
regarding multivitamin supplement use in late pregnancy that needs to be investigated
by other studies.
In the next chapter, I extend the investigation commenced in this chapter by
measuring iron status in pregnant mothers using sensitive and specific biomarkers, and
including a measure of the vascular system of the baby, arterial stiffness, as an
outcome, in addition to size at birth and preterm delivery.
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4 Associations of maternal iron status in
early pregnancy with birth outcomes and
infant arterial stiffness: the Baby VIP study
In chapter 3, I investigated the association of maternal iron intake with size at birth
and preterm delivery. In this chapter, I move a step forward by measuring iron status
in mothers early in pregnancy and investigate its association with the same outcomes
assessed in chapter 3 plus an additional innovative outcome measuring arterial
stiffness in the infant: PWV.
The results presented in this chapter have been submitted as a peer-reviewed article
for publication. This work has also formed the basis of three conference presentations
(one already presented and two accepted abstracts).
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4.1 Chapter summary
This chapter aims to examine the association between maternal iron status during the
first trimester of pregnancy, and infant brachio-femoral PWV (bfPWV) at 2-6 weeks of
age. Data from the Baby VIP study were used. This is a historical birth cohort that
recruited 362 babies and their mothers after hospital delivery in Leeds, UK. sF and sTfR
were measured in maternal samples previously obtained in the first trimester of
pregnancy. Maternal Hb, birth weight, gestational age and other covariables used to
derive customised birth weight centile were extracted from the medical records.
Baby’s bfPWV was measured during a home visit at 2-6 weeks.
The cohort included 33 (9%) preterm (<37 weeks gestation) and 64 (18%) SGA infants.
Out of 348 pregnant women with information on sF in the first trimester, 79 (23%) had
iron depletion (<15 ug/l). Prevalence of anaemia at ≤20 weeks (<11 g/dl) and >20 
weeks gestation (<10.5 g/dl) was 5% (16/329) and 14% (48/337) respectively. Mean
infant bfPWV was 6.7 m/s (SD=1.3, n=284). Maternal iron depletion in the first
trimester was associated with a higher risk of a SGA baby (adjusted OR 2.2, 95% CI 1.1,
4.1). However, this relationship was attenuated when including early pregnancy Hb in
the model (adjusted OR 1.6, 95% CI 0.8, 3.2). For every 1g/dl increase in maternal Hb
level in the first half of pregnancy the risk of SGA was reduced by 30% (adjusted 95% CI
0-40%), with levels <11 g/dl associated with a 3-fold increase in the risk of SGA (95%
1.0, 9.0). There was no evidence of association between maternal iron status and
preterm birth or gestational age.
Maternal anaemia at ≤20 weeks gestation was associated with a 1.0 m/s increase in 
infant PWV (adjusted 95% CI 0.1, 1.9, P=0.02). There was no evidence of association
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between infant bfPWV and maternal sF analysed as a continuous variable (adjusted
change in PWV in m/s per 10 ug/l change in sF = 0.02, 95% CI -0.01, 0.1, P=0.3), nor
with maternal iron depletion (adjusted change in PWV in m/s = -0.2, 95% CI -0.6, 0.2,
P=0.3). No evidence of association was observed between maternal sTfR or log R/F
ratio with infant PWV.
In this chapter, depleted iron stores in early pregnancy were found to be associated
with higher risk of having a SGA baby. However, this relationship seems to be
mediated by maternal Hb levels. Increased arterial stiffness in the first few weeks of
life was associated with maternal anaemia in the first half of pregnancy, but not with
ID in the first trimester.
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4.2 Background
The previous evidence on the association of maternal ID in pregnancy with birth
outcomes was explored in sections 2.2.4 and 2.2.5. There are very few studies which
have assessed iron status in the mother early in pregnancy and using multiple
biomarkers, including sF and sTfR, in addition to Hb. Ferritin is the most widely used
biomarker in the assessment of iron status in the general population. In women, levels
under 15 ug/l indicate depleted iron stores (WHO, 2011). However, it is affected by
inflammatory conditions and therefore may not be specific to distinguishing ID.
Measuring STfR may provide more specific information, and it has the advantage over
sF is that it can distinguish IDA from anaemia of chronic inflammation, as well as
identify iron depletion and functional ID in patients with concurrent inflammation
(Allen et al., 1998). The R/F ratio is considered the gold standard marker of iron status
(Zimmermann, 2008), and has been used to assess iron status in pregnant populations
such as the United States National Health and Nutrition Examination Survey (Mei et al.,
2011). The advantages and disadvantages of these biomarkers have been explored
further earlier in this thesis (section 2.4).
The clinical significance of arterial stiffness and its measurement method used in this
chapter, PWV, was also explored in detail earlier in section 2.5.1. Few studies have
examined the relationship between maternal nutritional exposures and arterial
stiffness in the offspring (Larnkjaer et al., 2006, Gale et al., 2007, Kinra et al., 2008). So
far, there have been no comparable studies published that have assessed the
relationship between indicators of maternal nutritional status during pregnancy and
neonatal or infant arterial stiffness.
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4.3 Hypothesis and objectives
It is hypothesised that infants of women with ID in early pregnancy have less
favourable cardiovascular risk profile indicated in this study by lower birth weight and
stiffer arteries, expressed as increased PWV.
The objectives of this chapter are:
1. Examine the relationship of maternal iron status at the end of the first
trimester of pregnancy with offspring’s arterial stiffness measured by brachio-
femoral PWV (bfPWV) within the first few weeks of life (2-6 weeks of age)
2. Examine the relationship of maternal iron status at the end of the first
trimester of pregnancy with birth weight and preterm birth
3. Examine the relationship of birth weight/SGA and gestational age/preterm
birth with offspring’s arterial stiffness measured by bfPWV within the first few
weeks of life (2-6 weeks of age)
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4.4 Methods
4.4.1 Study design
Baby VIP study is a retrospective cohort study. The cohort comprises women aged 18
years or over who have given live birth at the Leeds Teaching Hospitals Trust Maternity
Unit at a gestational age of 34 weeks or over in the period between February 2012 to
January 2013. The participants were recruited from the postnatal wards of Leeds
General Infirmary and St James’s University Hospital after delivery. Upon consenting to
taking part in the study, mothers were asked permission to access theirs’ and their
babies’ medical notes from which clinical information relating to pregnancy and birth
was extracted. They were also asked if the research team could contact them after
they were discharged home to arrange a home visit within 6 weeks. The home visit
was made by a research nurse after an appointment was arranged with the mother
over the phone. During the visit, the nurse obtained mothers’ consent for their babies
to have PWV measured on them, and went on to perform the measurements as
described below. Figure 8 illustrates the Baby VIP study participant flowchart.
Appendices 10.3.1 and 10.3.2 include the study’s consent forms and participant
information sheet.
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Figure 8: Baby VIP study participant flowchart
4.4.2 Exposure measurement
Maternal serum samples previously stored during the first trimester of pregnancy as
part of routine antenatal care were analysed. sF was measured using ELISA
(Demedeitic, Kiel, Germany) following the manufacturer’s instructions. Briefly, 10 ul of
plasma was treated in a sandwich ELISA method, using fluoremetric measurements
and calibrated using standards supplied by the manufacturer. Quality controls were
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included as appropriate. Data are expressed in ug/l. The WHO cut-off of 15 ug/l in sF
was used to indicate depleted iron stores (WHO, 2011). STfR assays were performed
using a commercially available kit based on a polyclonal antibody in a sandwich
enzyme immunoassay (EIA) format (DTFR1; R&D Systems, Minneapolis, MN). This
yielded sTfR levels in nmol/l units. The values were converted to ug/l using a molecular
weight of sTfR of 75000 daltons (R&D technical data sheet). The R/F ratio was obtained
by dividing sTfR over sF (ug/l: ug/l). This was logged to obtain a normal distribution.
In the UK, Hb is measured routinely in pregnancy at around 12 and 28 weeks gestation.
Maternal Hb values were extracted from the antenatal care records and/or the
hospital electronic results server. A cut-off of 11 g/dl in Hb was used to indicate
anaemia at 20 weeks gestation or less, and 10.5 g/dl to indicate anaemia beyond 20
weeks gestation, following the NICE guidelines (National Institute for Clinical
Excellence (NICE), 2008).
4.4.3 Outcome measurement
4.4.3.1 Pulse wave velocity
Brachio-femoral PWV was measured using the Vicorder device (Skidmore Medical),
which uses an oscillometric technique to measure PWV (Figure 9). This kit provides a
non-invasive and minimally-intrusive method of measuring PWV, and is thought to be
less time consuming and less dependent on operator skills (van Leeuwen-Segarceanu
et al., 2010). A standard operating procedure was developed and followed for each
measurement (Appendix 10.3.3). Two infant-size cuffs were attached to the device.
The arm cuff was wrapped around the bare skin of the baby’s arm, with the mid cuff
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(marked) being halfway between the shoulder and the elbow. The leg cuff was
wrapped around the bare skin of the baby’s ipsilateral thigh with the mid cuff point
(marked) being halfway between the groin and the knee. Using a tape measure, the
distance was measured in centimetres between the midpoint of the arm cuff to the
midpoint of the left cuff in a straight line while keeping the baby’s ipsilateral thigh
straight, with the tape kept on the internal side of the arm alongside the trunk, not
externally over the elbow and forearm. The pressure applied was 35 mmHg for both
the arm and the leg. The pulse recording at the two arterial sites (brachial and femoral)
was obtained simultaneously. Transit time was measured as the time delay between
the feet of the proximal and the distal pulse waves. A minimum of two PWV readings
was obtained from each baby. If they were more than 0.3 m/s different, a third reading
was obtained. The average of all available readings for each baby was derived and
used in the analyses. The baby’s age and position at the time of PWV measurement
(sleeping, feeding, lying down or in mother’s arms) was recorded and taken into
account in all the statistical models.
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Figure 9: Vicorder kit (Skidmore Medical)
4.4.3.2 Size at birth
Birth weight in grams and gestational age in days were extracted from the medical
notes. Customised birth weight centile was calculated using charts that take into
account gestational age, maternal height, weight, ethnicity, parity, and neonatal sex
(Gardosi, 2004). SGA was defined as less than the 10th centile. Duration of gestation
was calculated from the date of the last menstrual period, and confirmed by
ultrasound scans dating at around 12 and 20 weeks gestation. Preterm birth was
defined as delivery at less than 37 weeks (259 days) gestation.
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4.4.4 Covariable assessment
A basic demographic and lifestyle questionnaire was administered to the mother by
the research team at the time of recruitment. IMD was derived from each participant’s
postcode using the GeoConvert tool utilising the 2001 UK census data
(geoconvert.mimas.ac.uk). Parity, maternal height, weight, ethnicity, smoking,
pregnancy complications (pre-eclampsia, GDM), BP measurements and intake of iron
supplements were extracted from the mother and the baby’s clinical records.
4.4.5 Statistical methods
Statistical analysis was performed using Stata version 11 (College Station, TX, 2009).
Univariable analysis was performed using the independent samples t-test, one-way
analysis of variance or Mann-Whitney test for continuous variables, and the chi-
squared test for categorical variables. Multivariable linear regression was performed
with PWV, customised birth weight centile, SGA, gestational age and preterm birth as
outcomes, and indicators of maternal iron status including maternal sF, sTfR, Hb and
R/F as predictors. When the outcome was PWV, the models were adjusted for baby
covariables at birth (customised birth weight centile) and at measurement (age,
position, measurement side and type of feeding), and maternal covariables including
age, smoking status, the presence of GDM or pre-eclampsia, systolic and diastolic BP at
booking and 36 weeks gestation, and IMD deprivation score. When the outcomes were
birth weight centile/SGA, the models were adjusted for maternal age, smoking status,
the presence of GDM or pre-eclampsia, and IMD deprivation score. When the
outcomes were gestational age/preterm birth, the models were adjusted for maternal
age, ethnicity, parity, pre-pregnancy BMI, smoking status, the presence of GDM or pre-
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eclampsia, and IMD deprivation score. In all models, sensitivity analyses were
performed taking into account the intake of iron supplements during pregnancy.
When examining the association between infant PWV and birth weight centile or SGA,
multivariable models were adjusted for maternal factors including smoking, pre-
eclampsia, GDM, systolic and diastolic BP at booking and 36 weeks, IMD deprivation
score, and infant factors including type of feeding, baby’s age, position and whether
asleep or awake at the time of measurement.
4.4.6 Sample size calculation
For a difference of 0.3 m/s in neonatal aortic PWV between iron-deficient and non-iron
deficient mothers, using a mean of 4.7 m/s, a SD of 0.6 m/s (Koudsi et al., 2007), and a
prevalence of ID of 20% (Bergmann et al., 2002, Beard, 1994), a sample size of 265
mother-baby pairs was required to achieve a 90% power with P=0.05.
4.4.7 Ethical approval
Ethical approval was obtained from the South Yorkshire Research Ethics Committee of
the NHS National Research Ethics Service (Reference number 11/YH/0064). All
procedures were in accordance with the Helsinki Declaration of 1975 as revised in
1983. Mothers provided their written informed consent for themselves and their
children to participate in this study.
4.4.8 Funding
The work included in this chapter was supported by the Wellcome Trust [Grant
number WT87789 to N.A.A.] and the Scottish Government Rural and Environmental
Services (RESAS) for the laboratory analysis of samples undertaken at the Rowett
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Research Institute, University of Aberdeen, UK. The funders had no influence on the
design or analysis of the study.
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4.5 Results
4.5.1 Sample characteristics
In total, 362 women living in Leeds, UK and surrounding area were recruited for this
study. 288 (80%) were of white ethnic origin. Mean maternal age was 31 years (SD 6),
and mean maternal pre-pregnancy BMI was 26 kg/m2 (SD 6). 47 women delivered by
elective caesarean section (13%), and 68 (19%) by emergency section. 173 women
were primiparous (40%). The average BP at booking was 112/67 mmHg, and at 36
weeks gestation 116/71 mmHg. 192 women said they never smoked (54%), compared
to 49 (14%) smokers and 113 (32%) ex-smokers. 6 (2%) women had pre-eclampsia
during pregnancy and a similar number had GDM. Half of the babies born to
participants were male. 123 (43%) of those who were followed up at home were
reported to be exclusively breast-fed, 110 (39%) bottle-fed and 53 (19%) received
mixed breast and bottle feeding.
4.5.1.1 Infant pulse wave velocity
The total number of babies with PWV measurements performed at home was 284, out
of a total of 362 mother-baby pairs recruited in hospital (79%). Out of these, 248 (87%)
had a third measurement taken because the first two measurements differed by more
than 0.3 m/s. Mean infant bfPWV was 6.7 m/s (SD 1.3). Mean baby age at the time of
PWV measurement was 25 days (SD 6). 48 babies (16%) were asleep at the time of
measurement.
Baby being asleep was, on average, associated with 0.9 m/s reduction in infant bfPWV
(95% CI 1.3, 0.5, P<0.0001). The baby’s feeding in his/her mother’s arms at the time of
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measurement was, on average, associated with a 0.7 m/s increase in infant bfPWV
(95% CI 0.3, 1.0, P<0.0001), compared to being held in mother’s arms without being
fed. On the other hand, lying in a cot, on a sofa or on the floor at the time of PWV
measurement was associated with a 0.4 m/s reduction in bfPWV (95% CI 0.1, 0.8,
P=0.03) compared to being held in mother’s arms without being fed. Baby’s age at the
time of PWV measurement, type of feeding (breast/bottle/mixed), and side of
measurement (left or right arm and leg) were not associated with bfPWV in this study.
Table 11 describes infant PWV in relation to measurement conditions and baby
characteristics.
Mothers of infants who were followed up at home were likely to be older, primiparous
and have taken multivitamin supplements during pregnancy compared to those whose
infants did not have PWV measurements because a home visit was not possible to
arrange or the mother decline the visit. Otherwise, there were no significant
differences in baseline characteristics of the two groups.
Table 12 compares the characteristics of participants with PWV measurements (n=284)
and those who were not followed up with a home visit (n=78).
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Infant brachio-femoral pulse wave velocity (m/s)
n Mean SD P
Sleeping status <0.001*
asleep 48 5.9 1.1
awake 239 6.8 1.3
Position during
measurement
<0.001**
In mother's arms 121 6.5 1.3
Feeding in mother's arms 101 7.2 1.2
In cot / on sofa or floor 61 6.1 1.1
Measurement side 0.2*
Right 98 6.8 1.4
Left 181 6.6 1.2
Baby's age 0.7*
<28 days 206 6.6 1.3
≥28 days 77 6.7 1.4  
Type of feeding 0.06**
Breast 122 6.9 1.4
Bottled 109 6.5 1.3
Mixed 53 6.4 1.2
*Independent samples t-test
*** One-way analysis of variance
Table 11: Infant brachio-femoral pulse wave velocity (m/s) in relation to
measurement conditions and infant characteristics in the Baby VIP study.
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With PWV measurements N With no PWV measurements N P#
Gestational age (days) (mean, sd*) 277 (14) 284 276 (14) 78 0.5
Birth weight (grams) (mean, sd) 3339 (636) 284 3293 (621) 78 0.6
Maternal age at antenatal booking (years) (mean, sd) 31.1 (5.5) 284 28.6 (6.0) 78 0.0007
Maternal body mass index at antenatal booking (Kg/m2) (mean, sd) 26.5 (6.1) 281 25.3 (4.9) 77 0.1
Index of multiple deprivation (IMD) (mean, sd) 28.6 (19.1) 284 32.7 (19.6) 78 0.1
Maternal haemoglobin at ≤20 weeks gestation (g/dl) (mean, sd) 12.6 (1.0) 263 12.4 (1.2) 66 0.1
Maternal haemoglobin at >20 weeks gestation (g/dl) (mean, sd) 11.6 (1.0) 266 11.4 (1.1) 71 0.2
First trimester maternal serum ferritin (sF) (ug/l) (median, IQR**) 33.4 (17.4, 61.6) 273 28.6 (13.1, 68.7) 75 0.5
First trimester maternal serum transferrin receptor (sTfR) (nmol/l) (median, IQR) 13.1 (10.4, 16.1) 273 12.3 (10.1, 16.1) 75 0.6
First trimester maternal sF/STfR ratio (ug/l) (median, IQR) 27.5 (15.3, 61.9) 273 32.0 (14.0, 72.9) 75 0.6
Primiparous (n, %, 95% CI***) 144, 51 (45, 57) 284 29, 37 (27, 49) 78 0.03
Male baby (n, %, 95% CI) 137, 48 (42, 54) 284 45, 58 (47, 69) 78 0.1
Maternal White ethnicity (n, %, 95% CI) 220, 78 (72, 82) 284 68, 87 (78, 94) 78 0.1
Maternal smoking at antenatal booking (n, %, 95% CI) 36, 13 (9, 18) 278 13, 17 (9, 28) 76 0.5
Gestational diabetes (n, %, 95% CI) 5, 2 (1, 4) 284 1, 1 (0, 7) 78 0.1
Pre-eclampsia (n, %, 95% CI) 3, 1.1 (0, 3) 284 3, 3.9 (1.0, 11) 78 0.1
Anaemia at ≤20 weeks gestation (<11 g/dl) (n, %, 95% CI) 10, 4 (2, 7) 263 6, 9 (3, 19) 66 0.1
Anaemia at >20 weeks gestation (<10.5 g/dl) (n, %, 95% CI) 35,13 (9, 2) 266 13, 18 (10, 29) 71 0.3
Taken iron supplements in pregnancy (n, %, 95% CI) 92, 32 (27, 38) 284 29, 38 (27,49) 77 0.4
Taken multivitamin supplements in pregnancy (n, %, 95% CI) 157, 55 (49, 61) 284 32, 42 (30, 53) 77 0.03
*Standard deviation **Inter quartile range ***Confidence interval
# Independent samples t-test or Mann-Whitney test for continuous variables, and chi-square test for categorical variables
Table 12: Characteristics of Baby VIP study participants (n=362) by whether babies were followed-up by a home visits to measure pulse
wave velocity (PWV)
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4.5.1.2 Birth outcomes
In this study sample (n=362), mean birth weight was 3329 grams (SD 632), with 40
(11%) babies weighing less than 2500 grams. 358 women had information to derive
customised birth weight centile. Mean customised birth weight centile was 41 (SD 29),
with 64 (18%) babies weighing less than the 10th centile (SGA), and 29 (8%) babies
weighing less than the 3rd centile. 20 (6%) babies weighed more than the 90th centile,
of those, only 1 (5%) was born to a mother with GDM. Mean gestational age was 277
days (SD 14) i.e. 39.6 weeks. 33 (9%) babies were born preterm (between 34 and 37
weeks gestation).
Women with SGA babies were more likely to smoke, have lower early pregnancy Hb,
be anaemic at ≤20 weeks gestation, be iron depleted in the first trimester (sF<15 ug/l) 
and have suffered from pre-eclampsia during pregnancy, compared to women with
AGA babies. SGA babies were more likely to be born preterm (<37 weeks gestation),
and to have lower bfPWV compared to AGA babies. Table 13 describes the
characteristics of participants whose babies were born SGA compared to those with
AGA babies.
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SGAα N AGAαα N P#
Gestational age (days) (mean, sd*) 270 (15) 64 279 (13) 294 <0.0001
Birth weight (grams) (mean, sd) 2499 (446) 64 3510 (516) 294 <0.0001
Maternal age at antenatal booking (years) (mean, sd) 30.4 (6.0) 64 30.5 (5.7) 294 0.8
Maternal body mass index at antenatal booking (Kg/m2) (mean, sd) 25.7 (5.8) 64 26.3 (5.8) 294 0.4
Index of multiple deprivation (IMD) (mean, sd) 30.6 (19.2) 64 29.2 (19.8) 294 0.6
Maternal haemoglobin at ≤20 weeks gestation (g/dl) (mean, sd) 12.3 (1.1) 54 12.7 (1.0) 272 0.02
Maternal haemoglobin at >20 weeks gestation (g/dl) (mean, sd) 11.6 (1.1) 55 11.6 (1.0) 279 0.9
First trimester maternal serum ferritin (sF) (ug/l) (median, IQR**) 33.5 (12.4, 52.5) 58 30.7 (17.9, 65.7) 286 0.8
First trimester maternal serum transferrin receptor (sTfR) (nmol/l) (median, IQR) 13.6 (10.0, 17.9) 58 12.5 (10.3, 16.0) 286 0.1
First trimester maternal sF/STfR ratio (ug/l) (median, IQR) 38.1 (16.4, 101.2) 58 28.0 (14.4, 61.2) 286 0.6
Infant brachio-femoral pulse wave velocity (m/s) (mean, sd) 6.3 (1.1) 48 6.7 (1.3) 233 0.04
Primiparous (n, %, 95% CI***) 26, 41 (29, 54) 64 145, 49 (44, 55) 294 0.2
Male baby (n, %, 95% CI) 29, 45 (33, 58) 64 151, 51 (46, 57) 294 0.4
Preterm birth (<37 weeks gestation) 12, 19 (10,31) 64 21, 7 (5, 11) 294 0.004
Maternal White ethnicity (n, %, 95% CI) 48, 75 (63, 85) 64 237, 81 (76, 85) 294 0.3
Maternal smoking at antenatal booking (n, %, 95% CI) 13, 22 (13, 35) 58 36, 12 (9, 17) 292 0.04
Gestational diabetes (n, %, 95% CI) 2, 3 (0, 11) 62 4, 1 (0, 3) 294 0.3
Pre-eclampsia (n, %, 95% CI) 3, 5 (1, 13) 64 3, 1 (0, 3) 294 0.04
Anaemia at ≤20 weeks gestation (<11 g/dl) (n, %, 95% CI) 6, 11 (4, 23) 54 10, 4 (2, 7) 272 0.02
Anaemia at >20 weeks gestation (<10.5 g/dl) (n, %, 95% CI) 8,15 (6, 27) 55 40, 14 (10, 19) 279 0.9
Taken iron supplements in pregnancy (n, %, 95% CI) 20, 31 (20, 44) 64 100, 34 (29, 40) 293 0.7
Taken multivitamin supplements in pregnancy (n, %, 95% CI) 30, 47 (34, 60) 64 156, 53 (47, 59) 293 0.4
* Standard deviation  **Inter quartile range  ***Confidence interval α Small for gestational age (<10
th
 birth weight centile) αα Appropriate for gestational age (≥ 10
th
birth weight centile) # Independent samples t-test or Mann-Whitney test for continuous variables, and chi-square test for categorical variables
Table 13: Characteristics of Baby VIP study participants (n=362) by size at birth
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4.5.1.3 Biomarkers of maternal iron status
The first trimester serum samples of 348 mothers were accessed and analysed for sF
and sTfR. Median sF was 13.7 ug/l (Interquartile range [IQR] 16.9, 62.4). 79 women
(23%) had depleted iron stores by the end of the first trimester with sF <15 ug/l, and
278 women (80%) had sF levels < 70 ug/l. Median sTfR was 12.8 nmol/l (IQR 10.2,
16.1). According to the assay manufacturer (DTFR1; R&D Systems, Minneapolis, MN),
the 2.5th - 97.5th percentile range of the reference distribution of sTfR concentration is
0.85 to 3.05 mg/l (n = 1,000) (Punnonen et al., 1997). In our pregnant study population
(n=348), the range between the 2.5th and 97.5th percentiles was 0.6 to 2.0 mg/l after
conversion to equivalent units. Median R/F was 28.4 ug/l (IQR 14.6, 65.4).
Mean maternal Hb was 12.6 g/dl and 11.6 g/dl (SD 1.0) in the first and second halves of
pregnancy respectively. The prevalence of anaemia at ≤20 weeks (<11 g/dl) and >20 
weeks gestation (<10.5 g/dl) was 5% (16/329) and 14% (48/337) respectively. Only half
of anaemic women in the first half (n=8), and 45% of anaemic women in the second
half of pregnancy (n=22), had a first trimester sF of less than 15 ug/l. However, 14
(89%) of anaemic women in the first half of pregnancy and 43 (90%) of anaemic
women in the second half of pregnancy had sF of less than 70 ug/l.
4.5.1.4 Iron supplements
121 women (34%) took iron supplements at some stage during pregnancy. 8 (2%)
started taking them in the first trimester, compared to 67 (18.6%) in the second
trimester, and 46 (13%) in the third trimester. Out of those with iron depletion in the
first trimester (sF<15 ug/l), only 46 (58%) had iron supplements during their
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pregnancy, compared to 13 (81%) of anaemic women in the first half of pregnancy,
and 40 (83%) of anaemic women in the second half of pregnancy.
4.5.2 Regression models
4.5.2.1 Maternal iron status and infant pulse wave velocity models
There was no evidence of association between infant bfPWV and maternal sF analysed
as a continuous variable (adjusted change in PWV in m/s per 10 ug/l change in sF 0.02,
95% CI -0.01, 0.1, P=0.3), nor with maternal iron depletion (adjusted change in PWV in
m/s -0.2, 95% CI -0.6, 0.2, P=0.3). No evidence of association was observed between
maternal sTfR and log R/F with infant bfPWV. However, mothers who were anaemic in
the first half of pregnancy (Hb<11 g/dl) had infants with higher PWV by 1.0 m/s on
average (95% CI 0.1, 1.9, P=0.2) (Table 14). All the multivariable models adjusted for
baby's age, PWV measurement circumstances (position, sleep, side, feeding), maternal
age, smoking, GDM, pre-eclampsia, BP at booking and 36 weeks gestation, area
deprivation score, and customised birth weight centile.
No association was observed between maternal intake of iron supplements at any
stage in pregnancy and infant bfPWV (unadjusted change -0.1, 95% CI -0.5, 0.2).
Adjusting for iron supplement intake in sensitivity analyses did not alter the results of
the models examining the association between biomarkers of maternal iron status (sF,
sTfR and R/F) with infant bfPWV. However, adjusting for maternal iron supplement
intake strengthened the association between maternal anaemia in the first half of
pregnancy and infant PWV. On average, there was 1.2 m/s increase in infant PWV if
maternal Hb before 20 weeks gestation was less than 11 g/dl (95% CI 0.3, 2.1).
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Predictor
Change in infant brachio-femoral pulse wave velocity (m/s)
Unadjusted 95% CI* P Adjusted** Adjusted 95%
CI
P n (multivariable
model)
Maternal serum ferritin (sF) at 12 weeks gest (per
10 ug/l change)
0.02 -0.01, 0.1 0.2 0.02 -0.01, 0.1 0.3 261
Maternal iron depletion at 12 w gest (sF<15 ug/l) -0.2 -0.5, 0.3 0.4 -0.2 -0.6, 0.2 0.3 261
Maternal serum transferrin receptor (sTfR) at 12
weeks gestation (nmol/l)
0.03 -0.004, 0.1 0.1 0 -0.01, 0.04 0.3 261
Maternal log R/F# ratio at 12 weeks gestation
(ug/l)
0 -0.1, 0.1 0.9 0 -0.2, 0.1 0.5 261
Maternal haemoglobin (Hb) at ≤20 weeks 
gestation (g/dl)
0.1 -0.1, 0.3 0.3 0.1 -0.1, 0.2 0.6 253
Maternal Hb at >20 weeks gestation (g/dl) 0.2 -0.001, 0.3 0.05 0.2 -0.004, 0.3 0.06 256
Maternal anaemia at ≤20 weeks gestation (<11 
g/dl)
0.7 -0.1, 1.6 0.08 1.0 0.1, 1.9 0.02 253
Maternal anaemia at >20 weeks gestation (<10.5
g/dl)
-0.1 -0.5, 0.4 0.8 0.01 -0.5, 0.5 0.9 256
* Adjusted for baby's age, PWV measurement circumstances (position, feeding, asleep or awake, side), maternal age, smoking, gestational diabetes, pre-eclampsia, blood
pressure at booking and 36 weeks gest, deprivation score and customised birth weight centile (takes into account maternal pre-pregnancy weight, height, ethnicity, parity,
gestational age and baby's sex)
Table 14: Associations of infant brachio-femoral pulse wave velocity at 2-6 weeks (m/s) with indicators of iron status during pregnancy in
the Baby VIP study
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4.5.2.2 Maternal iron status and birth weight centile/SGA models
There was no evidence of association between maternal sF, sTfR, log R/F with birth
weight centile. In univariable analysis, maternal anaemia in early pregnancy was
associated with reduction of 15 centile points in birth weight (95% CI 1, 29, P=0.04).
However, this association was attenuated when adjusting for maternal age, smoking,
GDM, pre-eclampsia and IMD (adjusted change= -11 centile points, 95% CI -25, 3,
P=0.1) (Table 15).
Maternal iron depletion in the first trimester (sF <15 ug/l) was associated with a higher
risk of a SGA baby (adjusted OR 2.2, 95% CI 1.1, 4.1, P=0.02). Adjusting for maternal
iron supplement intake in a sensitivity analysis did not alter this association (adjusted
OR 2.3, 95% CI 1.2, 4.5, P=0.02). However, this relationship was attenuated when
including early pregnancy Hb in the model (adjusted OR 1.6, 95% CI 0.8, 3.2, P=0.2). For
every 1g/dl increase in maternal Hb level in the first half of pregnancy the risk of SGA
was reduced by 30% (adjusted 95% CI 0-40%, P=0.03), with levels <11 g/dl associated
with 3-fold increase in the risk of SGA (95% 1.0, 9.0, P=0.05) (Table 16). Maternal sTfR
was also associated with SGA in the multivariable model adjusting for maternal age,
smoking, GDM, pre-eclampsia and IMD (adjusted OR 1.1 for every 1 nmol/l increase in
sTfR, 95% CI 1.0,1.1, P=0.04).
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Predictor
Change in birth weight centile#
Unadjusted 95% CI* P Adjusted** Adjusted 95%
CI
P n (multivariable
model)
Maternal serum ferritin (sF) at 12 weeks gest (per
10 ug/l change)
-0.1 -1.0, 0.6 0.9 0.1 -0.6, 0.7 0.9 341
Maternal iron depletion at 12 w gest (sF<15 ug/l) -4.2 -11.3, 2.3 0.3 -4.6 -11.7, 2.5 0.2 341
Maternal serum transferrin receptor (sTfR) at 12
weeks gestation (nmol/l)
-0.2 -0.7, 0.4 0.5 -0.3 -0.8, 0.3 0.3 341
Maternal log R/F ratio at 12 weeks gestation (ug/l) -0.8 -3.4, 1.7 0.5 -1.2 -3.8, 1.3 0.3 341
Maternal haemoglobin (Hb) at ≤20 weeks 
gestation (g/dl)
1.4 -1.7, 4.5 0.4 1.0 -2.0, 4.1 0.6 326
Maternal Hb at >20 weeks gestation (g/dl) -0.8 -3.7, 2.2 0.6 -1.2 -4.4, 1.4 0.3 334
Maternal anaemia at ≤20 weeks gestation (<11 
g/dl)
-15.0 -29.2, -1.0 0.04 -11.2 -25.4, 3.1 0.1 326
Maternal anaemia at >20 weeks gestation (<10.5
g/dl)
-4.5 -13.1, 4.2 0.3 -1.4 -10.1, 7.3 0.8 334
*Confidence interval
** Adjusted for maternal age, smoking, gestational diabetes, pre-eclampsia, and area deprivation score (IMD)
# Customised birth weight centile (takes into account maternal pre-pregnancy weight, height, ethnicity, parity, gestational age and baby's sex)
Table 15: Associations of customised birth weight centile with indicators of iron status during pregnancy in the Baby VIP study
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Predictor
Odd ratio of SGA#
Unadjusted 95% CI* P Adjusted** Adjusted 95%
CI
P n (multivariable
model)
Maternal serum ferritin (sF) at 12 weeks gest (ug/l) 1.0 0.9, 1.0 0.8 1.0 0.9, 1.0 0.7 341
Maternal iron depletion at 12 w gest (sF<15 ug/l) 2.0 1.1, 3.7 0.02 2.2 1.1, 4.1 0.02 341
Maternal serum transferrin receptor (sTfR) at 12
weeks gestation (nmol/l)
1.0 1.0, 1.1 0.1 1.1 1.0, 1.1 0.04 341
Maternal log R/F ratio at 12 weeks gestation (ug/l) 1.1 0.9, 1.4 0.3 1.2 0.9, 1.5 0.1 341
Maternal haemoglobin (Hb) at ≤20 weeks 
gestation (g/dl)
0.7 0.6, 1.0 0.03 0.7 0.6, 1.0 0.03 326
Maternal Hb at >20 weeks gestation (g/dl) 1.0 0.7, 1.3 0.9 1.1 0.8, 1.4 0.7 334
Maternal anaemia at ≤20 weeks gestation (<11 
g/dl)
3.3 1.1, 9.4 0.03 3.0 1.0, 9.0 0.05 326
Maternal anaemia at >20 weeks gestation (<10.5
g/dl)
1.0 0.5, 2.3 0.9 0.8 0.4, 2.0 0.7 334
*Confidence interval
** Adjusted for maternal age, smoking, gestational diabetes, pre-eclampsia, and area deprivation score (IMD)
# <10th customised birth weight centile (takes into account maternal pre-pregnancy weight, height, ethnicity, parity, gestational age and baby's sex)
Table 16: Associations of being born small for gestational age with indicators of iron status during pregnancy in the Baby VIP study
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4.5.2.3 Maternal iron status and gestational age/preterm birth models
There was no evidence of association between maternal iron status measured by sF,
sTfR or log R/F with preterm birth or gestational age. However, there was an
association observed between early pregnancy maternal Hb and gestational age in
univariable analysis. For every 1 g/dl increase in early pregnancy Hb, there was an
increase in gestational age by 2 days (95% CI 0.2, 3.0, P=0.03). This association was
attenuated in the multivariable model adjusting for maternal age, ethnicity, parity,
pre-pregnancy BMI, smoking, GDM, pre-eclampsia and IMD score. Mothers who were
anaemic in the first half of pregnancy had on average a gestation shorter by 7 days
(adjusted 95% CI 0, 14, P=0.05) compared to non-anaemic mothers. Association
estimates are listed in Table 17 and Table 18.
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Predictor
Change in gestational age (days)#
Unadjusted 95% CI* P Adjusted** Adjusted 95%
CI
P n (multivariable
model)
Maternal serum ferritin (sF) at 12 weeks gest (per
10 ug/l change)
0.1 -0.2, 0.4 0.6 -0.2 -0.4, 0.2 0.6 341
Maternal iron depletion at 12 w gest (sF<15 ug/l) 0.3 -3.4,4.0 0.9 0.02 -3.4, 3.4 0.9 341
Maternal serum transferrin receptor (sTfR) at 12
weeks gestation (nmol/l)
-0.1 -0.2, 0.2 0.5 -0.1 -0.3, 0.2 0.5 341
Maternal log R/F ratio at 12 weeks gestation (ug/l) -0.6 -1.8, 0.6 0.3 0.01 -1.2, 1.3 0.9 341
Maternal haemoglobin (Hb) at ≤20 weeks 
gestation (g/dl)
1.6 0.2, 3.0 0.03 1.1 -0.4, 2.6 0.1 326
Maternal Hb at >20 weeks gestation (g/dl) 0.1 -1.3, 1.5 0.9 -0.5 -1.9, 0.9 0.5 334
Maternal anaemia at ≤20 weeks gestation (<11 
g/dl)
-9.1 -15.8, -2.4 0.008 -6.8 -13.6, 0.1 0.05 326
Maternal anaemia at >20 weeks gestation (<10.5
g/dl)
1.6 -2.4, 5.6 0.4 3.7 -0.4, 7.8 0.07 334
*Confidence interval
** Adjusted for maternal age, pre=pregnancy body mass index, ethnicity, parity, smoking, gestational diabetes, pre-eclampsia, and area deprivation score (IMD)
Table 17: Associations of gestational age with indicators of iron status during pregnancy in the Baby VIP study
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Predictor
OR of preterm birth (<37 weeks gestation)
Unadjusted 95% CI* P Adjusted** Adjusted 95%
CI
P n (multivariable
model)
Maternal serum ferritin (sF) at 12 weeks gest (ug/l) 1.0 0.9, 1.0 0.6 1.0 0.9, 1.0 0.6 341
Maternal iron depletion at 12 w gest (sF<15 ug/l) 1.6 0.7, 3.7 0.3 1.5 0.6, 3.8 0.4 341
Maternal serum transferrin receptor (sTfR) at 12
weeks gestation (nmol/l)
1.0 1.0, 1.1 0.5 1.0 1.0, 1.1 0.5 341
Maternal log R/F ratio at 12 weeks gestation (ug/l) 1.1 0.8, 1.4 0.8 1.0 0.7, 1.5 0.8 341
Maternal haemoglobin (Hb) at ≤20 weeks 
gestation (g/dl)
0.8 0.6, 1.1 0.2 0.9 0.6, 1.4 0.7 326
Maternal Hb at >20 weeks gestation (g/dl) 1.2 0.8, 1.7 0.5 1.3 0.9, 1.9 0.2 334
Maternal anaemia at ≤20 weeks gestation (<11 
g/dl)
2.6 0.7, 9.5 0.2 1.3 0.3, 6.2 0.8 326
Maternal anaemia at >20 weeks gestation (<10.5
g/dl)
0.4 0.1, 1,9 0.3 0.2 0.04, 1.0 0.05 334
*Confidence interval
** Adjusted for maternal age, pre=pregnancy body mass index, ethnicity, parity, smoking, gestational diabetes, pre-eclampsia, and area deprivation score (IMD)
Table 18: Associations of being born preterm with indicators of iron status during pregnancy in the Baby VIP study
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4.5.2.4 Infant pulse wave velocity and birth outcomes models
Infant bfPWV was inversely associated with SGA in a multivariable model that adjusted
for baby's age, PWV measurement circumstances (position, sleep, side, feeding),
maternal age, smoking, GDM, pre-eclampsia, BP at booking and 36 weeks gestation,
and IMD score (adjusted change -0.5 m/s, 95% CI -1.0, -0.1, P=0.01). However, there
was less evidence of this association for very SGA babies (<3rd birth weight centile).
There was no evidence that infant PWV was associated with birth weight centile,
gestational age or preterm birth (Table 19).
Change in infant brachio-femoral pulse wave velocity (m/s)
Unadjusted 95% CI* P Adjusted** Adjusted
95% CI
P
Birth weight centile#
(per 10 points centile increase)
0.04 -0.01, 0.1 0.1 0.1 -0.01, 0.1 0.08
Small for gestational age## -0.4 -0.9, 0 0.04 -0.5 -1.0, -0.1 0.01
Very small for gestational age### -0.4 -0.9, 0.2 0.2 -0.4 -1.0, 0.2 0.2
Gestational age
(per 10 days)
0.1 (-0.1, 0.2) 0.4 0.01 -0.1, 0.1 0.8
Preterm birth
(<37 weeks gestation)
-0.5 -1.1, 0.1 0.1 -0.3 -0.9, 0.4 0.4
*Confidence interval
** Adjusted for baby's age, PWV measurement circumstances (position, sleep, side, feeding), maternal
age, smoking, gestational diabetes, pre-eclampsia, blood pressure at booking and 36 weeks gestation,
and deprivation score in case of birth weight centile and SGA as predictors, plus maternal parity,
ethnicity and pre-pregnancy BMI in case of gestational age and preterm birth as predictors
# Takes into account maternal pre-pregnancy weight, height, ethnicity, parity, gestational age and
baby's sex
##<10th birth weight centile ### <3rd birth weight centile
Table 19: Associations of infant brachio-femoral pulse wave velocity with size at birth
and gestational age in the Baby VIP study (n=267)
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4.6 Discussion
PWV, a potential marker of cardiovascular health later in life, was ascertained in 284
babies aged 2-6 weeks at home in the Baby VIP study. There was no evidence of
association between maternal iron status biomarkers in early pregnancy and infant
PWV. However, maternal anaemia in the first half of pregnancy was associated with
increased infant PWV, which indicates stiffer arteries. Maternal iron depletion in early
pregnancy was associated with higher risk of SGA birth. This relationship seems to be
mediated by early pregnancy maternal Hb, which was independently inversely
associated with SGA.
4.6.1 Strengths and limitations
4.6.1.1 Exposure measures
This study assessed the exposure of interest prospectively, as the maternal serum
samples were collected in the first trimester of pregnancy. Information on maternal Hb
and iron supplements was ascertained objectively from the medical records, rather
than by self-reporting. The best available measure, which utilised the ferritin and
transferrin receptor biomarkers in a ratio that relates directly to total body iron stores,
was used to assess maternal iron status (Zimmermann, 2008). A study set out to
determine the diagnostic value of R/F ratio to determine body iron stores against bone
marrow aspirate examination showed that R/F ratio had the best diagnostic efficiency
with the sensitivity of 81% and a specificity of 97%. SF alone, with a cut-off of 60 ug/l,
had the same specificity but lower sensitivity (76%) (Ruivard et al., 2000).
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Deriving body iron stores estimates from R/F ratio is limited by the current availability
of several commercial assays that yield different sTfR values. The calculation formula
provided by Cook et al. used to deduct body iron stores values can only be used if sTfR
assay commutability is established. Unfortunately, this is not the case in our study. It
was not possible to convert values generated by the R&D assay into values that would
be appropriate for the Cook formula which used another assay to measure sTfR (Cook,
2003). There is a pressing need to calibrate sTfR assays against international reference
standards to provide comparability across studies.
4.6.1.2 Outcome measures
Birth weight was ascertained objectively from the medical birth records. Gestational
age was calculated using information from a dating ultrasound scan at the end of the
first trimester of pregnancy and extracted from the medical records. Therefore, these
two outcome measures were not subject to measurement bias.
PWV, a new and innovative measure of cardiovascular health in neonates and young
infants, was assessed in this study on a relatively large study population compared to
other studies that have assessed PWV in this age group (Alhashemi et al., 2013,Koudsi
et al., 2007). A potential source of error in measuring PWV in peripheral arteries is the
use of the nearest superficial arterial site as a surrogate for inaccessible central
arteries (Cheung, 2010). In this case, the brachial artery was used as a surrogate for the
carotid. The study team have tried, at the pilot stage of Baby VIP, to measure carotid-
femoral PWV, but have found that wrapping a cuff around the baby’s neck caused
distress to parents.
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The estimation of the actual distance between the recording sites using surface
measurements is another potential source of error. The shorter the distance, the -
greater the absolute error in determining transit time (Laurent et al., 2006). However,
the PWV data spread in this study, as reflected by the standard deviation, corresponds
well with most other studies that measured PWV. Also any errors in measuring the
distance between the arterial sites would be non-differential in terms of the exposure
of interest (iron status) as the researcher who performed the measurements was blind
to it. Confounders such as the baby being asleep or awake or position during the time
of the measurement are known to potentially affect the PWV reading (Laurent et al.,
2006). Therefore, these were adjusted for in all the statistical models.
Despite these limitations, PWV remains the most widely used technique for
assessment of arterial stiffness (Cheung, 2010), and in babies, it causes less distress
than measuring BP. It is difficult to compare studies using different measures used to
assess arterial stiffness including PWV, central pressure and augmentation index. PWV
is a direct measure while the other two are indirect surrogate measures but they
provide additional information about wave reflection (Laurent et al., 2006).
4.6.2 Interpretation of results
4.6.2.1 Maternal iron status and infant pulse wave velocity
The elastic properties of the conduit arteries vary along the arterial tree; with more
elastic proximal arteries and stiffer distal arteries. The amplitude of the pressure wave
is higher in peripheral arteries than in central arteries. This is called the ‘amplification
phenomenon’ (Laurent et al., 2006). Also, in younger subject the central arteries are
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usually more elastic than the peripheral arteries (Laurent et al., 2006). This may explain
the relatively higher PWV average that we got in our study (6.7 m/s) compared to the
average in the other study which measured aortic PWV in infants (4.7 m/s) (Koudsi et
al., 2007, Alhashemi et al., 2013). The mean brachio-ankle PWV in children with a
mean age of 14 years is 10 m/s (Niboshi et al., 2006, Im et al., 2007). In adults, average
brachio-ankle PWV was approximately 20% higher than carotid-femoral PWV (Tanaka
et al., 2009). Given this, it is inaccurate to use brachial pressure as a surrogate for
aortic or carotid pulse pressure, particularly in young subjects. Therefore, an
association between maternal iron status in pregnancy and central arterial stiffness in
babies cannot be excluded on the basis of this study.
There is very little research on the ability of PWV measured very early in life to predict
later cardiovascular health. Although we did not find an association with maternal iron
status early in pregnancy, this does not exclude the possibility that maternal iron
status, as measured by R/F ratio, may be linked to offspring cardiovascular indicators
in adulthood. To investigate this relationship, long term follow up of a birth cohort
with information on maternal iron status in pregnancy is required.
In this study, there was an association between maternal anaemia early in pregnancy
and infant arterial stiffness. Anaemia could reflect the extreme of the ID spectrum, and
thus this association would support the hypothesis that ID early in pregnancy is linked
to cardiovascular risk in the offspring. However, only about half of anaemic women in
the study had ferritin values less than 15 ug/l. Analysis in chapter 5 from ALSPAC found
no association between early pregnancy maternal Hb (<18 weeks gestation) and
offspring PWV at 10 years of age (Alwan et al., 2014). In this chapter, this observed
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association could be an expression of a true effect of early pregnancy maternal
anaemia on arterial function in the baby, which may subside later in life. Alternatively,
it could be due to residual confounding as other causes of poor health in the mother
are likely to be associated with both the predictor and outcome.
4.6.2.2 Measures of maternal iron status and birth outcomes (birth
weight and gestational age)
4.6.2.2.1 Maternal anaemia/Hb levels
In this study, anaemia in the first half of pregnancy was associated with a higher risk of
having a baby who is SGA, and every 1 g/dl increase in early pregnancy maternal Hb
was associated with a 30% reduction in the risk of SGA. This result supports the
previous evidence of association between early maternal Hb and anaemia with the risk
of LBW reviewed in section 2.2.4 of this thesis. Maternal Hb in the second half of
pregnancy was not associated with SGA in Baby VIP , while in the analysis presented in
chapter 3 of pregnant women participating in the CARE study, there was a 40%
increase in the risk of SGA with every I g/dl increase in maternal Hb at 28 weeks
gestation. The latter analysis was, however, performed on a bigger sample, so a type II
error due to insufficient sample size in the Baby VIP sample is a possibility.
There was no evidence of association between the incidence of preterm birth and
early pregnancy maternal Hb or anaemia in this study contrary to the findings of
previous studies (Scanlon et al., 2000, Scholl et al., 1992). However, maternal anaemia
in the first half of pregnancy was marginally associated with a reduction in gestational
age when analysed as a continuous outcome, while maternal anaemia in the second
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half of pregnancy was marginally associated with a reduction in the risk of preterm
birth.
The evidence available in the literature of the association between maternal anaemia
and birth outcomes suggests that it is U-shaped (Rasmussen, 2001). Causes of adverse
birth outcomes may differ at the two extremes of the maternal Hb range. While low
Hb in early pregnancy may reflect ID or other nutritional deficiencies such as vitamin B
or folic acid, high Hb values later in pregnancy may reflect inadequate expansion of
plasma volume. Rasmussen suggests that this U-shaped association is spurious due to
the design of research evidence available, as it is more apparent in studies that use
“lowest Hb” than in those that control for the stage of gestation or include data only
from women very early in pregnancy, when changes in plasma volume are minimal
(Rasmussen, 2001, Scanlon et al., 2000, Zhou et al., 1998).
4.6.2.2.2 Maternal ferritin and transferrin receptor levels
Participants in this study who were iron depleted at the beginning of pregnancy were
twice as likely to have SGA babies. Maternal sTfR level measured in the first trimester
of pregnancy, which increases in ID, was also marginally associated with higher risk of
SGA. These results are in line with findings from previous studies (Ribot et al., 2012).
The relationship between maternal iron depletion in the first trimester and SGA was
tested for mediation by maternal Hb, as it was an independent predictor of SGA.
Including maternal Hb in the model attenuated the relationship between maternal iron
depletion and SGA. This may point to the possibility that the mechanism through
which inadequate body iron could potentially result in small size at birth is through the
efficiency of carrying oxygen to the placenta which is reduced by a reduction in
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maternal Hb. IDA increases oxidative stress levels in the liver, heart, kidney and
placenta as well as resulting in hypoxia and inflammation in placenta (Allen, 2001).
4.6.2.3 Infant pulse wave velocity and size at birth
In this study, SGA (<10th birth weight centile) was associated with 0.5 m/s lower infant
PWV on average, while no association was observed in those who were born very SGA
(<3rd birth weight centile). The evidence linking size at birth with PWV later in life was
discussed earlier in section 2.5.1.3 of this thesis. There is some evidence that newborn
arterial stiffness, measured by ultrasound and pulse BP measurement techniques, is
associated with very SGA (section 2.5.1.5). Cheung et al. found that among 8 year old
children who were born preterm, only those with IUGR had increased brachio-radial
PWV (Cheung et al., 2004). Also, using pulse pressure measurement (distensibility
coefficient and whole body arterial compliance by ultrasound recording or aortic pulse
pressure), increased arterial stiffness was observed as early as the fifth day of life in
very low gestational age infants, and persisted at least until the 7th week of life (Tauzin
et al., 2006). Sehgal et al. calculated arterial wall stiffness index and found an increase
with very SGA (<3rd centile) (Sehgal et al., 2014). Akira et al. found decreased arterial
distensibility in SGA (<5th centile) infants using the stiffness index, however, this index
also increased with gestational age at birth (Akira and Yoshiyuki, 2006).
The association observed between SGA and lower PWV is surprising. However, before
interpreting it as contradictory to previous evidence of association and the mechanical
basis for this relationship, there are a few considerations. First, It is cannot be assumed
that PWV at this early age predicts PWV later in life, as there is no evidence to support
such an assumption. Therefore, lower PWV in infancy does not necessarily mean more
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favourable arterial stiffness profile in adulthood. Secondly, the observed association
disappeared when examining it in very SGA babies, who are more likely to be small due
to IUGR. Thirdly, the method of measuring PWV is relevant as the evidence of
association between SGA and increased PWV comes from studies that have used
different methods to assess arterial stiffness in newborns. The mechanism of
association between LBW and increased arterial stiffness in childhood and adulthood
remains unclear. One potential mechanism is altered synthesis of elastin in the arterial
wall, while another is endothelial dysfunction in preterm and SGA babies leading to
functional alterations in arterial tone (Cheung, 2010). Therefore, this relationship may
not be apparent when using structural methods to assess arterial stiffness such as
PWV.
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4.7 Conclusion
To my knowledge, no previous studies have measured PWV in the first weeks of life to
examine its association with maternal iron status in pregnancy. Also, this is the largest
population study published to date which assessed PWV as a measure of arterial
stiffness in infants. There was no evidence of association detected between maternal
iron status early in pregnancy and bfPWV in babies aged 2-6 weeks. This study
demonstrates that infant arterial stiffness can be feasibly assessed using non-invasive
techniques of measuring PWV in population studies. Further research is needed to
validate PWV measured early in life as a potential indicator of cardiovascular risk later
in life and to investigate the relationship between biomarkers of maternal nutritional
status during pregnancy and PWV in the child and adult offspring using prospective
study design. This would help inform the understanding of potential pathways
underlying the developmental origins of CVD.
In the next chapter, I move one step further in the life course and investigate the
association of PWV and other cardiovascular indicators measured in 10 year old
children in the ALSPAC cohort with indicators of maternal iron status including Hb and
iron intake from diet and supplements.
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5 Associations of maternal iron intake and
haemoglobin in pregnancy with offspring
vascular phenotypes and adiposity at age
10 in the ALSPAC study
In chapters 3 and 4 I have explored the relationship between maternal iron intake and
status during pregnancy and short-term offspring outcomes at birth and in infancy.
Following on from that, this chapter evaluates these relationships with more long-term
outcomes through analysis of data from the ALSPAC cohort. This includes offspring
indicators of cardiovascular risk measured at age 10.
Work from this chapter has formed the basis of a peer-reviewed paper (Alwan et al.,
2014) and a conference presentation.
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5.1 Chapter summary
The aim of this chapter is to examine the relationship between maternal pregnancy
dietary and supplement iron intake and Hb, with offspring’s arterial stiffness measured
by carotid-radial PWV, endothelial function measured by brachial artery flow mediated
dilatation (FMD), BP, and adiposity (measured by BMI), test for mediation by cord
ferritin, birth weight, gestational age, and child dietary iron intake, and for effect
modification by maternal vitamin C intake and offspring sex.
Prospective data from 2958 mothers and children pairs at 10 years of age enrolled in
an English birth cohort, the ALSPAC study in Bristol, was analysed. In this cohort, 2639
(89%) mothers reported dietary iron intake in pregnancy below the UK reference RNI
of 14.8 mg/day. 1328 (45%) reported taking iron supplements, and 129 (4%) were
anaemic by 18 weeks gestation. No evidence of association was observed in this
analysis between indicators of maternal iron status including dietary iron intake in
pregnancy and maternal Hb concentration (which is less likely to be biased by
subjective reporting) and markers of cardiovascular risk in the offspring, apart from a
modest association between taking iron supplements in pregnancy with lower
offspring systolic BP at 10 years (-0.8 mmHg, 99% CI -1.7 to 0, P=0.01 in the sample
with all relevant data observed, and -0.7 mmHg, 99% CI -1.3 to 0, P=0.008 in the
sample with missing data imputed).
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5.2 Background
5.2.1 Previous studies
Although evidence from animal models suggests that maternal ID during pregnancy
can result in the development of obesity and hypertension in the offspring (Gambling
et al., 2003b, Gambling et al., 2003a, Crowe et al., 1995, Gambling et al., 2004b),
evidence in humans regarding the effect of maternal ID on cardiovascular risk
indicators in childhood remains inconclusive. Few studies have investigated the
association of indicators of maternal iron status in pregnancy and BP in childhood.
These are referred to briefly here, and their findings discussed earlier in section 2.3.3
of this thesis.
In a previous analysis of data from the same birth cohort analysed here, the ALSPAC
cohort, Brion et al. reported an association between maternal anaemia and BP at 7
years only in women who did not take iron supplements during pregnancy (Brion et al.,
2008). In another study, Belfort et al, with a sample size of 1167 pregnant American
women, there was no association between first and second trimester maternal
anaemia with offspring BP at 3 years. However, offspring BP was positively associated
with first trimester iron intake, in contrast to animal studies findings (Gambling et al.,
2003b, Gambling et al., 2003a, Crowe et al., 1995, Gambling et al., 2004b), while no
relationship was observed for second trimester iron intake (Belfort et al., 2008). Other
studies examining the association between maternal anaemia in pregnancy and
offspring childhood BP reported conflicting findings ranging from positive to negative,
and including null associations (Whincup et al., 1994, Bergel et al., 2000, Law et al.,
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1991, Godfrey et al., 1994). The characteristics of these studies are summarised in
Table 2.
5.2.2 Mediation in the relationship between iron intake in
pregnancy and offspring cardiovascular health
It has been shown in animal studies that offspring outcomes such as birth weight are
dependent on mother’s iron status and not that of the neonate (Gambling et al., 2002).
However, umbilical cord ferritin is strongly associated with maternal iron status
(Agarwal et al., 1983, Kaneshige, 1981, Singla et al., 1996). There is also evidence of an
association between cord ferritin levels and health outcomes such as mental and
psychomotor development in children (Tamura et al., 2002). Therefore, cord ferritin
could be a potential mediator in the relationships between maternal iron measures in
pregnancy and offspring cardiovascular risk outcomes.
Other potential mediators include child’s dietary iron intake, child’s birth weight, and
gestational age. As noted above, maternal iron levels in pregnancy are related to lower
birth weight and preterm delivery; birth weight and gestational age are in turn
inversely associated with CVD (Barker, 2004). Maternal diet is related to child’s diet
(Brion et al., 2010), and therefore it is likely that maternal iron intake in general,
including during pregnancy, will be related to offspring dietary iron intake and this in
turn may influence the child’s vascular phenotypes and hence mediate the association.
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5.2.3 Effect modification in the relationship between iron intake
in pregnancy and offspring cardiovascular health
Animal studies suggest that the inverse association of maternal iron status with later
offspring cardiovascular outcomes differs by offspring sex, being stronger in males
(Gambling et al., 2003b, Lisle et al., 2003). Furthermore, since vitamin C is a key
enhancer of iron absorption (Gibney et al., 2004, Collings et al., 2013), the relationship
between maternal iron intake and perinatal or longer term outcomes may be stronger
with adequate intake of vitamin C, as has been presented in chapter 3 of this thesis
(Alwan et al., 2011). Therefore, both offspring sex and maternal vitamin C intake in
pregnancy were considered as potential effect modifiers in the relationships under
investigation.
5.2.4 Vascular markers in the offspring
Prediction of CVD morbidity and mortality can be realized through studying endothelial
function and arterial stiffness in adults. FMD of the arm arteries is the most common
technique to measure endothelium-dependent vasodilator function. The technique
measures the ability of the arteries to respond with endothelial nitric oxide release
during reactive hyperaemia (flow mediated) after a 5-minute occlusion of the brachial
artery with a BP cuff (Flammer et al., 2012). It is diminished in patients with
atherosclerosis and with coronary risk factors, and improves with risk-reduction
therapy (Moens et al., 2005). There is evidence that endothelial function is prognostic
of cardiovascular risk (Halcox et al., 2009, Halcox et al., 2002). Endothelial dysfunction
in children, measured by brachial artery FMD, has also been linked to LBW (Leeson et
al., 1997).
171
PWV, a measure of arterial stiffness, measures the time taken for the systolic pressure
wave to travel a known distance. It is considered a convenient, precise, reliable, and
integrated index of vascular pathology over the lifecourse (Cruickshank et al., 2009). It
has been widely used as a predictor of CVD in adults (Weber et al., 2008, Jadhav and
Kadam, 2005), and is associated with higher CVD mortality, coronary heart disease,
and stroke (Vlachopoulos et al., 2010, Sutton-Tyrrell et al., 2005). The use of PWV as a
lifecourse marker in investigating the developmental origins of disease has been
explored earlier in this thesis in section 2.5.1.
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5.3 Hypothesis and objectives
It is hypothesised that women with adequate iron intake and those who are not
anaemic during pregnancy have, on average, children with healthier cardiovascular risk
profile.
This chapter builds on the work of Brion et al. utilising ALSPAC data (Brion et al., 2008)
using offspring‘s BP at a later age than the previous analysis, and utilising other
indicators of offspring cardiovascular health as outcomes including PWV, FMD and
BMI, all measured at around 10 years of age.
The objectives of this study are:
1. Examine the associations between indicators of maternal iron status in
pregnancy (maternal iron intake and Hb concentrations) and indicators of
child’s circulatory health (BP, adiposity as assessed by BMI, endothelial
function as assessed by brachial artery FMD, and arterial stiffness as assessed
by carotid-radial PWV).
2. Examine whether any observed associations were mediated by cord blood
ferritin levels, gestational age, offspring’s birth weight, and dietary iron intake
3. Explore whether offspring sex and maternal vitamin C intake moderate any of
these associations as effect modifiers.
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5.4 Methods
5.4.1 Study design and participants
ALSPAC is a longitudinal population-based birth cohort study investigating influences
on health and development across the life course, which recruited pregnant women
between 1990 and 1992 and followed-up their children (n=14541) in the South West
region of England (Fraser et al., 2012, Boyd et al., 2013). All pregnant women resident
in a defined area (the Bristol area) were eligible for recruitment. The women who have
been recruited and have not dropped-out of the study, have completed up to 20
questionnaires, and have had detailed data abstracted from their medical records, plus
a detailed biobank of stored DNA, serum and plasma. Follow-up for the children
included 59 questionnaires and 9 clinical assessment visits to date. The study website
contains details of all the available data through a fully searchable data dictionary
(www.bris.ac.uk/alspac/researchers/data-access/data-dictionary).
Figure 10 shows participants flow-chart for the complete case analysis performed for
this study.
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Figure 10: ALSPAC participant flowchart for the study samples used to investigate the
associations of maternal iron and offspring vascular phenotypes
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5.4.2 Exposure assessment
5.4.2.1 Maternal dietary iron intake
Iron intake from food was assessed using a FFQ sent to mothers at 32 weeks gestation
covering all the main foods consumed in Britain. Mothers were asked how often they were
currently consuming each of 43 food groups (Rogers and Emmett, 1998). The questionnaire
administered to mothers including the food frequency questions can be retrieved from the
ALSPAC study website (www.bristol.ac.uk/alspac/researchers/resources-available/data-
details/questionnaires). Intakes for a range of nutrients, including iron, were derived using
nutrient information on standard-sized portions based on the 5th edition of McCance and
Widdowson’s Composition of Food tables (Holland et al., 1991). The FFQ was used to
calculate an approximate daily nutrient intake for each woman by multiplying the weekly
frequency of consumption of a food by the nutrient content. The nutrient values obtained
were then divided by seven to convert this to a daily intake including energy, protein, total
fat, saturates, monounsaturates and polyunsaturates, total sugar, non-milk extrinsic sugar,
dietary fibre, nine vitamins and five minerals (Rogers and Emmett, 1998).
5.4.2.2 Maternal iron supplements intake
Maternal iron supplement use was obtained from questionnaires sent at 18 weeks
gestation (relating to anytime during pregnancy before the questionnaire date), and 32
weeks gestation (relating to 3 months of pregnancy between the first and second
questionnaire). Mothers were asked whether they had taken iron supplements, vitamins, or
any other supplements. In a separate question, women were also asked to list all pills,
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medicines, and ointments they used, with a reminder to include iron tablets, vitamins,
herbal medicines, etc. Responses at 18 and 32 weeks regarding iron supplements were
combined to generate a binary variable (yes/no) for ‘iron supplement used anytime during
pregnancy up to 32 weeks gestation’.
5.4.2.3 Maternal haemoglobin
Maternal Hb concentrations were extracted from antenatal medical records of study
participants as it was measured routinely in all pregnant women. An ‘Early pregnancy
haemoglobin’ variable was derived, defined as the first measurement of Hb before 18
weeks. A mother was classified as having ‘early pregnancy anaemia’ if her Hb measurement
was less than 11 g/dl, the threshold used to define pregnancy anaemia according to WHO
guidelines (WHO, 2001).
5.4.3 Outcome assessment
BP, PWV, FMD and BMI were measured in child clinics at ages 10-11 years by six trained
research technicians/fieldworkers over a two year study period (Donald et al., 2010).
Carotid-radial pulse wave velocity was measured transcutaneously using a high-fidelity
micromanometer (SPC-301, Millar Instruments, Houston, TX, USA). Integral software
processed the data to calculate the mean time difference between R-wave and pressure
wave on a beat-to-beat basis over 10 seconds, and the PWV was then calculated using the
mean time difference and arterial path length between the two recording points
(SphygmoCor version 7.1, Scanmed, UK) (Donald et al., 2010).
177
The right brachial artery was imaged, 5–10 cm above the antecubital fossa, using high-
resolution ultrasound (ALOKA 5500) with the probe held in a stereotactic clamp that
allowed micrometre positional adjustment. Brachial artery FMD was induced by a 5 min
inflation of a pneumatic cuff to 200 mmHg, around the forearm immediately below the
medial epicondyle, followed by rapid deflation using an automatic air regulator (Logan
Research, UK). The diameter of the brachial artery was measured using edge detection
software (Brachial Tools, MIA, IA, USA) from ECG-triggered ultrasound images captured at 3
second intervals throughout the 11 min recording protocol. FMD was expressed as the
maximum percentage change in vessel diameter from baseline. The magnitude of the flow
stimulus was recorded continuously by pulse wave Doppler and expressed as per cent
reactive hyperaemia, derived from the maximum change in flow within 15 seconds of
deflation of the pneumatic cuff, relative to the baseline flow. The coefficients of variation
between technicians for FMD and PWV were 10.5% and 4.6% respectively at the beginning
of the study, and reached 7.7% and 4.1% at the end of the study (Donald et al., 2010).
Weight to the nearest 0.1 kg was measured in light clothing and without shoes using SECA
scales. Height to the nearest 0.1 cm was measured using a Leicester height meter. From
these, BMI was calculated (weight in kg/height in metres2).
5.4.4 Covariable assessment
5.4.4.1 Confounders
Current age of the child was recorded in months at the time of the assessment clinic. Child
sex was recorded at birth from the obstetric records. We considered the following
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covariables to be potential confounders (associated with both exposures and outcomes);
maternal age, pre-pregnancy BMI, educational level (as a marker of socioeconomic status),
smoking in pregnancy, parity, and maternal total energy intake as assessed by FFQ at 32
weeks.
Highest maternal educational qualification was self-reported at 32 weeks gestation, and
was categorized as university degree, A-level or equivalent (A-level is Advanced-level and
indicates a qualification usually taken around 18 years of age by individuals who have
remained in school beyond the legal minimum age at which they can leave (16 years) and
are likely to go on to higher or further education or train for a semi-skilled job), and less
than A-level. Maternal smoking was self-reported at the 18 and 32 weeks gestation
questionnaire. A variable was generated for any smoking during pregnancy reported at
either or both of these time points.
5.4.4.2 Mediators and effect modifiers
On the basis of it being plausible that maternal iron status would affect them and that they
could plausibly causally affect the offspring’s cardiovascular profile (Tamura et al., 2002,
Brion et al., 2010), we considered the following potential mediators of the association; cord
ferritin, gestational age, offspring birth weight and offspring dietary iron intake. Gestational
age at delivery and birth weight were obtained from the obstetric records. Ferritin was
measured in cord heparin plasma at the ALSPAC laboratory using the DELFIA time resolved
fluoroimmunoassay system. Ferritin assays were duplicated where possible and a
coefficient of variation of approximately 4% was obtained. Offspring dietary iron intake was
assessed by a FFQ administered at 3, 4, 7 and 9 years of age (Boyd et al., 2013). We used
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the mean iron intake of these 4 assessments. Maternal vitamin C intake (which we
considered a potential effect modifier of maternal iron status on offspring outcomes) was
calculated from the FFQ as described above for iron intake. A binary variable for dietary
vitamin C intake was created using the UK RNI cut-off of 50 mg/day and used to test for
interaction (Food Standards Agency, 2003). Baby’s sex (also a potential effect modifier) was
obtained from the birth records.
5.4.5 Statistical methods
Analysis was performed using Stata version 11 (StataCorp LP, College Station, TX, USA).
Characteristics of women with iron intake above or equal to the RNI were compared to
those with intake below the RN using two-sample t-test for continuous variables and chi-
squared test for categorical variables.
Linear regression was used to examine the association of maternal dietary iron intake
(assessed as a continuous variable per 10mg/day and also as a binary variable < versus ≥ 
14.8mg/day), whether or not the mother took iron supplements in pregnancy and early
pregnancy Hb (assessed as a continuous 1g/dl and as a binary variable < versus ≥11g/dl) 
with offspring PWV, FMD, BP and BMI all measured at mean age 10 years. Initially,
univariable (no adjustment for covariables) analyses were undertaken followed by
multivariable models that adjusted first for potential confounding factors (maternal age,
pre-pregnancy BMI, educational level, smoking in pregnancy, parity, and maternal total
energy intake for analyses involving dietary iron intake as the exposure), then for potential
mediation by birth weight, gestational age and offspring postnatal dietary iron intake.
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Finally, in the subgroup with data on cord ferritin levels, its role as a mediator was
examined.
The possibilities that offspring sex or maternal adequate intake of vitamin C (≤ versus > 50 
mg/day) modified the association of maternal exposures with offspring outcomes were
assessed by examining stratified (by sex and maternal adequate vitamin C intake) analyses
and by including an interaction term in the confounder adjusted models.
A statistical significance level of 1%, with 99% confidence intervals, was used in the
regression models to reduce the risk of type I error due to multiple statistical testing. Other
strategies for correction for multiple testing, such as the Bonferroni correction, are over-
conservative, and this is a more pragmatic approach that more easily facilitates the use of
confidence intervals.
5.4.5.1 Sensitivity analyses
Sensitivity analysis which aimed at exploring whether missing data might have led to biased
estimates was undertaken. To do this, multivariable multiple imputation was performed in
Stata as described by Royston (Royston, 2004) to impute missing values for variables
included in the main analysis models for any ALSPAC participant in the 12116 sample with
dietary iron intake data. Twenty imputation datasets were generated in which missing
variables values were imputed by chained equations including exposures, outcomes and
covariables as used in the main confounder-adjusted models. The sensitivity analysis results
are obtained by averaging over the results from each of the 20 datasets using Rubin’s rules
(Royston, 2004).
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We also carried out another sensitivity analysis, adding maternal Hb to the models
exploring the associations of maternal iron supplement intake with childhood outcomes.
This was to account for potential reverse causality (the reason for taking the iron
supplements is the mother’s awareness of being anaemic).
5.4.6 Ethical approval
Ethical approval was obtained from the ALSPAC Law and Ethics Committee and the local
research ethics committees, and procedures were in accordance with the Helsinki
Declaration of 1975 as revised in 1983. Participants provided their written informed consent
to participate in this study.
5.4.7 Funding
The work included in this chapter was supported by the Wellcome Trust [Grant number
WT87789 to N.A.A.]. Core support for ALSPAC is provided by the UK Medical Research
Council, the Wellcome Trust and the University of Bristol. Funding for vascular
measurements used in this study was obtained from the British Heart Foundation. The
funders had no influence on the design, analysis or reporting of the study.
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5.5 Results
5.5.1 Study sample descriptives
The ALSPAC live births sample was 14597. Mean birth weight was 3382 grams (SD 581) with
mean gestational age of 38.4 weeks (SD 5.4). The main analysis sample for this chapter was
2958 with complete data on all exposures, outcomes, confounders and mediators (except
for cord ferritin). A description of the study sample characteristics, compared with the total
ALSPAC sample with available maternal dietary data is shown in Table 20.
Mean maternal pregnancy iron intake was 10.7 mg/day (SD 3.2). The mean age of the child
at the time of the focus clinic was 119 months (9.9 years, SD 0.3). Mean child iron intake
was 6.8 mg/day (SD=2.2), 6.8 mg/day (SD=2), 8.8 mg/day (SD 2.5) and 9.2 mg/day (SD 2.6)
at 3, 4, 7 and 9 years of age respectively.
Table 21 summarized participants’ characteristics by dietary maternal iron intake. Women
with dietary iron intake equal to or more than the UK RNI for iron were more likely to be
older, vegetarian, with higher educational qualification, report higher total energy and
vitamin C intake, have lower pre-pregnancy BMI, and were less likely to smoke during
pregnancy.
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Complete case sample Whole ALSPAC sample
with dietary data
Dietary iron intake# (mg/day) (m, sd*) 10.7
(3.2)
10.4
(3.4)
Dietary iron intake <UK RNI## (%, 95% CI**) 89.2
(88.0, 90.3)
90.3
(89.7, 90.8)
Dietary iron intake <UK LRNI### (%, 95% CI) 18.0
(16.7, 19.5)
25.0
(24.2, 25.8)
Dietary vitamin C intake## (mg/day) (m, sd) 85.9
(34.5)
80.1
(35.3)
Age of mother (yrs) (m, sd) 29.5
(4.2)
28.5
(4.8)
Pre-pregnancy BMI (kg/m2) (m, sd) 22.8
(3.5)
22.9
(3.6)
Total energy intake (kj) (m, sd) 7,483
(1,908)
7,415
(2,081)
Smoking in pregnancy (%, 95% CI**) 15.4
(14.1, 16.7)
25.2
(24.4, 26.0)
Caucasian (%, 95% CI) 98.8
(98.4, 99.2)
97.5
(97.2, 97.8)
University degree (%, 95% CI) 18.6
(17.2, 20.0)
13.8
(13.1, 14.4)
Vegetarian (%, 95% CI) 6.1
(5.3, 7.0)
5.2
(4.8, 5.6)
Primigravida (%, 95% CI) 48.8
(47.0, 50.6)
44.8
(43.9, 45.7)
Early pregnancy maternal anaemia (<11 g/dl)
(%, 95% CI)
4.4
(3.7, 5.1)
5.1
(4.6, 5.5)
Report taking iron supplements Before 32
wks gestation (%, 95% CI)
44.9
(43.1, 46.7)
47.5
(46.6, 48.4)
Child gender (male) (%, 95% CI) 50.8
(49.0, 52.6)
51.5
(50.6, 52.4)
Birth weight (g) (m, sd) 3,448
(499)
3,411
(544)
Gestational age (wks) (m, sd) 39.6
(1.6)
39.5
(1.8)
#Food frequency questionnaire at 32 weeks gestation
## UK Reference Nutrient Intake (14.8 mg/day)
###UK Lower Reference Nutrient Intake (8 mg/day)
*Mean, standard deviation
**95% confidence intervals
Table 20: Study sample characteristics (complete cases for exposures, outcomes,
confounders and mediators n=2958) and ALSPAC sample characteristics (with dietary iron
intake data n=12116)
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Dietary iron intake
≥14.8 mg/day
#
(n=319)
<14.8 mg/day
(n=2,639)
P value*
Dietary iron intake## (mg/day) (m, sd**) 16.9
(1.9)
10.1
(2.5)
-
Dietary vitamin C intake## (mg/day) (m, sd) 119.3
(35.6)
81.8
(32.1)
<0.001
Age of mother (yrs) (m, sd) 30.0
(4.2)
29.5
(4.2)
0.02
Pre-pregnancy BMI (kg/m2) (m, sd) 21.7
(2.5)
22.9
(3.6)
<0.001
Total energy intake (kj) (m, sd) 10,100
(1,921)
7,167
(1,645)
<0.001
Smoking in pregnancy (%, 95% CI***) 10.7
(7.5, 14.6)
15.0
(14.6, 14.4)
0.001
Caucasian (%, 95% CI) 98.1
(96.0, 99.3)
99.0
(98.4, 99.3)
0.2
University degree (%, 95% CI) 27.0
(22.2, 32.2)
17.6
(16.2, 19.1)
<0.001
Vegetarian (%, 95% CI) 11.9
(8.3, 16.6)
5.5
(4.6, 6.4)
<0.001
Primigravida (%, 95% CI) 48.0
(42.4, 53.6)
51.0
(47.0, 50.9)
0.8
Early pregnancy maternal anaemia (<11 g/dl)
(%, 95% CI)
6.6
(4.1, 9.9)
4.1
(3.4, 4.9)
0.04
Report taking iron supplements Before 32 wks
gestation (%, 95% CI)
48.3
(42.7, 53.9)
44.5
(42.6, 46.4)
0.2
Cord ferritin (ug/l) (m, sd) 151.9 (n=-83)
(104.8)
165.4 (n=712)
(123.6)
0.3
Child systolic blood pressure (mmHg) (m, sd) 103.9
(8.7)
103.6
(8.8)
0.5
Child diastolic blood pressure (mmHg) (m, sd) 60.3
(7.3)
59.5
(7.8)
0.08
Child pulse wave velocity (m/s) (m, sd) 7.7
(1.3)
7.5
(1.2)
0.1
Child flow mediated dilatation (%) (m, sd) 8.3
(3.5)
8.0
(3.4)
0.1
Child body mass index (kg/m2) (m, sd) 17.9
(2.7)
18.1
(3.0)
0.2
Child gender (male) (%, 95% CI) 55.2
(49.5, 60.7)
50.3
(48.3, 52.2)
0.1
Birth weight (g) (m, sd) 3,439
(486)
3,450
(500)
0.7
Gestational age (wks) (m, sd) 39.5 (1.6) 39.6 (1.6) 0.3
# Reference nutrient intake (RNI) for iron for women aged 19-50 years in the UK ##Food frequency questionnaire at 32 weeks gestation
* P-value using two-sample t-test for continuous variables, chi-squared test for categorical variables
**Mean, standard deviation *** 95% confidence intervals
Table 21: Sample characteristics by dietary iron intake (n=2958 for all, except where cord
ferritin data is used: n=795)
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5.5.2 Complete case regression analyses
In unadjusted analyses, maternal dietary iron intake was associated with offspring BMI, and
maternal pregnancy supplement intake was associated with offspring systolic BP. Child
dietary iron intake was associated with maternal iron intake in pregnancy , from both diet
and supplements, and early pregnancy Hb. Birth weight was associated with both maternal
iron intake from supplements and early pregnancy Hb (Table 22).
With adjustment for confounding characteristics, there were no associations between the
primary exposures and outcomes of interest apart from the inverse association between
maternal iron supplement intake and offspring systolic BP which remained largely
unchanged, with marginal statistical significance at the 1% significance level (0.8 mmHg
lower with reporting taking iron supplements, 99% CI 0 to 1.7, P=0.01). This association was
not markedly affected by adjustment for mediators (birth weight, gestational age, and
offspring dietary iron intake), but was attenuated to the null in the smaller sub-sample with
further adjustment for cord ferritin as a fourth mediator. The results from the unadjusted
and the three adjusted models (confounders, confounders plus 3 mediators, and
confounders plus 4 mediators) are illustrated in table 23 for maternal iron intake and Table
24 for maternal Hb and anaemia.
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Outcomes Mediators
Exposures Offspring
pulse wave
velocity
(m/s)
Offspring
flow
mediated
dilatation
(%)
Offspring
systolic
blood
pressure
(mmHg)
Offspring
diastolic
blood
pressure
(mmHg)
Offspring
body mass
index
(kg/m2)
Cord
ferritin
(ug/l)
Birth
weight (g)
Gestational
age (wks)
Child dietary
iron intake
(mg/d)*
Maternal pregnancy dietary iron
intake (continuous) (per 10mg/d)
0.2
(0, 0.3)
0.2
(-0.3, 0.5)
-0.1
(-1.6, 0.4)
0.4
(-0.5, 1.3)
-0.8
(-1.2, -0.5)
15.7
(-11.8, 43.1)
22.5
(-33.8, 78.8)
0
(-0.2, 0.2)
1.7
(1.6, 1.9)
Maternal iron intake < 14.8 mg/d -0.1
(-0.3, 0)
-0.3
(-0.7, 0.1)
0.3
(-1.3, 0.7)
-0.8
(-1.7, 0.1)
0.2
(0.1, 0.6)
13.5
(-14.2, 41.3)
10.7
(-47.3, 68.8)
0.1
(-0.1, 0.3)
-1.1
(-1.3, -0.9)
Maternal pregnancy iron supplement
use
0.1
(0, 0.2)
0.2
(0, 0.5)
-1.0
(-1.6, -0.3)
-0.4
(-1.0, 0.2)
-0.1
(-0.3, 0.1)
9.5
(-7.5, 26.6)
93.0
(56.9, 129.0)
0
(-0.1, 0.1)
0.1
(0, 0.2)
Maternal early pregnancy
haemoglobin (g/dl)
-0.1
(-0.1, 0)
-0.1
(-0.2, 0.1)
0.4
(0, 0.7)
0
(-0.3, 0.3)
0.1
(0., 0.2)
0.7
(-8.9, 10.3)
-29.5
(-49.7, -9.3)
0
(-0.1, 0.5)
-0.1
(-0.1, 0)
Maternal early pregnancy anaemia
(<11 g/dl)
0
(-0.2, 0.2)
-0.2
(-0.8, 0.4)
-1.5
(-3.1, 0.1)
-0.4
(-1.8,0.9)
-0.1
(-0.7, 0.4)
-18.3
(-55.6, 17.7)
69.1
(-19.0, 157.2)
-0.2
(-0.4, 0.1)
0.1
(-0.2, 0.4)
Regression coefficients are reported with 95% confidence intervals between brackets
Greyed cell indicate statistical significance at the 5% level
*Average of intake reported over the 4 assessment points (3, 4, 7 and 9 years)
Table 22: Univariable linear regression estimates of exposure-outcome and exposure-mediator relationships (n=2,958 for all, except where
cord ferritin data is used: n=795)
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Offspring pulse wave
velocity (m/s)
Offspring flow mediated
dilatation (%)
Offspring systolic blood
pressure (mmHg)
Offspring diastolic blood
pressure (mmHg)
Offspring body mass index
(kg/m2)
Β
# 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P
Maternal pregnancy dietary iron intake (continuous) (per 10mg/d)
Unadjusted 0.2 0, 0.4 0.02 0.2 -0.4, 0.6 0.5 -0.6 -1.9, 0.7 0.3 0.4 -0.8, 1.5 0.4 -0.8 -1.3, -0.4 <0.001
Model 1* 0.1 -0.2, 0.4 0.5 0.4 -0.3, 1.2 0.1 -0.3 -2.2, 1.7 0.7 0.7 -1.1, 2.4 0.3 0.1 -.0.5, 0.7 0.7
Model 2** 0.1 -0.2, 0.4 0.3 0.5 -0.3, 1.2 0.1 -0.1 -2.1, 2.0 0.9 1.0 -0.8, 2.8 0.2 0.1 -0.6, 0.7 0.8
Model 3*** 0.5 -0.1, 1.1 0.04 0.3 -1.2, 1.9 0.6 0.7 -3.5, 4.9 0.7 1.2 -2.4, 4.8 0.4 0.2 -1.1, 1.5 0.7
Maternal iron intake < 14.8 mg/d
Unadjusted -0.1 -0.3, 0.1 0.1 -0.3 -0.8, 0.2 0.1 -0.3 -1.7, 1.0 0.5 -0.8 -2.0, 0.4 0.08 0.2 -0.2, 0.7 0.2
Model 1* 0 -0.3, -0.2 0.7 -0.5 -1.1, 0.1 0.05 -0.7 -2.3, 0.8 0.3 -0.9 -2.3, 0.4 0.08 -0.4 -0.9, 0.1 0.03
Model 2** 0 -0.3, 0.2 0.7 -0.5 -1.1, 0.1 0.04 -0.8 -2.3, 0.8 0.2 -1.0 -2.4, 0.3 0.05 -0.4 -0.9, 0.1 0.03
Model 3*** -0.1 -0.6, 0.3 0.5 0.1 -1.0, 1.2 0.8 -0.8 -3.9, 2.2 0.5 -1.2 -3.9, 1.5 0.3 -0.5 -1.5, 0.4 0.2
Maternal pregnancy iron supplement use
Unadjusted -0.1 -0.1, 0.2 0.07 0.2 -0.1, 0.5 0.1 -1.0 -1.8, -0.1 0.003 -0.4 -1.1, 0.3 0.2 -0.1 -0.4, 0.2 0.3
Model 1* 0.1 -0.1, 0.2 0.2 0.2 -0.1, 0.6 0.07 -0.8 -1.7, 0 0.01 -0.3 -1.1, 0.4 0.3 0 -0.2, 0.3 0.7
Model 2** 0.1 -0.1, 0.2 0.1 0.2 -0.1, 0.6 0.06 -0.8 -1.6, 0.1 0.02 -0.2 -1.0, 0.5 0.5 0 -0.3, 0.3 0.9
Model 3*** 0 -0.2, 0.3 0.7 0.1 -0.6, 0.7 0.8 -0.9 -2.6, 0.8 0.2 0.1 -1.4, 1.5 0.9 -0.2 -0.7, 0.3 0.4
# Change per 1 outcome unit
* Adjusting for confounders: maternal age, pre-pregnancy body mass index, smoking in pregnancy, educational qualification (as a proxy for socioeconomic status), parity
(and maternal total energy intake in the models with dietary iron intake as exposure)
** Adjusting for confounders and three mediators: birth weight, gestational age, offspring dietary iron intake
*** Adjusting for confounders and four mediators: birth weight, gestational age, offspring dietary iron intake, cord ferritin
Table 23: Linear regression estimates for associations between maternal iron intake in pregnancy with offspring vascular indicators and
body mass index (n=2958 for all, except where cord ferritin data is used: n=795)
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Offspring pulse wave
velocity (m/s)
Offspring flow mediated
dilatation (%)
Offspring systolic blood
pressure (mmHg)
Offspring diastolic blood
pressure (mmHg)
Offspring body mass index
(kg/m2)
Β
# 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P
Maternal early pregnancy haemoglobin (g/dl)
Unadjusted -0.1 -0.1, 0 0.07 -0.1 -0.2, 0.1 0.5 0.4 -0.1, 0.8 0.05 0 -0.4, 0.4 0.8 0.1 0, 0.3 0.06
Model 1* 0 -0.1, 0 0.09 -0.1 -0.3, 0.1 0.3 0.2 -0.3, 0.7 0.2 0 -0.5, 0.4 0.8 0 -0.2, 0.1 0.7
Model 2** -0.1 -0.1, 0 0.08 -0.1 -0.3, 0.1 0.3 0.2 -0.3, 0.7 0.3 -0.1 -0.5, 0.4 0.7 0 -0.2, 0.2 0.9
Model 3*** -0.1 -0.2, 0.1 0.3 0 -0.4, 0.3 0.8 0.3 -0.6, 1.3 0.4 -0.1 -0.9, 0.7 0.7 0.1 -0.2, 0.4 0.6
Maternal early pregnancy anaemia (<11 g/dl)
Unadjusted 0 -0.3, 0.3 0.8 -0.2 -1.0, 0.6 0.5 -1.5 -3.6, 0.6 0.06 0.4 -2.2, 1.4 0.5 -0.1 -0.8, 0.6 0.6
Model 1* 0 -0.3, 0.3 0.8 -0.2 -1.0, 0.6 0.6 -1.3 -3.3, 0.8 0.1 -0.3 -2.1, 1.5 0.6 0.1 -0.5, 0.8 0.7
Model 2** 0 -0.3, 0.3 0.8 -.0.2 -0.9, 0.6 0.6 -1.2 -3.2, 0.9 0.1 -0.2 -2.0, 1.6 0.7 0 -0.6, 0.7 0.8
Model 3*** 0 -0.7, 0.3 0.2 -0.1 -1.4, 1.3 0.9 -1.0 -4.6, 2.6 0.5 -0.3 -3.4, 2.8 0.8 0.1 -1.0, 1.2 0.7
# Change per 1 outcome unit
* Adjusting for confounders: maternal age, pre-pregnancy body mass index, smoking in pregnancy, educational qualification (as a proxy for socioeconomic status), parity
(and maternal total energy intake in the models with dietary iron intake as exposure)
** Adjusting for confounders and three mediators: birth weight, gestational age, offspring dietary iron intake
*** Adjusting for confounders and four mediators: birth weight, gestational age, offspring dietary iron intake, cord ferritin
Table 24: Linear regression estimates for associations between maternal haemoglobin and anaemia in pregnancy with offspring vascular
indicators and body mass index (n=2958 for all, except where cord ferritin data is used: n=795)
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5.5.3 Multiply imputed data regression analyses
The main adjusted associations were largely similar when conducted using the multiple
imputation databases (Table 25 & Table 26), compared to those conducted on complete
data presented as primary analyses in this paper (Table 23 & Table 24). However, adjusting
for cord ferritin as a mediator in the inverse association between maternal iron supplement
use and offspring systolic BP in the imputed dataset had less impact than in the complete
dataset (Table 25).
Adjusting for early pregnancy maternal Hb in the association between maternal iron
supplement use and offspring systolic BP as sensitivity analysis did not change the
magnitude of association (-0.8 mmHg, 99% CI 0.1 to -1.7, P=0.03 in the main complete
dataset, and -0.6 mmHg, 99% CI 0 to -1.3, P=0.01 in the imputed dataset).
5.5.4 Interaction and mediation
There was also no evidence of effect modification by maternal vitamin C intake or child sex
on any of the relationships (Table 27 & Table 28). There was also no association between
cord ferritin and either maternal dietary iron intake or maternal Hb.
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Offspring pulse wave
velocity (m/s)
Offspring flow mediated
dilatation (%)
Offspring systolic blood
pressure (mmHg)
Offspring diastolic blood
pressure (mmHg)
Offspring body mass index
(kg/m2)
Β 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P
Maternal pregnancy dietary iron intake (continuous) (per 10mg/d)
Unadjusted 0 -0.1, 0.1 0.3 0.1 -0.3, 0.4 0.6 -1.0 -1.9, -0.1 0.004 -0.5 -1.3, 0.3 0.1 -0.7 -1.1, -0.4 <0.001
Model 1* -0.1 -0.2, 0.1 0.5 0.5 -0.1, 1.0 0.03 0.2 -1.9, 1.4 0.7 -0.3 -1.6, 1.0 0.6 0.2 -0.3, 0.7 0.3
Model 2** 0 -0.4, 0.3 0.5 0.5 -0.1, 1.0 0.02 0 -1.6, 1.6 0.9 0 -1.3, 1.4 0.9 0.1 -0.4, 0.6 0.6
Model 3*** 0 -0.2, 0.1 0.5 -0.2 -0.1, 1.1 0.6 0.1 -1.7,1.6 0.9 0 -1.4, 1.4 0.9 0 -0.4, 0.6 0.6
Maternal iron intake < 14.8 mg/d
Unadjusted -0.1 -0.2, 0 0.06 -0.2 -0.6, 0.2 0.1 0.6 -0.4, 1.6 0.1 0 -0.9, 0.9 0.9 0.3 0.1, 0.6 0.002
Model 1* -0.1 -0.2, 0.1 0.3 -0.4 -0.8, 0.1 0.03 0 -1.3, 1.3 0.9 -0.3 -1.3, 0.7 0.5 -0.2 -0.5, 0.1 0.06
Model 2** -0.1 -0.2, 0.1 0.2 -0.4 -0.8, 0.1 0.03 -0.1 -1.3, 1.2 0.9 -0.4 -1.4, 0.6 0.3 -0.2 -0.5, 0.1 0.08
Model 3*** -0.1 -0.2, 0.1 0.2 -0.4 -0.8, 0.1 0.02 -0.1 -1.3, 1.2 0.9 -0.4 -1.4, 0.6 0.3 -0.2 -0.5, 0.1 0.08
Maternal pregnancy iron supplement use
Unadjusted 0.1 0, 0.1 0.2 0.1 -0.1, 0.4 0.2 -0.8 -1.4, -0.2 0.001 -0.3 -0.8, 0.2 0.2 -0.2 -0.4, 0 0.002
Model 1* 0 -0.1, 0.1 0.3 0.1 -0.1, 0.4 0.1 -0.7 -1.3, 0 0.008 -0.2 -0.7, 0.4 0.4 0 -0.2, 0.2 0.9
Model 2** 0 -0.1, 0.1 0.2 0.2 -0.1, 0.4 0.08 -0.6 -1.2, 0 0.01 -0.1 -0.7, 0.4 0.5 -0.1 -0.2, 0.1 0.5
Model 3*** 0 0, 0.1 0.2 0.2 -0.1, 0.4 0.08 -0.6 -1.3, 0 0.01 -0.2 -0.7, 0.4 0.4 0 -0.2, 0.1 0.5
# Change per 1 outcome unit
* Adjusting for confounders: maternal age, pre-pregnancy body mass index, smoking in pregnancy, educational qualification (as a proxy for socioeconomic status), parity
(and maternal total energy intake in the models with dietary iron intake as exposure)
** Adjusting for confounders and three mediators: birth weight, gestational age, offspring dietary iron intake
***Adjusting for confounders and four mediators: birth weight, gestational age, offspring dietary iron intake, cord ferritin
Table 25: Linear regression estimates for associations of maternal iron intake in pregnancy with offspring vascular indicators and adiposity
using multiple imputation dataset based on the sample with dietary iron intake data (n=12116)
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Offspring pulse wave
velocity (m/s)
Offspring flow mediated
dilatation (%)
Offspring systolic blood
pressure (mmHg)
Offspring diastolic blood
pressure (mmHg)
Offspring body mass index
(kg/m2)
Β
# 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P Β 99% CI P
Maternal early pregnancy haemoglobin (g/dl)
Unadjusted 0 -0.1, 0 0.1 0 -0.1, 0.1 0.8 0.3 -0.1, 0.7 0.05 0.1 -0.3, 0.4 0.6 0.1 0, 0.3 0.02
Model 1* 0 -0.1, 0 0.3 0 -0.1, 0.1 0.9 0.2 -0.2, 0.5 0.3 0 -0.3, 0.3 0.8 -0.1 -0.2, 0.1 0.2
Model 2** 0 -0.1, 0 0.3 0 -0.1, 0.1 0.9 0.1 -0.2, 0.5 0.3 0 -0.4, 0.3 0.8 0 -0.2, 0.1 0.3
Model 3*** 0 -0.1, 0 0.3 0 -0.1, 0.1 0.9 0.1 -0.2, 0.5 0.3 0 -0.3, 0.3 0.8 -0.1 -0.2, 0.1 0.3
Maternal early pregnancy anaemia (<11 g/dl)
Unadjusted 0 -0.3, 0.2 0.6 0 -0.6, 0.6 0.9 -0.1 -1.5, 1.2 0.8 0 -1.4, 1.2 0.9 0.1 -0.5, 0.6 0.8
Model 1* -0.1 -0.3, 0.2 0.6 0 -0.6, 0.6 0.9 0.1 -1.2, 1.5 0.8 0.2 -1.2, 1.6 0.8 0.4 -0.2, 0.9 0.07
Model 2** -0.1 -0.3, 0.2 0.5 0 -0.6, 0.6 0.9 0.1 -1.2, 1.5 0.8 0.1 -1.3, 1.5 0.8 0.4 -0.2, 0.9 0.08
Model 3*** -0.1 -0.3, 0.2 0.5 0 -0.6, 0.6 0.9 0.1 -1.2, 1.5 0.8 0.2 -1.2, 1.6 0.7 0.4 -0.2, 0.9 0.07
# Change per 1 outcome unit
* Adjusting for confounders: maternal age, pre-pregnancy body mass index, smoking in pregnancy, educational qualification (as a proxy for socioeconomic status),
parity (and maternal total energy intake in the models with dietary iron intake as exposure)
** Adjusting for confounders and three mediators: birth weight, gestational age, offspring dietary iron intake
***Adjusting for confounders and four mediators: birth weight, gestational age, offspring dietary iron intake, cord ferritin
Table 26: Linear regression estimates for associations of maternal haemoglobin and anaemia in pregnancy with offspring vascular
indicators and adiposity using multiple imputation dataset based on the sample with dietary iron intake data (n=12116)
192
Offspring pulse wave
velocity (m/s)
Offspring flow mediated
dilatation (%)
Offspring systolic blood
pressure (mmHg)
Offspring diastolic blood
pressure (mmHg)
Offspring body mass index
(kg/m2)
Β
# 99% CI P* Β# 99% CI P* Β# 99% CI P* Β# 99% CI P* Β# 99% CI P*
Maternal pregnancy dietary iron intake (continuous) (per 10mg/d)
In participants
with vitamin C
intake> 50
mg/day
0 -0.3, 0.3 0.5 0.6 -0.2, 1.5 0.5 -0.3 -2.4, 1.9 0.7 0.8 -1.1, 2.7 0.8 0 -.0.7, 0.6 0.3
In participants
with vitamin C
intake≤ 50 
mg/day
0.2 -0.7, 1.1 -0.3 -2.7, 2.1 -1.8 -7.3, 3.7 1.2 -4.0, 6.4 1.2 -1.1, 3.5
Maternal pregnancy iron supplement use
In participants
with vitamin C
intake> 50
mg/day
0 -0.1, 0.2 0.2 0.3 0, 0.7 0.1 -0.8 -1.7, 0.1 0.9 -0.4 -1.2, 0.5 0.9 0.1 -0.2, 0.3 0.9
In participants
with vitamin C
intake≤ 50 
mg/day
0.2 -0.1, 0.5 -0.3 -1.1, 0.6 -0.8 -2.7, 1.2 -0.1 -2.0, 1.8 0 -0.8, 0.8
#Change per 1 unit in outcome adjusting for potential confounding characteristics: maternal age, pre-pregnancy BMI, smoking in pregnancy, educational qualification (as a proxy for
socioeconomic status), parity, and maternal total energy intake in the models with dietary iron intake as exposure)
*Interaction P value, testing the null hypotheses that associations do not differ by maternal vitamin C level
Table 27: Multivariable linear regression estimates from stratified analyses for associations between maternal iron intake in pregnancy with
offspring vascular indicators and body mass index with testing for effect modification by maternal vitamin C intake during pregnancy
(n=2958)
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Offspring pulse wave
velocity (m/s)
Offspring flow mediated
dilatation (%)
Offspring systolic blood
pressure (mmHg)
Offspring diastolic blood
pressure (mmHg)
Offspring body mass index
(kg/m2)
Β
# 99% CI P* Β# 99% CI P* Β# 99% CI P* Β# 99% CI P* Β# 99% CI P*
Maternal pregnancy dietary iron intake (continuous) (per 10mg/d)
Males 0.2 -0.2, 0.6 0.4 0.6 -0.4, 1.6 0.2 0.4 -2.3, 3.1 0.9 0.9 -1.5, 3.2 0.7 0.2 -0.7, 1.0 0.4
Females 0 -0.4, 0.4 0.5 -0.7, 1.6 -0.9 -3.8, 2.0 0.7 -1.9, 3.3 0.1 -0.9, 1.0
Maternal pregnancy iron supplement use
Males 0.1 -0.1, 0.2 0.8 0.2 -0.2, 0.6 0.9 -0.9 -2.1, 0.3 0.7 -0.9 -1.9, 0.1 0.06 -0.1 -0.4, 0.3 0.5
Females 0.1 -0.1, 0.2 0.3 -0.3, 0.7 -0.7 -1.9, 0.5 0.2 -0.8, 1.3 0.1 -0.3, 0.5
Maternal early pregnancy anaemia (<11 g/dl)
Males 0 -0.4, 0.4 0.9 0.2 -0.9, 1.2 0.3 -1.3 -4.1, 1.4 0.8 0.3 -2.1, 2.6 0.4 0.4 -0.5, 1.2 0.2
Females -0.1 -0.5, 0.4 -0.5 -1.7, 0.7 -1.0 -4.1, 2.1 -0.9 -3.7, 1.8 -0.2 -1.2, 0.8
#Change per 1 unit in outcome adjusting for potential confounding characteristics: maternal age, pre-pregnancy BMI, smoking in pregnancy, educational qualification (as a proxy for
socioeconomic status), parity, and maternal total energy intake in the models with dietary iron intake as exposure)
*Interaction P value, testing the null hypotheses that associations do not differ by offspring sex
Table 28: Multivariable linear regression estimates from stratified analyses for associations between maternal iron intake and haemoglobin
in pregnancy with offspring vascular indicators and body mass index with testing for effect modification by child sex (n=2958)
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5.6 Discussion
In this study, associations of maternal pregnancy iron intake and early-pregnancy Hb
with several markers of offspring cardiovascular health at 10 years were examined. Of
the 25 main associations examined, only one was observed that was statistically
significant, that of an inverse association of maternal report of taking a supplement
that contained iron before 32 weeks gestation with offspring systolic BP at 10 years of
age. However, although the direction of the latter association is consistent with results
from previous animal studies that support a causal relationship between maternal ID
in pregnancy and raised offspring BP (Gambling et al., 2003b, Gambling et al., 2003a,
Crowe et al., 1995, Gambling et al., 2004b), its magnitude was modest (1 mmHg lower
offspring systolic BP on average in children whose mothers reported taking
supplements compared to those who did not).
To take some account of multiple testing, a p-value threshold of 0.01 was used as a
statistical significance level in this analysis, giving the association observed between
maternal iron supplement intake and offspring BP only marginal statistical significance
in the main complete dataset. Therefore, this result should be treated with caution as
a potential chance finding.
5.6.1 Residual confounding
The association between maternal iron supplement intake and offspring BP could be
heavily confounded by the detection of anaemia or ID in the mother. Mothers who are
aware or suspect that they are anaemic are more likely to consume iron supplements
during their pregnancy. The potential confounding of maternal Hb was taken into
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account in a sensitivity analysis which did not change this result much. However, the
detection of ID without anaemia during antenatal care through measuring sF
concentrations could still constitute unmeasured confounding, as mothers may opt to
take iron supplements if they become aware that they are iron deficient. There is also
the possibility that these mothers may change their diet to contain more iron towards
the end of their pregnancies.
5.6.2 Comparison with previous ALSPAC findings
The previous analysis in ALSPAC by Brion et al. reported an association between
maternal anaemia and offspring BP at 7 years only in women who did not take iron
supplements during pregnancy. The total sample size with data on maternal Hb
(before stratification by supplement intake) was considerably smaller (n=1255) than
this analysis (n=2958) (Brion et al., 2008). Also the definition of early anaemia differed
in that analysis in that it included both the first and second trimester, while here Hb
concentrations before 18 weeks gestation were used to define early pregnancy Hb. In
this analysis, using a bigger sample, stratification by intake of iron supplements did not
change the null result of the association between maternal anaemia with offspring BP.
Analysis presented in chapter 4 found no evidence of association between intake of
iron supplements in pregnancy and infant PWV, however adjusting for iron
supplement intake strengthened the association observed between early pregnancy
maternal anaemia and infant PWV (section 4.5.2.1).
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5.6.3 Comparison with Baby VIP findings (chapter 4)
In contrast to the association between maternal anaemia in early pregnancy and
increase infant PWV observed in Baby VIP, this study found no such association with
PWV measured 10 years later in life. One possible explanation for this difference in
findings is that PWV in the first few weeks of life may not reflect later cardiovascular
risk and may not correlate strongly with PWV later in life. Also, central PWV was
assessed in ALSPAC (carotid-radial) in comparison with peripheral PWV in Baby VIP
(brachio-femoral), which may explain the difference in findings. Another possibility is a
true effect of IDA on offspring cardiovascular profile as reflected by PWV in the short
term, which is potentially modifiable by other environmental factors during the first
years of life, leading to attenuating this relationship later in life.
5.6.4 Strengths & limitations of the study
5.6.4.1 Study sample
This is a relatively large study and the first to examine the association of maternal iron
intake and maternal Hb in pregnancy with measures of offspring arterial stiffness,
endothelial function and adiposity, as well as with BP. This sample size allowed the
assessment of mediation and effect modification based on existing evidence to explain
the mechanisms underlying any observed associations. However, the study sample
analysed to test mediation by cord ferritin was considerably smaller. Therefore, when
examining the association between maternal iron supplement intake and offspring
systolic BP, lack of statistical power may explain the difference in the results between
the complete data and multiple imputation models (Table 25 & Table 26).
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5.6.4.2 Exposure measures
Maternal Hb in early pregnancy was objectively measured as part of routine antenatal
care, and extracted for cohort participants from medical records, making bias due to
selection and measurement unlikely. Although anaemia does not represent a specific
or sensitive measure of body iron stores, it is likely to reflect ID when it is pronounced,
particularly in the first trimester (Milman, 2006a).
An important limitation of this study is that a biomarker of maternal iron status during
pregnancy, such as sF, or sTfR was not available in this study. Although there are
reservations about the use of sF as a sole measure of iron status as it is an acute
inflammatory marker (Zimmermann, 2008), it remains a better indicator compared to
self-reported iron intake or Hb concentration (Zimmermann, 2008). Dietary iron was
assessed by self-report, using a FFQ, which may provide less accuracy than more
detailed methods of dietary assessment such as weighed food diaries. Furthermore,
the long term outcomes of interest are cardiovascular events, which we are unable to
assess in this cohort due to their young age.
It is also known that haem iron is absorbed better than non-haem iron. Although
vegetarians often take iron supplements, these may not be as effective as the haem
iron that is missing from their diets, and this may have a bearing on the interpretation
of our results. However, results based on Hb concentrations in the blood were broadly
consistent with those based on dietary intake, suggesting that the source of the iron
was not relevant here.
Iron supplement intake was self-reported and the nature of the questions used in this
study mean that we do not know the amount of supplementation or whether the iron
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supplementation was in the form of iron only or as part of a multivitamin preparation.
Therefore the association we observed between maternal reported iron
supplementation and offspring systolic BP could be attributable to other micronutrient
supplements that the mother was taking as well or our null associations may be
masked since iron taken as part of a multivitamin preparation may be less readily
absorbed compared to when taken on its own (Gambling et al., 2008, Gambling et al.,
2003a, Kelleher and Lönnerdal, 2006).
It is difficult to conduct analyses in a British cohort study of iron-only supplements as
the exposure. Firstly because, in the UK, these are not recommended routinely in
pregnancy, therefore a small proportion of pregnant women would be expected to use
them. Secondly, those who take iron-only supplements are likely to be taking the
prescribed high-dose as opposed to the low-dose recommended routinely during
pregnancy in other countries.
5.6.4.3 Outcome measures
Offspring cardiovascular and adiposity indicators (PWV, FMD, BP and BMI) were
measured by trained skilled staff using standardised methods in this study. However,
definite correlation between cardiovascular measures during childhood and
cardiovascular end-points in adulthood, which are the main interest in the hypothesis
underlying these investigations, is yet to be established. Therefore, re-testing of these
associations using adult indicators of cardiovascular risk remains desired.
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5.6.5 Implications for research and practice
There is a need to examine the main relationship of interest in this study utilising valid
biomarkers of iron status in the mother such as R/F ratio. However, the results of this
analysis are still relevant to the current debate regarding the long-term benefit of
routine iron supplementation in pregnancy (Alwan and Cade, 2011). Some
international and national guidelines recommend routine iron supplements during
pregnancy including the World Health Organization and the US Centers for Disease
Control and Prevention (CDC) (CDC, 1998, WHO, 2006). However, iron supplements
can be associated with side-effects such as nausea, vomiting and constipation (British
Medical Association and Royal Pharmaceutical Society of Great Britain, 2010). In the
UK, routine iron supplementation during pregnancy is not recommended (National
Institute for Clinical Excellence (NICE), 2008), although there is no recommendation for
detection/intervention in pregnant women who are iron-deficient but not anaemic.
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5.7 Conclusion
The findings in this chapter suggest that maternal dietary iron intake and Hb
concentrations during pregnancy are unlikely to be related to childhood indicators of
cardiovascular health at 10 years. However, they do not exclude a relationship
between maternal iron status in pregnancy and cardiovascular indicators that could
become apparent later in the offspring’s lives.
In conclusion, this study suggests that maternal anaemia during early pregnancy is not
an important determinant of future offspring cardiovascular health, using childhood
vascular and adiposity indicators at 10 years. No associations were observed between
maternal iron intake in pregnancy with offspring’s vascular markers and adiposity
except for a modest inverse association between self-reported maternal iron
supplement intake during pregnancy and offspring systolic BP.
In the next chapter, offspring cardiovascular indicators are assessed in adulthood and
their association with maternal iron status is examined using a Mendelian
randomisation study design utilising IV techniques.
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6 Exploring the association of maternal iron
status with adult offspring’s blood
pressure and adiposity using Mendelian
randomization: the UKWCS-IBPS
In the previous chapters, I have investigated the association between indicators of
maternal iron status in pregnancy and offspring cardiovascular risk indicators in infancy
and childhood. This chapter explores the relationship of maternal iron status with
adult offspring health indicators including BP and adiposity, which are known to be
strong predictors of CVD morbidity and mortality.
Work from this chapter has formed the basis of one peer-reviewed paper (Alwan et al.,
2012b), and one conference presentation with a published peer-reviewed abstract
(Alwan et al., 2012a).
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6.1 Chapter summary
An IV analysis, using maternal C282Y as an instrument for mother’s iron status, was
undertaken to examine its association with offspring BP, WC and BMI, and the results
were compared to that of ordinary least squares (OLS) regression. Offspring of a sub-
cohort of mothers from the UK Women Cohort Study were recruited in 2009-10
(n=348, mean age=41 years). Their BP, height and weight were measured at their local
general medical practice, and they were asked to self-measure their WC. About half
were offspring of C282Y carriers. Maternal ferritin was used as a biomarker of
maternal iron status.
Maternal C282Y was strongly associated with maternal ferritin (mean difference per
allele=84 ug/l, 95% CI 31, 137, P=0.002). Using IV analyses, maternal ferritin was not
linked to offspring’s BP, BMI or WC. The first stage F statistic for the strength of the
instrument was 10 (Kleibergen-Paap rk LM P-value=0.009). Maternal ferritin was linked
to offspring diastolic BP, WC and BMI in univariable, but not in multivariable OLS
analysis. There was no difference between the OLS and the IV models coefficients for
any of the outcomes considered.
There was no evidence of association between maternal iron status and adult
offspring’s BP and adiposity using both multivariable OLS and IV modelling. This is the
first study examining this relationship using offspring outcomes in adulthood. Further
exploration in larger studies that have genetic variation assessed in both mother and
offspring should be considered.
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6.2 Background
6.2.1 Mendelian randomization
Association studies of specific nutrient effects with health outcomes in humans are
difficult because of the likelihood of important confounding by other nutrients or
dietary characteristics, as well as other lifestyle factors such as smoking and alcohol
consumption, and socioeconomic factors potentially affecting these associations. Most
of these studies are observational, as randomised controlled trials are often not
feasible or ethical to study such relationships. One way to try and tackle this limitation
is the use of the random assortment of genes from parents to offspring which provides
one method for assessing the causal nature of some environmental exposures (Lawlor
et al., 2004). This approach, known as Mendelian randomization (MR), uses genetic
variants as instrumental variables for the environmental exposures of interest (Davey
Smith, 2003).
Genetic variants are randomised at birth and are not influenced by the many lifestyle
and environmental characteristics with which risk factors, such as ID, are associated.
Since these genetic variants are allocated at conception, they cannot be influenced by
either the later occurrence of disease processes or treatment (Davey Smith et al.,
2007). Therefore associations derived from MR analysis are less likely to be affected by
confounding and reverse causality that can bias established multivariable approaches
to epidemiological association studies (Lawlor et al., 2008a).
In the context of CVD research, MR can be used to investigate causation of risk factors
such as obesity. MR can also provide a valuable tool in the study of the developmental
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origins of obesity by using paternal/maternal genes to control for the effect of
offspring genes, and hence to separate ‘developmental’ effects during fetal life and
early childhood from genetic inherited effects. For example, Lawlor et al. examined the
effect of maternal adiposity measured by BMI on offspring fat mass. Using maternal
FTO genotype as an IV in the analysis, and hence controlling for the offspring's FTO
genotype, which would directly affect their fat mass, there was no evidence of
association between maternal BMI and offspring fat mass (Lawlor et al., 2008b).
It is important to note that MR has important caveats. These include confounding by
polymorphisms in linkage disequilibrium with the genetic variant under study, the fact
that variants may have several phenotypic effects associated with the outcome of
interest, canalisation which is the buffering of genetic effects during development, and
the absence of a suitable polymorphism for studying the exposure of interest (Davey
Smith, 2003).
6.2.1.1 Instrumental variable analysis
IV methods are commonly used for statistical analysis in econometrics. This approach
is generally recommended for data analysis in MR studies (Lawlor et al., 2008a). An IV
is a variable associated with the outcome only through its robust association with an
intermediary variable, which is the exposure of interest in the case of MR (Figure 11).
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Figure 11: Illustration of IV analysis
There are conditions for IV analysis (Lawlor et al., 2008a). These are:
1. Z is robustly associated with X
2. Z is not associated with U (this can be tested in the study data)
3. Z is related to Y only through X
4. All associations are linear and unaffected by statistical interaction
In this study IV analysis uses the proportion of the variation in maternal iron status
that is explained by the C282Y mutation in the HFE gene to provide an un-confounded
estimate of the relationship with adult offspring’s BP and obesity.
6.2.2 Genetic susceptibility to iron overload
Women who carry a C282Y mutation in the HFE gene are more likely, in the
homozygous state, to suffer from haemochromatosis, a condition which is
characterised by iron overload in the liver (Rhodes et al., 1997, Willis et al., 1999).
C282Y homozygotes (aa) have significantly higher sF, TS and serum iron levels
compared to wild type individuals (gg) (Cade et al., 2005).
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About 12-20% of Northern Europeans are heterozygotes for this mutation (ag) (Rhodes
et al., 1997). These HFE gene mutation carriers are usually asymptomatic, however
there is evidence that C282Y heterozygotes have higher total body iron stores
reflected by higher TS levels (Chan et al., 2005, Cade et al., 2005, Beutler et al., 2002,
Jackson et al., 2001), and reflected by lower R/F ratio (Chan et al., 2005). In a survey in
Denmark, Pedersen and Milman found that, among C282Y homozygotes, 89% had
elevated TS (>=50%) and 94% had elevated sF (>300 mcg/L). Among C282/wild type
(ag) heterozygotes, 9% had elevated TS, 9% had elevated sF, and 1.2% had elevated
both markers (n=2550) (Pedersen and Milman, 2009) compared to wild type.
6.3 Hypothesis and aim
It is hypothesised that women who carry the C282Y mutation in the HFE gene are at
lower risk of ID during pregnancy, and therefore their adult offspring will have on
average lower BP and less adiposity, as indicated by BMI and WC, than the offspring of
wild-type mothers.
The aim of this study is to use the concept of Mendelian randomisation study design to
examine the relationship between maternal iron status, using maternal sF as the
environmental measure of exposure (modifiable risk factor) and maternal C282Y
genotype as the IV, with offspring BP and adiposity measures (BMI and WC) in
adulthood, utilising both ordinary multivariable regression and IV regression methods
and comparing between their results.
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6.4 Methods
6.4.1 The cohort: the UK Women’s Cohort Study
The UK Women’s Cohort Study (UKWCS), which includes 35,372 women aged 35-69 at
recruitment across England, Wales, and Scotland, was established in 1994 to examine
the association of diet with cancer. Subjects in the cohort were selected to ensure that
there was a wide range of dietary patterns represented. The cohort was constructed to
have similar, large numbers of subjects in three main groups: vegetarian, fish-eaters
and meat-eaters.
The cohort was taken from responders to the World Cancer Research Fund’s (WCRF)
direct mail survey. This included people living in England, Wales and Scotland and used
direct mail lists, targeted towards females, with an overall response rate of 17%. Using
this approach, about 16 000 self-reported vegetarians and a similar number of other
non red-meat-eaters aged 35–69 years were identified, out of a total of 500 000
responders. Eighty-ﬁve per cent of the responders were women, and 75% indicated 
that they would be willing to participate in a more detailed survey. These women
formed the population to be contacted to become part of the UK Women’s Cohort. All
of the vegetarians and the non red-meat-eaters were invited to take part in the study.
A comparison group was selected from the remaining eligible women by selecting, for
each vegetarian, the next non-vegetarian in the list aged within 10 years of the
vegetarian. Further women were recruited from responders to the baseline data
collection, who were asked to identify friends and relatives of a similar age group who
were vegetarians and meat-eaters.
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One hundred and seventy-four local research ethic committees were contacted and
permission to carry out the study was obtained. Baseline data were collected between
1995 and 1998 via a postal questionnaire to each subject (Cade et al., 2004).
6.4.2 Exposure assessment in the second phase of UKWCS
Approximately 15,000 women from UKWCS were contacted for a second time between
1999 and 2002 to acquire more detail on diet. They were sent 2 cytology brushes and
asked to provide cheek cell samples for DNA extraction (phase II data collection). These
samples were returned by mail and refrigerated until DNA extraction could be
undertaken.
A protocol for high throughput screening was developed for the HFE mutations
associated with haemochromatosis. This involved a simple DNA extraction method
that uses sodium hydroxide cell lysis for cheek cells, adapted from the method of
Rudbeck and Dissing (Rudbeck and Dissing, 1998). This was followed by a highly
sensitive fluorescent Amplification Refractory Mutation System (ARMS) technique.
DNA from the buccal cells was of insufficient quality to use a traditional restriction
digest for detection of the 2 mutations, C282Y and H63D (Worwood et al., 1997). The
ARMS technique is a sensitive analysis that can be used for any point mutation
(Newton et al., 1989, Baty et al., 1998).
All subjects who were found to be homozygous or heterozygous for the C282Y gene
mutation were also asked to provide a blood sample, to confirm the result from the
cheek cell DNA and to measure markers of iron status including sF. This was measured
with a 2-site chemiluminometric (sandwich) immunoassay (Bayer, Newbury, United
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Kingdom) performed in the Department of Clinical Biochemistry and Immunology.
Methods were validated by participation in recognized quality-assurance schemes. In
addition, 3000 women were randomly selected and asked to provide a blood sample
for both measurement of iron storage markers and DNA to act as a control group (Cade
et al., 2005).
C282Y homozygotes were found to have significantly higher sF, transferring saturation
and serum iron levels compared to wild type women. C282Y heterozygotes had
significantly higher TS levels compared to wild type women. Cade et al. describe the
full results of this analysis (Cade et al., 2005) . The genotype assessed in this study was
used as a proxy (IV) for maternal iron status in our sub-cohort as described below.
6.4.3 The sub-cohort: the UK Women’s Cohort Study - Iron and
Blood Pressure sub-cohort
For this analysis, 1416 mothers, identified as reporting having at least one live child in
the first UKWCS questionnaire, were contacted between 2008 and 2010, of whom 716
were C282Y allele carriers (aa or ag), and 700 were wild type HFE genotype (gg). H63D
carriers were not included in the sampling as this mutation on its own is not clinically-
important unless it occurs in combination with the C282Y mutation (compound
heterozygotes) (Waheed et al., 1997). The non-exposed in this sample were randomly
selected from the pool of women with one or more children who were tested and
found to have a wild type genotype. The total number of offspring for women
contacted in this study was 3376, of whom 1686 were children to C282Y carrier
mothers and 1690 to wild type mothers (Figure 12)
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Figure 12: UKWCS- IBPS participant flowchart
6.4.3.1 Recruitment stages
Recruitment started in December 2008 and finished in October 2010.
Stage 1 – Study sample was identified as a sub-cohort of the UKWCS (as described
above) and mailed in batches
Stage 2 –A study pack was sent to the mothers, containing a study invitation, a study
information sheet, a pack for them to pass on to each of their offspring over the age of
18 with a stamped envelope for each of these packs. The offspring pack contained the
offspring’s study invitation letter, an offspring’s information sheet, a study consent
form to fill in, sign and send back to the study team with their contact details and a
stamped, addressed envelope for the consent forms.
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Stage 3 – Offspring who have replied wanting to take part in the study were sent a
study pack including a tape measure with instructions on how to measure waist and
hip circumference, a form to write down them down, a lifestyle and diet questionnaire
to complete, a GP/practice nurse pack and an addressed freepost envelope for the
participant to return the two measurement forms and the completed lifestyle
questionnaire to the study team. The GP pack contained a GP/practice nurse
information letter, BP, height and weight standard operating procedure (SOP), a
measurement form, and a stamped envelope for the practice to claim any charges for
the measurements (up to £15 per participant). Participants were asked to make an
appointment with their practice requesting to have the measurements done as part of
the study and to take the measurement form with them for the GP/nurse to fill-in and
return to the study team.
Stage 4 – Reminder letters were sent to the mothers whose children had not replied.
Also letters were sent to these mothers’ alternative contacts to find out if the mothers’
addresses were valid and obtain new addresses if appropriate.
Stage 5 – Second reminders were sent to the mothers with prepaid reply slips to let
the study team know if they have passed the study packs to their children or if they do
not wish to be contacted further in relation to this specific study.
Stage 6 – Reminders were sent to the children who have consented but not completed
the study.
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Stage 7 – Second reminders to the children who have consented but not completed
the study were sent by e-mail. A telephone contact was made for participants who
have not supplied a valid e-mail address.
All the study documents described above are included in appendix 10.5.
6.4.4 Outcome measurement
6.4.4.1 Blood pressure, height and weight
Height, weight and BP were measured at each participant’s general practice. A
standard operating procedure for the measurement of height, weight and BP sheet
was attached to the GP/practice nurse’s letter, and practice staff were asked to follow
it when taking the measurements. We asked for two BP measurements at least 1
minute apart. If the first and second measurement differed by more than 5 mmHg for
either the systolic BP or diastolic BP, a third measurement was requested at least 1
minute after the second measurement. The mean of the 2 or 3 readings was used in all
analyses. The type of the BP machine, brand name if automatic, position
(sitting/standing), left or right arm, and cuff size were asked to be recorded on the
measurement form.
6.4.4.2 Waist circumference
The offspring who consented to take part in the study were asked to self-measure
their WC following specific instructions using a tape measure supplied in the study
pack. Two measurements were requested (in inches or centimetres), and their mean
used in all analyses.
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6.4.5 Covariable measurement
Each participant was asked to fill in a diet and lifestyle questionnaire. This included
information on birth weight, siblings, educational attainment, employment, ethnic
background, marital status, smoking, alcohol and caffeinated drinks use, physical
activity, medical conditions, and medications consumed. The questionnaire included a
123-item FFQ as well as questions about other dietary habits including vegetarian
status and salt intake.
6.4.6 The causal model
Figure 13 demonstrates the hypothesised causal relationships underlying the models
tested in this study.
6.4.7 Sample size calculation
The SD for diastolic BP from the Health Survey for England 2003 is 11.6 mmHg for men
aged 35-44 years and 11.0 mmHg for women of the same age group (Craig and
Mindell, 2003). Using a SD of 11.3 mmHg (average), the sample size required to
achieve adequate power for a range of effect sizes for a two-sample t-test at the 5%
significance level to detect a difference in diastolic BP between offspring of women
with the C282Y allele and offspring of women with the wild type allele was calculated
using different levels of response rate (Table 29).
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* The minus sign indicate a hypothesised inverse relationship
Figure 13: Causal diagram for the relationship between maternal iron status in
pregnancy and BP/obesity in the offspring using IV analysis in the UKWCS – IBPS
Response rate Number per
group (n)
Minimum difference
in diastolic BP in
mmHg to detect at
80% power
Minimum difference in
diastolic BP in mmHg to
detect at 90% power
100% 1675 1.1 1.3
50% 840 1.6 1.8
30% 500 2.0 2.3
10% 160 3.6 4.1
Table 29: Sample size calculations for the UKWCS-IBPS
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6.4.8 Statistical analysis
Analysis was performed using Stata, version 11 (Stata Corporation, College Station, TX).
The relationship of interest was examined using both OLS regression and IV regression
modelling using the ‘ivreg2’ command in Stata. The two modelling methods used (OLS
and IV regression) are examining the same association of maternal iron status and
offspring adiposity and BP outcomes, using the difference in offspring systolic BP,
diastolic BP, WC and BMI per 10 ug/l greater maternal sF. Neither is testing the direct
link between the maternal C282Y genotype and offspring outcomes.
Clustering of siblings (where there was more than one sibling per mum included in the
study) was adjusted for using the ‘robust cluster’ command in Stata which computes a
cluster-robust standard error of the difference in both the OLS and the IV analyses.
6.4.8.1 IV regression
We used two-stage least square (2SLS) as a method of estimation for IV regression,
with maternal C282Y genotype (aa, ag or gg) as the instrument, under an additive
model, and maternal ferritin as the modifiable risk factor of interest. We included
systolic BP, diastolic BP, WC, and BMI, as outcomes. In the first stage of the 2SLS
model, the regression of maternal ferritin on C282Y (instrument) is fitted. In the
second stage, the outcome is regressed on the predicted values of maternal ferritin,
the coefficient of which is the estimate of the causal effect. The standard errors of the
second stage parameters are appropriately corrected to account for the uncertainty in
the predicted values of the exposure from the first stage.
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The first stage F-statistic is reported to provide an indicator of the instrument strength.
Values of 10 and over are taken to be sufficient to exclude weak identification using
the specified instrument (maternal C282Y) (Staiger and Stock, 1997). The weak
identification F statistic we used for the IV regression in the case of specification of
‘robust cluster’ in the model is based on the Kleibergen–Paap rk statistic, the null
hypothesis being that the estimator is weakly identified by the instrument (Baum et
al., 2007). Rejecting the null hypothesis indicates the instrument has sufficient
strength (Baum et al., 2007).
6.4.8.2 OLS regression
The exposure in these analyses was maternal sF and the main outcomes were offspring
BP, MI and WC. Child age, maternal age (at phase II of the UKWCS) and child gender
were considered confounders and adjusted for in the multivariable OLS models. In
addition, maternal BMI (at phase II) and maternal social class (as classified according to
the three category National Statistics Socio-economic Classification) were considered
confounders and adjusted for in the multivariable OLS models with offspring BMI and
WC as outcomes. Other potential confounding factors were tested for association with
the exposure and offspring’s BP and adiposity, and were included in the multivariable
OLS model if they showed a statistically significant relationship with both.
6.4.8.3 The difference between the IV and the OLS estimates
The standard errors of the differences between the IV and the multivariable OLS
estimates were estimated using 10,000 bootstrapped replications (Schluchter, 2008).
P-values were then calculated from these standard errors based on a normal
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approximation for the sampling distribution of the mean differences. The Stata code
for this analysis is attached in appendix 10.5.3.
6.4.9 Ethical approval
This study was conducted according to the guidelines laid down in the Declaration of
Helsinki and all procedures involving human subjects were approved by the NHS North
West Research Ethical Committee (REC reference number 07/H1010/68). Written
informed consent was obtained from all participants.
6.4.10 Funding
The work included in this chapter was supported by the Wellcome Trust [Grant
number WT87789 to N.A.A.] The mailing and GP reimbursement costs were covered by
grants from the Rural Environmental Scientific and Analytical Service (RESAS) of the
Scottish Government and the European Union (EARNEST) to Professor Harry J McArdle
at the Rowett Institute of Nutrition and Health, University of Aberdeen.
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6.5 Results
6.5.1 Response rate
Of the original 3376 offspring, 517 (17%) consented to take part, and 348 offspring of
277 mothers completed the study (10% of the invited sample, 61% of those who
consented). 170 (49%) were children of C282Y mutation genotype mothers, of whom
12 were children of 11 homozygotes mothers (aa), and 158 were children of
heterozygous mothers (ag).
6.5.2 Sample characteristics
Of those 348 who completed the study, 247 (71%) were females and 101 (29%) were
males. The mean age was 41 years for women (95% CI 40, 41) and 40 years (95% CI 38,
42) for men. All participants who reported ethnicity information (n=335) described
their ethnic group as white. 212 offspring had no other siblings, 117 had one sibling
included in the study, 15 had 2 siblings and 4 had 3 siblings included. Four percent
(n=13) had systolic, and 2% (n=7) had diastolic hypertension, according to the WHO
cut-off points of 140/90 mmHg (Whitworth, 2003). Around 10% of participants had
BMI equal to or more than 30 kg/m2. This is lower than the Health Survey for obesity
estimate of 25% (Health Survey for England (HSE), 2010). Fifty eight percent of
participants reported having professional or senior management jobs. The mean BMI
was 24, and the mean BP was 117/73 mmHg.
The characteristics and measurements of the study participants are described in table
30 and table 31.
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Number Percentage 95% CI
Body mass index (kg/m2) (n=335)
<25
25-29
≥30
214
88
33
63.9
26.3
9.9
58.5, 69.0
21.6, 31.3
6.9, 13.6
Smoking (n=340)
Current smoker
Ex-smoker
Never smoked
33
106
201
9.7
31.2
59.1
6.8, 1.3
26.3, 36.4
53.7, 64.4
Alcohol intake (n=339)
Regular
Once/week
Occasional / never
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46
86
61.1
13.6
25.4
55.6, 66.3
10.1, 17.7
20.8, 30.4
Marital status (n=333)
Married
Single
Divorced/separated/widowed
105
115
33
55.6
34.5
9.9
50.0, 60.9
29.4, 39.9
6.9, 13.6
Vegetarian (self-reported) (n=332)
44 13.3 10.0, 17.4
Hypertension (self-reported, n=340)
21 6.2 3.9, 9.3
Systolic blood pressure >140 mmHg
(n=336) 13 3.9 2.1, 6.5
Diastolic blood pressure >90 mmHg
(n=336) 7 2.1 0.8, 4.2
Any exercise during the week
Vigorous (n=332)
Moderate (n=337)
Light (n=339)
197
259
315
59.5
76.6
92.9
53.8, 64.7
72.0, 81.3
89.6, 95.4
Self-reported occupation (n=286)
Professional/senior managers
Intermediate/technical
Routine/semi-routine manual
Self-employed
Student
Unemployed
165
54
15
41
9
2
57.7
18.9
5.2
14.3
3.2
0.7
51.7, 63.5
14.5, 24.1
3.0, 8.5
10.5, 18.9
1.4, 5.9
0.08, 2.5
Self-reported low birth weight (<2500g)
(n=230) 15 6.5 3.7, 10.5
Table 30: UKWCS-IBPS offspring’s characteristics by sex
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Mean SD 95% CI Median
Height (cm) (n=335)
F
M
169
165
180
9.8
7.0
8.1
168, 170
164, 166
178, 181
168
165
179
Weight (kg) (n=338)
F
M
70
66
81
14.3
12.1
13.3
69, 72
78, 84
64, 67
67
64
80
BMI (kg/m2) (n=335)
F
M
24.3
24.0
25.0
4.2
4.3
3.9
23.9, 24.8
23.5, 24.6
24.2, 25.8
23.6
23.3
24.6
Systolic BP (mmHg) (n=336)
F
M
117
114
124
13.6
12.6
13.5
115, 118
112, 115
121, 126
116
113
123
Diastolic BP (mmHg) (n=336)
F
M
73
71
76
9.2
8.7
9.7
72, 74
70, 73
74, 78
72
71
76
Waist circumference (cm) (n=341)
F
M
83
81
90
12.4
11.3
12.7
82, 85
79, 82
87, 92
81
78
90
Hip circumference (cm) (n=342)
F
M
99
99
99
10.1
10.1
10.1
98, 100
98, 100
97, 101
99
98
100
Waist/hip ratio (n=341)
F
M
0.84
0.81
0.91
0.09
0.07
0.11
0.83, 0.85
0.81, 0.82
0.89, 0.93
0.83
0.81
0.91
Table 31: UKWCS-IBPS offspring’s measurements
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6.5.3 Differences between genotype groups
There were no statistically significant differences between offspring of C282Y mutation
mothers (aa & ag) and those of wild-type (gg) mothers in age, gender, smoking, marital
status, reported LBW, vegetarian status, frequency of takeaway foods, frequency of
exercise, occupational classification (as a measure of socioeconomic status), systolic
and diastolic hypertension, systolic BP, BMI category, BMI, and WC (adjusting for
clustering of siblings within families). Figure 14 shows the average offspring BP, WC
and BMI per each maternal genotype. There was a positive relationship between
diastolic BP in females and maternal C282Y genotype (change 2.5 mmHg, 95% CI 0.3,
4.8, P=0.03). There was a statistically significant interaction between gender and
maternal genotype on offspring’s diastolic BP (P=0.05).
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Figure 14: Mean offspring systolic and diastolic blood pressure (SBP & DBP), body
mass index (BMI) and waist circumference (WC) per maternal genotype
6.5.4 Associations of the modifiable risk factor (maternal ferritin)
versus the IV (maternal C282Y) with potential confounders
Maternal sF was associated with maternal age, offspring age, maternal and offspring
vegetarian status, whereas there was no statistical evidence that maternal C282Y
genotype was associated with any of these factors (Table 32). Maternal vegetarian
status was significantly linked to both maternal ferritin and offspring DBP, and
therefore was additionally entered in the multivariable OLS model with DBP as the
outcome.
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Maternal Ferritin Maternal C282Y
Maternal age <0.0001 0.9
Offspring age <0.0001 0.9
Offspring gender 0.3 0.4
Maternal vegetarian status <0.0001 0.8
Offspring vegetarian status 0.003 0.9
Maternal smoking 0.1 0.1
Maternal social class 0.5 0.9
Maternal body mass index 0.2 0.8
Table 32: Univariable P values of the association between maternal serum ferritin
and maternal C282Y with potential confounders in the relationship between
maternal iron status and offspring outcomes
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6.5.5 Associations of the modifiable risk factor (maternal ferritin)
with the IV (maternal C282Y) and study outcomes
Maternal C282Y was strongly associated with maternal sF, with a mean difference per
each additional allele of 84 ug/l (95% CI 31,137, P=0.002).
In univariable analysis, maternal ferritin was linked to offspring’s diastolic BP
(0.1mmHg for every 10 ug/l increase in maternal sF, 95% C 0-.03, 0.3, P=0.02),
offspring WC (0.2 cm for every 10 ug/l increase in maternal sF, 95% CI 0.06, 0.3,
P=0.006), and offspring’s BMI (0.05 kg/m2 for every 10 ug/l increase in maternal sF,
95% CI 0.002, 0.1, P=0.04). However, these associations did not persist in the
multivariable OLS model. Table 33 shows the results of associations of maternal sF
with each offspring outcome from both the confounder-adjusted multivariable
analyses and the IV analyses using maternal C282Y as the instrument. The first stage F
statistic for the strength of the instrument in the IV analysis was 10, and the
Kleibergen-Paap rk LM P-value = 0.009 for all outcomes considered. There was no
relationship between maternal sF and offspring BP, WC or BMI using both regression
methods. There was also no significant difference between the OLS and the IV analyses
regression coefficients for any of the outcomes considered.
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Outcome OLS* mean difference
in outcome per 10 ug/l
greater maternal
ferritin (95% CI)
IV** regression mean
difference in outcome
per 10 ug/l greater
maternal ferritin (95%
CI)
P value***
For the
difference in
regression
coefficients
Systolic BP
(mmHg)
0.03 (-0.1, 0.1) 0.2 (-0.2, 0.6) 0.5
Diastolic BP
(mmHg)
0.04 (-0.07, 0.2) 0.2 (-0.07, 0.5) 0.6
Body mass
index (kg/m2)
0.02 (-0.02, 0.07) 0.1 (-0.03, 0.2) 0.5
Waist
circumference
(cm)
0.1 (0, 0.2) 0.07 (-0.3, 0.5) 0.9
*Multivariable ordinary least squares models adjusted for maternal age, child age and gender in all
models, and additionally for maternal vegetarian status in the diastolic BP model, and maternal BMI and
social class (NS-SEC) in the BMI and WC models.
**Instrumental variable two stage least squares (2SLS), first stage F-statistic =10
*** Derived using 10,000 bootstrapped replications to estimate the standard errors of the differences
between the IV and multivariable OLS regression estimates
Table 33: Association of maternal iron status with offspring blood pressure and
adiposity measures using maternal C282Y status as an instrumental variable
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6.6 Discussion
In this analysis, the association of maternal iron status with adult offspring’s BP, BMI
and WC was examined. Two methods were compared; confounder-adjusted
multivariable analyses, and analyses where a genetic mutation (C282Y) in the HFE gene
was used as an IV for maternal iron status. The study shows that maternal iron status
was not associated with the three offspring outcomes considered in this study using
either method. There was also no statistical evidence that the associations differed
between these two statistical approaches. In this sample, maternal C282Y genotype
was associated with ferritin level. This supports the apriori hypothesis that HFE C282Y
could be used as an IV for iron status.
6.6.1 Previous studies
There are no previous studies examining the relationship of maternal iron status with
adult offspring BP and adiposity using either approach (OLS or MR). Previous studies
have examined the relationship of maternal iron intake and Hb levels in pregnancy
with children’s BP (Brion et al., 2008, Belfort et al., 2008). Belfort et al. reported a
positive, rather than an inverse, association between maternal iron intake in
pregnancy and child systolic BP at 3 years (Belfort et al., 2008), while Brion et al. found
no association (Brion et al., 2008). The findings of these studies are discussed in more
detail earlier in this thesis in section 2.3.3.
6.6.2 Study strengths
A key strength of this study is that it is the first to examine the association of maternal
iron status with adult offspring BP and adiposity in a human population. Thus, the
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observations from previous animal work (Gambling et al., 2003b, Gambling et al.,
2003a, Crowe et al., 1995, Gambling et al., 2004b) were tested in a human population.
Maternal genotype was robustly measured and ascertained, and the main outcomes
measures of offspring BP and BMI were objectively measured by the general
practitioner or the practice nurse following a standard operating procedure.
Maternal sF was used as a measure of iron status, as there is evidence that ferritin
alone provides a good approximation of total body iron reserves, as validated by R/F
ratio in people with un-elevated C-reactive protein (Yang et al., 2008). Although there
is a possibility this approximation may vary in pregnant women.
I have tried to examine the association using two statistical approaches with different
underlying assumptions for assessing causality that complement each other. The
multivariable approach assumes that potential confounding factors are accounted for,
correctly measured and modelled and that there is no possibility of reverse causality.
In this case, reverse causality is unlikely (i.e. we cannot see how offspring outcomes
could influence the mothers iron status). However, residual confounding is still
possible with this approach.
6.6.3 Study limitations
6.6.3.1 Measurement of maternal iron status
This study did not have information on maternal iron intake during pregnancy. We
have also used maternal sF concentrations assessed many years after they were
pregnant with the offspring, and are therefore assuming in these analyses that this is a
reasonable proxy for maternal iron status in pregnancy. Any potential measurement
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error because of this is likely to be non-differential with respect to the offspring
outcomes that we have assessed here, and therefore the expectation would be that
results would be biased towards the null. Thus, this measurement error might explain
the null multivariable observations.
For the IV analyses, using maternal iron concentrations outside of pregnancy is not a
major limitation as the genetic variant will have resulted in subtle differences in iron
status throughout the woman's lifecourse including during pregnancy. This approach is
also less influenced by residual confounding. However, the IV analysis assumes that
the instrument is associated with the risk factor of interest, which we know is the case
from previous studies and which we have demonstrated here, though the first stage F-
statistic of 10, suggests that the instrument’s strength to identify the estimator
(maternal ferritin) is borderline (Staiger and Stock, 1997). This would potentially bias
the IV analysis towards the null results seen in the multivariable analysis. Using
another measure of iron stores during pregnancy which is not affected by
inflammation, such as R/F ratio, could result in strengthening the genetic instrument.
6.6.3.2 Violation of IV analysis assumptions
It is further assumed that the IV (here C282Y mutation in the HFE gene) is not
associated with any measured or unmeasured confounding i.e. is naturally randomised
in the population. This is confirmed by testing the association between maternal C282Y
and selected measured factors in our data as shown in table 32. However, one of the
conditions of IV analysis is that the instrument should not be related to the outcome
except through the exposure of interest (Z related to Y only through X). The fact that
maternal genotype is linked to offspring genotype may constitute a violation to this
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assumption. Figure 15 shows the causal diagram for the relationships in this study with
this possibility taken into account. Such violation would be the case in all trans-
generational studies that attempt to use a MR design. Statistical simulation work may
be needed to simulate the genotype possibilities for the offspring and take them into
account in the analysis. The ideal way to tackle this problem would be to measure
offspring genotype and adjust for it. Hence, one of the main limitations in this study is
that offspring genotype was not measured.
There is some evidence linking C282Y heterozygotes with an increased risk of CVD
(Tuomainen et al., 1999, Rasmussen et al., 2001). . However, other studies show no
association (Gunn et al., 2004, Ellervik et al., 2005). If there is a true positive
relationship between offspring genotype and their BP, this may counteract an inverse
relationship between maternal genotype (used as a proxy for maternal iron status
here) and offspring’s BP, potentially leading to a spurious non-association in the
relationship of interest. However, it could be argued that it is the iron status at the
time of gestation that is the contributing factor to cardiovascular risk, and not the
phenotype of the fetus.
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The minus sign indicate a hypothesised inverse relationship, and the plus sign indicate a hypothesised
positive relationship
Figure 15: Causal diagram with the role of offspring genotype and iron status
included - the UKWCS - IBPS
6.6.3.3 Response rate
The study’s response rate of 10% meant that the study had a smaller sample size than
initially planned. MR studies require sample sizes larger than classical epidemiological
studies due to reduced precision of the estimates as genotype usually only explains a
proportion of the variation in the environmental exposure of interest. Also over half of
the offspring sample reported having professional/senior manager occupations,
suggesting potential selection bias with responders being more likely to be health
conscious with a lower prevalence of cardiovascular risk compared to the general
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population. This is supported by the low prevalence of obesity in the study sample.
Therefore, the results may not be generalisable to the general UK population.
The relatively poor response rate may be due to the indirect recruitment method
used, as mothers were asked to pass on the study information to their children in
paper format, which potentially involved posting it to them. Therefore, loss to follow
up occurred at two levels in this study: mother and child. Some of the mothers were
not contactable through their postal address, and the UKWCS database did not include
a comprehensive list of participants’ electronic contact addresses. However, every
effort was made to achieve a good response rate by sending reminder letters to
mothers whose children have not replied, as well as attempting to obtain the most
recent addresses by sending letters to mothers’ alternative contacts. Reminders were
also sent to the children who have consented but not completed the study by post, e-
mail or telephone contact.
Future MR studies should consider recruitment methods where the offspring are
directly contacted and invited to take part. However, careful consideration to ethical
issues implied in potentially sharing confidential maternal information (genotype)
should be given. Also consent must be sought from both mother and child regarding
mothers passing on contact information for their children to the research team.
The task of visiting the GP for the offspring which was involved in the study is likely to
have also played a part in reducing the study’s response rate, as over one third of the
offspring who consented to take part, did not send their measurements. Some of these
participants contacted the study team and apologised for not completing the study
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due to being too busy to obtain a suitable time and date for a GP appointment due to
work commitments.
6.7 Conclusion
In this chapter, there was no evidence of association between maternal iron status and
adult offspring’s BP and adiposity using both multivariable OLS regression and IV
modelling with maternal C282Y mutation in the HFE gene as the instrument. However,
the relatively small study sample for a MR design and the lack of measurement of the
offspring C282Y genotype in order to adjust for any possible effect on the relationship
of interest are likely to push the study results towards accepting the null hypothesis.
Therefore, replication of findings in MR studies that avoid these limitations should be
considered.
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7 General discussion
7.1 Chapter summary
Chapters 3, 4, 5 and 6 contain discussion sections for the individual studies included in
this thesis which include strengths, weaknesses and implications of findings for each
study. However, in this chapter I attempt to pull all the previous chapters’ findings
together and further discuss their implications. I start with summarising the results
across the four studies by type of exposure and exposure-outcome associations. This is
followed by reviewing the main strengths and limitations of this thesis as a whole. I
then discuss how the results from this thesis compare with findings of experimental
animal studies described earlier in section 2.3.1. The findings relating to maternal Hb
and iron intake from diet and supplements during pregnancy are further commented
on in this chapter in relation to possible underlying mechanisms and relevance to
practice. This leads to the general conclusion of this thesis and recommendations for
further research and practice.
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7.2 Summary of thesis findings
7.2.1 Maternal iron status indicators in pregnancy
I have shown in section 5.5.1, with data in the 1990s from ALSPAC based in the South
West of England, that 90% of women had dietary iron intake below the UK RNI (14.8
mg/day) and a quarter below the UK LRNI (8 mg/day). A decade later in the CARE study
in Leeds (section 3.5.3.1), this was much the same despite using different dietary
assessment methods in the two studies, with 80% of women having daily intakes in
early pregnancy below the UK RNI for iron, and nearly a quarter below the UK LRNI.
A considerable proportion of pregnant women reported taking iron supplements
during pregnancy despite the lack of a national recommendation for routine iron
supplements in the UK. In ALSPAC, 45% of women reported taking iron supplements
before 32 weeks gestation. In the CARE study, 24% of women reported taking iron-
containing supplements in the first trimester, 15% in the second trimester and 8% in
the third trimester. In Baby VIP, conducted 10 years after CARE and 20 years after
ALSPAC with supplement data extracted from the medical notes rather than self-
reported, only 2% of women took iron supplements in the first trimester, 19% in the
second trimester, and 13% in the third trimester. Out of those with iron depletion in
the first trimester, only 58% took iron supplements at any stage in their pregnancy.
In the Baby VIP study, 23% of women had iron depletion in the first trimester as
defined by WHO cut-off (sF <15 ug/l), and 80% had a sF of less than 70 ug/l, which is
considered by some experts as the threshold above which there is no benefit of
recommending iron supplements (Milman, 2006b). In this study, 5% of women were
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anaemic (Hb <11 g/dl) in the first half of pregnancy, while 14% were anaemic (Hb <10.5
g/l) in the second half. In the CARE study, 3% of women were anaemic at 12 weeks,
compared to 23% at 28 weeks gestation. In ALSPAC, 4% were anaemic by 18 weeks
gestation.
7.2.2 Exposure-outcome associations
It is important to note that all the research studies included in this thesis are of
observational study design, therefore causality cannot be inferred from any of the
associations observed. However, this type of study design may be the best available for
most associations examined in this thesis. Conducting RCTs to test the hypothesis of
interest can be considered unethical particularly concerning the exposures of maternal
dietary iron intake and ID in pregnancy.
In the CARE study, total iron intake from diet and supplements in early pregnancy was
positively associated with birth weight centile, though the intake of the well-absorbed
form of dietary iron, haem iron, was not. The potential explanation for this lack of
association was discussed in sections 3.6.1.1 and 3.6.3.3. In this study, maternal
dietary supplement intake at any stage in pregnancy was not associated with birth
weight centile/SGA. However, MVM supplements intake in the third trimester of
pregnancy, most of which contained iron, was associated with around a 3-fold increase
in the risk of preterm birth. This finding can be due to residual confounding as
discussed in section 3.6.2.1. Residual confounding may have also played a part in the
observed association between maternal iron supplement intake before 32 weeks
gestation and lower offspring systolic BP at 10 years in ALSPAC, as discussed in section
5.6.1. 1. In this study, maternal dietary iron intake assessed at 32 weeks gestation was
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not associated with offspring cardiovascular indicators at 10 years (PWV, FMD. BP and
BMI).
In the Baby VIP study, maternal anaemia in the first half of pregnancy was associated
with increased infant bfPWV at 2-6 weeks. However, no association was observed
between infant arterial stiffness and maternal iron depletion in early pregnancy. The
implications of these findings were further discussed in section 4.6.2.1. Maternal ID
was associated with increased risk of having a SGA baby, so was maternal anaemia (Hb
<11 g/dl) in the first half of pregnancy. In contrast, Hb at 28 weeks gestation was
positively associated with increased risk of SGA in the CARE study. However,
associations between maternal Hb/anaemia during pregnancy were not observed later
in life with offspring cardiovascular indicators at 10 years (PWV, FMD, BP and BMI).
There was no evidence of association in this thesis between maternal iron
status/depletion in early pregnancy (measured by sF and sTfR) and preterm
birth/gestational age/birth weight centile. However, there are other studies which
have found such associations as discussed earlier in section 2.2.5.
The association between maternal iron status and CVD risk indicators in the offspring
was investigated in the UKWCS-IBPS element of this thesis. There was no evidence of
association between Maternal sF and adult offspring BP/BMI/WC both using OLS and
IV modelling with C282Y genotype. This genotype was shown to be associated with
maternal sF in this dataset, justifying its utilisation as an IV. This was the first study to
my knowledge examining the association of maternal iron status with adult offspring
BP and adiposity in a human population using a MR design. The design of this study is
innovative and the offspring outcomes are measured in adulthood, however
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awareness of its limitations is essential before making solid conclusions about the lack
of association between the exposure and outcomes of interest. These limitations with
suggestions to improve the design in future studies were discussed in detail in section
6.6.3.
7.3 General strengths and limitations
7.3.1 Study design
All the four studies included in this thesis are of observational cohort study design. All
the exposures were assessed before the occurrence of outcomes, therefore minimising
the risk of bias incurred when the exposures are assessed after the assessment of
outcomes. Three of the studies were of prospective cohort design (ALSPAC, CARE and
UKWCS), while the Baby VIP study was of historical cohort design, where maternal iron
status was assessed from samples collected in the first trimester of pregnancy and
retrieved after recruitment at birth.
It is unethical to deprive participants of iron to induce ID before or during pregnancy. It
can also be considered difficult to randomise them not to have supplements if they are
routinely recommended in pregnancy as is the case in most countries, and following
international guidelines such as the WHO’s. However, in the UK routine iron
supplementation in pregnancy is not recommended, therefore the potential is there
for a RCT and a follow-up of a RCT to examine the effect of iron supplements on long
term offspring cardiovascular risk indicators. Also RCT design could be implemented to
compare the benefit of supplements versus dietary interventions in maximising iron
intake and absorption during pregnancy.
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7.3.2 Study sample
The collective sample size for all the studies investigated in this thesis was 4942
participants (CARE=1274, Baby VIP=362, ALSPAC=2958, UKWCS=348). Statistical power
calculations were performed based on clinically-important associations as reported in
the chapters’ methods sections. However, for novel outcome measures such as infant
PWV used in the Baby VIP study, a clinically or epidemiologically important effect size
is still unknown. Therefore, if smaller differences are clinically important, in terms of
predicting long-term health outcomes, then the current study will be underpowered to
detect such associations and a larger study could be justified. Also, the response rate
to recruitment and rate of study completion was relatively poor in some of the studies
e.g. 20% in the CARE study and 10% in the UKWCS-IBPS. This limitation and its
potential reasons is discussed further in section 6.6.3.3.
7.3.3 Exposure measures
In the UKWCS-IBPS, maternal genotype was robustly measured and ascertained.
Maternal iron status in pregnancy was also assessed objectively using biomarkers
including sF, sTfR and Hb. The best measure of body iron, R/F ratio, was used to assess
maternal iron status in the Baby VIP study (Zimmermann, 2008). However, this was not
feasible in all of the included studies. Although data on Hb levels was available in CARE,
ALSPAC and Baby VIP, the limitations of using Hb as a marker of iron status were
discussed earlier in section 2.4.1.
Supplement intake was assessed via ascertainment from the medical notes in Baby
VIP, a researcher-administered interview in CARE and a self-reported questionnaire in
ALSPAC, raising the possibility of misreporting bias. The limitations of the methods of
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assessment of supplement intake are discussed further in sections 3.6.3.3 and 5.6.4.2.
Dietary iron intake was reported using commonly-used dietary assessment methods
including FFQ and 24-hour dietary recall. These have their own limitations as discussed
in the corresponding chapters (sections 3.6.3.3 and 5.6.4.2), mainly the potential for
considerable measurement bias. This point is also discussed further below in section
7.6.
7.3.4 Outcome measures
One of the main strengths of this thesis is the inclusion of objectively-assessed
outcome measures including birth weight, gestational age, PWV, FMD, BP and BMI.
None of the outcomes were self-reported apart from WC in the UKWCS-IBPS, and
attempts were made to minimise the chance of bias in assessing them. These included
rigorously training the researchers performing the measurements and carefully
following standard operating procedures if measurements were made by people
outside the research team, such as GPs and practice nurses. In case of vascular and
adiposity outcomes in infanthood and childhood explored in Baby VIP and ALSPAC,
there is no solid evidence that these measures predict cardiovascular end-points in
adulthood. Therefore, examining these associations using adult indicators of
cardiovascular risk is required.
7.3.5 Using multiple epidemiological studies at different time
points in the lifecourse to address the hypothesis of interest
The hypothesis of interest addressed in this thesis would ideally be addressed with one
longitudinal study that spans from pregnancy to offspring’s old age, with valid and
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reliable exposure and outcome assessment. Such data are unavailable at present.
Therefore, a pragmatic approach was adopted here to examine different aspects of the
hypothesis using multiple studies which assessed the outcomes at different time
points in the offspring’s lifecourse. This approach has its limitations as the studies are
different in their design, exposure and outcome assessment methods, study
population and size. All these factors play a big role in formulating the findings and
influence the generalizability of the results. Synthesising the results together, as I
attempt to do in this chapter, is difficult because of the significant heterogeneity
between the studies. Therefore, each chapter has been written with a stand-alone
specific hypothesis which it proceeds to test. Recommendations for future research
studies that would potentially advance the science relating to the topic in this thesis
are presented in the next chapter (section 8.3).
7.4 How do the findings compare with the evidence from
experimental animal studies?
In this thesis, the clear-cut relationship generated by animal research between
maternal iron status in pregnancy and offspring cardiovascular outcomes was not
established. Neither has it been established in other research investigating this
relationship in population studies (Brion et al., 2008, Belfort et al., 2008), which was
reviewed in sections 2.3.3 and 5.6.2. Although there was an association in the
expected direction between maternal anaemia in early pregnancy and infant PWV in
the Baby VIP study, only half of the anaemic women in this sample were iron deficient.
This raises the possibility that maternal anaemia is potentially related to infant
outcomes through pathways other than ID such as chronic tissue hypoxia and
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heightened maternal and fetal stress responses (Allen, 2001). Although infant PWV
was unexpectedly inversely associated with SGA, but not very SGA (<3rd birth weight
centile), the results of chapter 4 back Koudsi et al. finding of a positive association
between infant aortic PWV and birth weight (Koudsi et al., 2007).
The other significant relationship observed in this thesis is from the ALSPAC analysis
where there was a modest inverse association between the mother taking iron
supplements in pregnancy any time before 32 weeks gestation and child systolic BP at
10 years. However, the possibility of residual confounding is high in this relationship,
as intake of iron supplements may not be directly dependent on iron status, as shown
in findings from the Baby VIP study (section 4.5.1.4). Rather it may be an indication of
health beliefs in the mothers, which are usually reflected in other lifestyle factors
(Conner et al., 2001).
There are some questions generated by comparing the findings in this thesis which
were derived from population studies, to those shown in experimental animal studies.
These are discussed with potential explanations below.
7.4.1 Is maternal iron more important to short term compared to
long term offspring outcomes?
The findings of this thesis suggest that maternal iron intake and status has a strong
association with immediate offspring birth outcomes such as size at birth. Other
evidence also suggest an association with other outcomes in the first few months in
life such as infant ID as discussed in section 2.2.6. However, such an association may
start to attenuate the further the outcomes are assessed down the offspring’s
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lifecourse. Therefore, the effect of ID could be real but potentially modifiable by later
diet and environment exposures throughout childhood and adolescence. This is hard
to examine with the available data. In ALSPAC although maternal iron intake in
pregnancy was associated with child offspring dietary iron intake in childhood, testing
for mediation by child dietary iron intake did not make a difference in the exposure-
outcome relationships. A long term follow up of a birth cohort with detailed dietary
and biomarker assessment of iron status during, and preferably before pregnancy, and
measurement of a combination of offspring cardiovascular markers from birth to later
in life could potentially answer this question. A long-term follow up of a RCT of iron
supplements during pregnancy might also shed light on these relationships.
7.4.2 Is the range of variation in iron status/intake too narrow in
humans to show an association?
Extreme ID in animals cannot be replicated in observational studies in high income
countries where most participants are nutrient-replete. This can only be explored
further in low income countries where pregnant populations have more severe ID
spanning a long period of time before conception, or in natural human experiments
such as the Dutch hunger winter (Lumey et al., 2007) and the siege of Leningrad
(Stanner and Yudkin, 2001).
The offspring adverse changes observed in animal studies could be due to severe ID in
the mother rather than moderate or mild. Therefore, generalizability of study results
should be carefully considered when considering evidence from different parts of the
world, particularly concerning the effect of iron supplements. Most supplement trials
are conducted in low or middle income countries (section 2.2.8.2), while most
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observational studies that assess dietary intake in detail are conducted in high income
countries.
7.4.3 Are the findings masked by measurement bias in population
studies?
Animal studies usually involve accurate exposure assessment as they are usually
controlled intervention studies. This compares to the big potential measurement bias
involved in observational population studies, particularly when it comes to dietary
assessment methods from which iron intake is derived. Measurement error is
profoundly associated with all of the commonly-used dietary assessment methods in
population health research such as FFQs, food diaries, and interviewer-administered
dietary recalls. Innovative population-level dietary assessment methods such as
methods based on information and communication technology are urgently needed
that combine accuracy and reliability with feasibility, acceptability and low cost to
assess nutritional exposures and deliver dietary interventions on a large population
scale (Alwan and Cade, 2013). Such tools are starting to be developed and tested for
effectiveness both as a method of dietary exposure assessment and as a dietary
intervention (Carter et al., 2012, Carter et al.,2013a, Carter et al., 2013b). These could
be implemented to assess dietary intake including iron at multiple stages during
pregnancy in a birth cohort.
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7.5 Maternal haemoglobin in pregnancy and birth
outcomes
In this thesis, low Hb in early pregnancy was associated with adverse birth outcomes,
including SGA and increased infant PWV. In contrast, low Hb in the second half of
pregnancy was associated with favourable SGA risk. These findings go in line with the
U-shaped relationship between maternal Hb and birth outcomes reported in other
studies. This relationship was further discussed earlier in sections 2.2.4 and 4.6.2.2.1
of this thesis. In a recent meta-analysis of 12 observational studies, SGA was associated
with moderate to severe (<9 g/dl), but not mild anaemia during pregnancy (<11 g/dl or
<10 g/dl) (Kozuki et al., 2012).
A major problem in interpreting Hb values and how they relate to maternal iron status
is the physiological process of plasma volume expansion in pregnancy. This leads to a
fall in Hb level which obscures the typical relationship between ID and Hb. Not only
that, it also makes it difficult to interpret plasma-based indicators of ID including sF
due to plasma dilution. Also, the point at which Hb is assessed is of utmost importance
as plasma volume and cell mass change in the different stages of pregnancy
(Rasmussen, 2001). Assessing Hb in early pregnancy, before the materialisation of
plasma expansion, reflects iron status better than later in pregnancy. However, many
studies did not take account of these important physiological changes and used ‘lowest
Hb in pregnancy as a main exposure in relation to birth outcomes, without indicating
when it was obtained, or adjusting for gestational age (section 2.3.3).
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Although in the Baby VIP study, it appeared that the association between maternal ID
and SGA was mediated by maternal Hb level, there could be another pathway of
association between anaemia in pregnancy and adverse offspring outcomes other than
ID, such as other nutrient deficiencies. Also, low Hb levels restrict oxygen circulation in
the body, creating an environment of oxidative stress or chronic hypoxia, which could
then cause fetal growth restriction (Kozuki et al., 2012).
7.6 Dietary iron intake during pregnancy
It has been shown in this thesis, including relatively large samples of British women
from Leeds and Bristol, that iron intake in pregnancy in the UK is considerably lower
than recommended. 80-90% of women had intakes less than the UK RNI and 25% less
than the UK LRNI based on the CARE and the ALSPAC study samples. Vegetarians were
less likely to report inadequate intakes of iron in their diet, but their net iron
absorption could be less than meat eaters as discussed earlier in section 2.2.7.1. There
is no focus in current UK antenatal care on providing specific dietary advice to
maximize iron intake from food during pregnancy. Research into providing antenatal
advice of how to ensure adequate iron intake during pregnancy using a public health
approach is needed.
7.6.1 The meat paradox
There is some evidence that high red meat intake in relation to carbohydrate intake
during late pregnancy has a possible negative influence from the developmental
origins of disease angle, including higher offspring BP and cortisol levels (Herrick et al.,
2003, Shiell et al., 2001, Godfrey et al., 1994). However, red meat also provides in
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abundance the well-absorbed type of iron, haem iron. Therefore, advice to pregnant
women about consumption needs to be tailored to this specific group of population
according to a risk assessment based on the available evidence. Although the UK
Scientific Advisory Committee on Nutrition (SACN) advise limiting red meat intake in
adults in general to reduce the risk of colorectal cancer (Scientific Advisory Committee
on Nutrition, 2010), recommending meat as the source of haem iron during the limited
span of pregnancy is unlikely to have adverse effects in relation to lifetime risk of
colorectal cancer given the available research evidence. Since iron intake seems to be
of most importance in early pregnancy, meat intake can specifically be encouraged in
moderate amounts during that period. Alternatively, small amounts of meat can be
recommended to consume with sources of non-haem iron to aid its absorption (Skikne
and Baynes, 1994).
7.7 Supplement intake during pregnancy
7.7.1 Multivitamin-mineral supplements
Analysis included in this thesis in chapter 3 demonstrates no evidence of association
between taking daily MVM supplements during any stage in pregnancy and birth
weight, SGA, or large for gestational age at any stage in pregnancy. However, taking
MVM supplements in the third trimester was associated with an increased risk of
preterm birth, with this effect being more pronounced in primiparous women.
Interactions between micronutrients in the same supplement or in different
supplements may provide a possible explanation to any adverse associations such as
the one observed in the CARE study in relation to preterm birth. Significant interaction
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may decrease the bioavailability of micronutrients and their transfer across the
placenta. For example, copper overload induces iron overload, by interfering with the
iron regulatory mechanism, and iron interacts with zinc affecting absorption (Fosset et
al., 2009, Gambling et al., 2008, Kelleher and Lönnerdal, 2006). A reduction in
availability of micronutrients to the fetus, by interactions between the nutrients at
maternal gut, liver or in the placenta itself, may result in adverse outcomes for the
baby, or ineffective interventions at best. There is very limited evidence regarding the
ideal doses of the micronutrients in the supplements that would prevent such
undesirable effects. Preparations used in different studies are heterogeneous in type,
ingredients and dosage. Another possible explanation for the conflicting evidence is
the heterogeneity in the period of administration of MVM during pregnancy, as need
and utilization of MVM may be substantially different in late compared to early
pregnancy.
Clinicians and midwives in countries where gross multiple micronutrient deficiencies
are not common should be cautious when recommending over-the-counter MVM
supplements to nutrient-replete women. As in any clinical situation, they should weigh
the potential risks and benefits when considering prescribing such supplements. It may
be more effective for the type of supplement recommended/prescribed to be more
focused on the specific vitamin/mineral deficiency the woman has. However, this
raises the question whether screening for micronutrient deficiencies during pregnancy
is a feasible and cost-effective option and there is little research examining this
question.
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Rigorous research is still needed to assess if routine MVM supplementation during
pregnancy is required. There is no solid evidence that MVM supplementations have
additional benefits over iron and folate alone in relation to the risk of infant mortality,
though there is evidence of reducing the risk of LBW/SGA (Haider et al., 2011). There is
no solid evidence to support the routine use of MVM supplements in developed
country settings to improve infant outcomes. The WHO recommends further studies
evaluating the effect of different combinations and dosages of the different
micronutrients in the supplements (Lumbiganon, 2007).
7.7.2 Iron supplements
In the Baby VIP study, out of those with iron depletion in the first trimester (sF <15
ug/l), only 58% had iron supplements during their pregnancy, compared to 81% of
anaemic women in the first half of pregnancy, and 83% of anaemic women in the
second half of pregnancy. Data from relatively big national samples of pregnant
women in the UK are needed to confirm these findings and provide national estimates
of the prevalence of ID in pregnancy. If they are confirmed then selective iron
supplementation during early pregnancy based on sF levels could be an option to
consider for routine UK antenatal policy. However, this would be considered as an
antenatal screening programme for ID and will need to be assessed for clinical and cost
effectiveness as well as meeting the criteria of the UK National Screening Committee
(www.screening.nhs.uk/criteria).
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7.7.2.1 Why are some iron depleted women not receiving iron
supplements?
In the UK, all pregnant women are screened for anaemia at their antenatal booking
appointment at the end of the first trimester. However unless the woman is anaemic
or the community midwife decides to test for ID by measuring sF, ID is not detected in
routine antenatal check-up at this stage in pregnancy. Some practices with high
proportion of registered population from ethnic minorities screen for ID at this stage,
however this is not routine practice, and the evidence shows that ID is still commonly
prevalent in women of Caucasian origin (Pavord et al., 2011). Pregnant women may
benefit from screening for ID earlier in their pregnancy at around 8-10 weeks
gestation, as the critical window of intervention to reverse adverse offspring effects
has been identified in the first trimester by animal studies (McArdle et al., 2006).
The other possible explanation for the fact that ID women are not replenished with
supplements is that iron supplements could be recommended and started in these
women but not tolerated, especially in high doses, due to side effects. Constipation,
nausea, vomiting and diarrhoea are commonly experienced side effects of iron
supplements. Some have suggested that intermittent rather than daily
supplementation may tackle this problem (Beaton and McCabe, 1999). Another option
is trying a tailored dietary intervention to increase iron intake and absorption from the
diet which could potentially help increase iron intake and absorption on its own, or in
addition to tolerable doses of supplements. This needs to be tested using a RCT study
design.
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8 Conclusion
8.1 What is new?
This thesis is very relevant to the hypothesis of the developmental origins of health
and disease, particularly the role of maternal diet and nutritional status during
pregnancy in influencing CVD risk in the offspring later in life. Although, the
importance of fetal nutrition on lifelong health was clearly emphasised in a British
Medical Association report published in 2009, the gap in the current evidence around
the effect of specific nutritional deficiencies on long term health outcomes was
pointed out (Hanson et al., 2009). This thesis specifically attempts to address this gap
in relation to maternal iron. Promoting a healthy diet during pregnancy to optimise
short and long term birth outcomes is essential to good antenatal care, and this can
only be achieved by conducting well designed investigations which would inform
clinical and public health guidance in this field.
The novelty of the epidemiological research methodology used in this thesis is
considered in detail earlier in section 2.6.1 of the background chapter. Each of the
four studies included in this thesis stand-alone independently, as well as collectively
addressing a common hypothesis generated from experimental animal studies which is
very relevant to clinical and public health care globally. In relation to other population
studies in the field of the developmental origins of health and disease, this thesis takes
an innovative angle of looking at a single micronutrient level during pregnancy at a
population level to assess its association with long-term offspring indicators, as well as
the conventional measures of immediate birth outcomes such as birth weight. The
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measurement of arterial stiffness in infancy and childhood using the non-invasive
technique of PWV used in chapters 4 and 5 of this thesis could potentially be a
promising new advancement in measuring predictors of CVD risk early in life in relation
to prenatal exposures.
In terms of research findings, this thesis is the first to link infant arterial stiffness with
maternal anaemia in early pregnancy. Only some of these anaemic mothers were iron
deficient. This required further investigation to understand the potential biological
mechanisms involved. This thesis is also the first to investigate and show no evidence
of association between maternal iron status and offspring CVD indicators in adulthood
in a population sample using Mendelian randomisation study design.
8.2 Implications for practice
This thesis falls in the realm of aetiological epidemiology research. Therefore, no direct
recommendations for practice can be drawn from it without taking the findings further
and using them to inform the design and testing of a healthcare and/or public health
intervention using RCT study design. However, a couple of discussion points relevant
to clinical and public health practice are considered below.
Currently in the UK, routine iron supplementation in pregnancy is not recommended.
Pregnant woman are only screened for anaemia which is at the extreme end of the ID
spectrum. Some argue for testing sF levels in the first trimester of pregnancy,
preferably at the first antenatal booking visit (Milman, 2006b). If sF is low at that point
in pregnancy indicating ID based on international cut-off values, then iron
supplementation may be recommended plus dietary advice to optimise intake from
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diet and maximise absorption of both non-haem iron and supplements. However, a
screening approach of routine testing and selective supplementation requires solid
evidence of clinical and cost effectiveness on a population level, taking into account
country-specific prevalence rates of SGA and ID in women of childbearing age before it
can be implemented. .
It is also important to address the issue of iron supplements’ side effects and
optimisation of their absorption in women who are deemed in need of them,
particularly those who are anaemic in early pregnancy. Delayed-release iron
preparations and intermittent oral iron supplementation are likely to lead to better
overall compliance and reduction in side effects (Beard, 2000). Administering iron to
the body through alternative routes such as the intravenous route has also been
assessed and found to be more effective in treating maternal anaemia than the oral
route (Al et al., 2005).
8.3 Implications for further research
There is much further epidemiological and interventional research needed to follow on
from this thesis, based on the findings as well as evidence gaps identified in the
process of designing and conducting the included studies.
Recommendations for further research studies include:
1. A systematic review and meta-analysis of observational studies to investigate
the association of maternal dietary iron intake in pregnancy with birth
outcomes
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2. A systematic review and meta-analysis of observational studies to investigate
the association between arterial stiffness at different points in the lifecourse
with size at birth and preterm birth
3. A systematic review and meta-analysis of trials of dietary interventions
(excluding trials of supplements alone) during pregnancy to improve birth
outcomes
4. A birth cohort with valid and reliable dietary assessment at multiple points in
pregnancy, preferably using easy to use and accessible innovative methods
utilising information and communication technology which generate individual
nutrient data in addition to dietary patterns, measuring offspring
cardiovascular indicators including arterial stiffness and adiposity measures
among other conventionally measured birth outcomes
5. A study aimed at standardising the different sTfR laboratory assays and
providing a reliable and transferrable method to derive total body iron in
pregnancy
6. A RCT to compare the effects of iron supplements alone against a dietary
intervention aimed at optimisation of iron intake and absorption from the diet,
with and without low dose supplements, measuring birth outcomes with
follow up to assess CVD risk factors in the offspring. The intervention can be
delivered using information and communication technology tools such as
online websites and smartphone apps.
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8.4 Summary
There are several important findings emerging from this thesis which examined the
role of maternal iron in the developmental origins of CVD in the offspring. Total
maternal iron intake in early, but not late, pregnancy was positively associated with
birth weight centile. There was no evidence of association between taking iron-
containing supplements in pregnancy with size at birth. However taking MVM
supplements, which usually contain iron, in late pregnancy was associated with an
increased risk of preterm birth. Also taking iron supplements up to 32 weeks gestation
was associated with an average of 1 mmHg lower offspring systolic BP at 10 years.
Maternal anaemia and ID, defined as sF<15 ug/l, in early pregnancy was associated
with an increased risk of giving birth to a SGA baby. Infant bfPWV measured at 2-6
weeks of age was found to be higher in babies of women who were anaemic in early
pregnancy, but not in those who were only iron deficient without anaemia. Finally,
using a Mendelian randomisation design, maternal iron status measured by sF with
C282Y mutation as an IV was not found to be associated with adult offspring BP and
adiposity.
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10 Appendices
10.1 Electronic search strategy for section 2.2.7.4
Ovid MEDLINE(R) (1950 to February Week 1 2013), EMBASE Classic + EMBASE (1947 to
2010 February 10), and Maternity and Infant Care (1971 to December 2009) databases
were searched using the following terms:
#1 pregnan*
#2 gestation*
#3 iron
#4 iron intake
#5 diet
#6 birth weight
#7 birth weight
#8 preterm
#9 small for gestation*
#10 an?emia
#11 birth outcome*
#12 postnatal
#13 1 or 2
#14 3 or 4
#15 6 or 7 or 8 or 9 or 10 or 11 or 12
#19 13 and 14 and 15 and 510.2 CARE study Dietary recall form
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10.3 Baby VIP study documents
10.3.1 Consent forms
10.3.2 Participant information sheet
10.3.3 Standard Operating Procedure for PWV measurement
10.3.4 Medical information sheet
10.3.5 Lifestyle questionnaire
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10.4 Stata code for multiple imputation analysis in
ALSPAC
misstable patterns, frequency
mi set mlong
mi register imputed pwv fmdp dp sp DVoffspringbmi
mi register regular DVcironRNI
mi set M = 20
mi impute mvn pwv fmdp dp DVoffspringbmi = ciron DVcironRNI, force
replace
mi describe
set level 99
**MI UV analysis**
mi estimate: regress pwv ciron
mi estimate: regress fmdp ciron
mi estimate: regress sp ciron
mi estimate: regress dp ciron
mi estimate: regress DVoffspringbmi ciron
mi estimate: regress cordferr ciron
mi estimate: regress kz030 ciron
mi estimate: regress GA ciron
mi estimate: regress DVavchildiron ciron
mi estimate: regress pwv DVcironRNI
mi estimate: regress fmdp DVcironRNI
mi estimate: regress sp DVcironRNI
mi estimate: regress dp DVcironRNI
mi estimate: regress DVoffspringbmi DVcironRNI
mi estimate: regress cordferr DVcironRNI
mi estimate: regress kz030 DVcironRNI
mi estimate: regress GA DVcironRNI
mi estimate: regress DVavchildiron DVcironRNI
mi estimate: regress DVavchildiron DVironsupppreg
mi estimate: regress GA DVironsupppreg
mi estimate: regress kz030 DVironsupppreg
mi estimate: regress cordferr DVironsupppreg
mi estimate: regress DVoffspringbmi DVironsupppreg
mi estimate: regress sp DVironsupppreg
mi estimate: regress dp DVironsupppreg
mi estimate: regress fmdp DVironsupppreg
mi estimate: regress pwv DVironsupppreg
mi estimate: regress pwv firsthaem
mi estimate: regress fmdp firsthaem
mi estimate: regress sp firsthaem
mi estimate: regress dp firsthaem
mi estimate: regress DVoffspringbmi firsthaem
mi estimate: regress cordferr firsthaem
mi estimate:regress kz030 firsthaem
mi estimate: regress GA firsthaem
mi estimate: regress DVavchildiron firsthaem
mi estimate: regress pwv DVmat_anaemia
mi estimate: regress fmdp DVmat_anaemia
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mi estimate: regress sp DVmat_anaemia
mi estimate: regress dp DVmat_anaemia
mi estimate: regress DVoffspringbmi DVmat_anaemia
mi estimate: regress cordferr DVmat_anaemia
mi estimate: regress kz030 DVmat_anaemia
mi estimate: regress GA DVmat_anaemia
mi estimate: regress DVavchildiron DVmat_anaemia
mi estimate: regress pwv cordferr
mi estimate: regress fmdp cordferr
mi estimate: regress sp cordferr
mi estimate: regress dp cordferr
mi estimate: regress DVoffspringbmi cordferr
mi estimate: regress pwv kz030
mi estimate: regress fmdp kz030
mi estimate: regress sp kz030
mi estimate: regress dp kz030
mi estimate: regress DVoffspringbmi kz030
mi estimate: regress pwv GA
mi estimate: regress fmdp GA
mi estimate: regress sp GA
mi estimate: regress dp GA
mi estimate: regress DVoffspringbmi GA
mi estimate: regress pwv DVavchildiron
mi estimate: regress fmdp DVavchildiron
mi estimate: regress sp DVavchildiron
mi estimate: regress dp DVavchildiron
mi estimate: regress DVoffspringbmi DVavchildiron
**MI MV analysis**
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy ciron
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy ciron
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy ciron
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy ciron
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 cenergy ciron
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy DVcironRNI
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy DVcironRNI
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy DVcironRNI
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy DVcironRNI
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 cenergy DVcironRNI
****add firsthaem as sensitivity analyses****
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVironsupppreg
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVironsupppreg
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mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVironsupppreg
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVironsupppreg
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 DVironsupppreg
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
firsthaem DVironsupppreg
********
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
firsthaem
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
firsthaem
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
firsthaem
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
firsthaem
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 firsthaem
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVmat_anaemia
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVmat_anaemia
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVmat_anaemia
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
DVmat_anaemia
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 DVmat_anaemia
**with 3 mediators**
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron ciron
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron ciron
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron ciron
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron ciron
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 cenergy kz030 GA DVavchildiron ciron
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron DVcironRNI
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron DVcironRNI
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron DVcironRNI
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron DVcironRNI
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 cenergy kz030 GA DVavchildiron DVcironRNI
****add firsthaem as sensitivity analyses****
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVironsupppreg
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mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVironsupppreg
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVironsupppreg
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVironsupppreg
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 kz030 GA DVavchildiron DVironsupppreg
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
firsthaem kz030 GA DVavchildiron DVironsupppreg
********
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron firsthaem
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron firsthaem
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron firsthaem
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron firsthaem
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 kz030 GA DVavchildiron firsthaem
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVmat_anaemia
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVmat_anaemia
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVmat_anaemia
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron DVmat_anaemia
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 kz030 GA DVavchildiron DVmat_anaemia
**with 4 mediators**
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr ciron
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr ciron
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr ciron
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr ciron
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 cenergy kz030 GA DVavchildiron cordferr ciron
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr DVcironRNI
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr DVcironRNI
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr DVcironRNI
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
cenergy kz030 GA DVavchildiron cordferr DVcironRNI
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 cenergy kz030 GA DVavchildiron cordferr DVcironRNI
****add firsthaem as sensitivity analyses****
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mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVironsupppreg
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVironsupppreg
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVironsupppreg
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVironsupppreg
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 kz030 GA DVavchildiron cordferr DVironsupppreg
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
firsthaem kz030 GA DVavchildiron cordferr DVironsupppreg
********
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr firsthaem
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr firsthaem
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr firsthaem
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr firsthaem
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 kz030 GA DVavchildiron cordferr firsthaem
mi estimate: regress pwv e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVmat_anaemia
mi estimate: regress fmdp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVmat_anaemia
mi estimate: regress sp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVmat_anaemia
mi estimate: regress dp e695 DVppbmi DVmatsmoke DVmatcatqual b032
kz030 GA DVavchildiron cordferr DVmat_anaemia
mi estimate: regress DVoffspringbmi e695 DVppbmi DVmatsmoke
DVmatcatqual b032 kz030 GA DVavchildiron cordferr DVmat_anaemia
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10.5 UKWCS-IBPS documents
10.5.1 Letters
10.5.1.1 Letter to mother
10.5.1.2 Letters to participant
10.5.1.3 Participant measurement instructions
10.5.1.4 Letter to GP/practice nurse
10.5.1.5 Standard operating procedure for GP
10.5.2 Measurement forms
10.5.2.1 GP measurement form
10.5.2.2 Self-measurement form
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10.5.3 Stata code for the differences between the
instrumental variable (IV) and the ordinary least square
(OLS) estimates
capture program drop comparison
program define comparison, eclass
ivreg2 av_sbp (ferritin = matgeno), robust cluster(Motherid)
local iv_ferritin=_b[ferritin]
xi:regress av_sbp age childage i.childgender ferritin, robust
cluster(Motherid)
local ols_ferritin=_b[ferritin]
ereturn scalar iv_ferritin=`iv_ferritin'
ereturn scalar ols_ferritin=`ols_ferritin'
end
use "C:\Nisreen Laptop\c drive\mednal\My Documents\HH
Study\databases\HHstudy_Sept2011.dta" , clear
bootstrap diff=(e(ols_ferritin)-e(iv_ferritin)) e(ols_ferritin)
e(iv_ferritin), reps(10000) cluster(Motherid) saving("C:\Nisreen
Laptop\c drive\mednal\My Documents\HH Study\databases\ols versus iv
comparison_final.dta", replace every (10)):comparison
ivreg2 av_sbp (ferritin = matgeno), first robust cluster(Motherid)
*************
capture program drop comparison
program define comparison, eclass
ivreg2 av_dbp (ferritin = matgeno), robust cluster(Motherid)
local iv_ferritin=_b[ferritin]
xi:regress av_dbp age childage i.vege i.childgender ferritin, robust
cluster(Motherid)
local ols_ferritin=_b[ferritin]
ereturn scalar iv_ferritin=`iv_ferritin'
ereturn scalar ols_ferritin=`ols_ferritin'
end
use "C:\Nisreen Laptop\c drive\mednal\My Documents\HH
Study\databases\HHstudy_Sept2011.dta" , clear
bootstrap diff=(e(ols_ferritin)-e(iv_ferritin)) e(ols_ferritin)
e(iv_ferritin), reps(10000) cluster(Motherid) saving("C:\Nisreen
Laptop\c drive\mednal\My Documents\HH Study\databases\ols versus iv
comparison_final.dta", replace every (10)):comparison
ivreg2 av_dbp (ferritin = matgeno), first robust cluster(Motherid)
*************
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capture program drop comparison
program define comparison, eclass
ivreg2 av_waist_all (ferritin = matgeno), robust cluster(Motherid)
local iv_ferritin=_b[ferritin]
xi:regress av_waist_all age childage p2bmi i.newclass i.childgender
ferritin, robust cluster(Motherid)
local ols_ferritin=_b[ferritin]
ereturn scalar iv_ferritin=`iv_ferritin'
ereturn scalar ols_ferritin=`ols_ferritin'
end
use "C:\Nisreen Laptop\c drive\mednal\My Documents\HH
Study\databases\HHstudy_Sept2011.dta" , clear
bootstrap diff=(e(ols_ferritin)-e(iv_ferritin)) e(ols_ferritin)
e(iv_ferritin), reps(10000) cluster(Motherid) saving("C:\Nisreen
Laptop\c drive\mednal\My Documents\HH Study\databases\ols versus iv
comparison_final.dta", replace every (10)):comparison
ivreg2 av_waist_all (ferritin = matgeno), first robust
cluster(Motherid)
*************
capture program drop comparison
program define comparison, eclass
ivreg2 bmi (ferritin = matgeno), robust cluster(Motherid)
local iv_ferritin=_b[ferritin]
xi:regress bmi age childage p2bmi i.newclass i.childgender ferritin,
robust cluster(Motherid)
local ols_ferritin=_b[ferritin]
ereturn scalar iv_ferritin=`iv_ferritin'
ereturn scalar ols_ferritin=`ols_ferritin'
end
use "C:\Nisreen Laptop\c drive\mednal\My Documents\HH
Study\databases\HHstudy_Sept2011.dta" , clear
bootstrap diff=(e(ols_ferritin)-e(iv_ferritin)) e(ols_ferritin)
e(iv_ferritin), reps(10000) cluster(Motherid) saving("C:\Nisreen
Laptop\c drive\mednal\My Documents\HH Study\databases\ols versus iv
comparison_final.dta", replace every (10)):comparison
ivreg2 bmi (ferritin = matgeno), first robust cluster(Motherid)
